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In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affiliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome Trust 
continues to fund the Witness Seminar programme via its support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several 
people associated with a particular set of circumstances or events are invited to 
come together to discuss, debate, and agree or disagree about their memories. To 
date, the History of Twentieth Century Medicine Group has held more than 50 
such meetings, most of which have been published, as listed on pages xiii–xvii.
Subjects  are  usually  proposed  by,  or  through,  members  of  the  Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been agreed, 
suitable participants are identified and invited. This inevitably leads to further 
contacts, and more suggestions of people to invite. As the organization of the 
meeting progresses, a flexible outline plan for the meeting is devised, usually with 
assistance from the meeting’s chairman, and some participants are invited to ‘set 
the ball rolling’ on particular themes, by speaking for a short period to initiate and 
stimulate further discussion.
Each meeting is fully recorded, the tapes are transcribed and the unedited 
transcript is immediately sent to every participant. Each is asked to check his 
or her own contributions and to provide brief biographical details. The editors 
1  The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.x
turn the transcript into readable text, and participants’ minor corrections and 
comments are incorporated into that text, while biographical and bibliographical 
details are added as footnotes, as are more substantial comments and additional 
material  provided  by  participants. The  final  scripts  are  then  sent  to  every 
contributor, accompanied by forms assigning copyright to the Wellcome Trust. 
Copies of all additional correspondence received during the editorial process 
are deposited with the records of each meeting in archives and manuscripts, 
Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
members of the programme Committee of the  
History of twentieth Century medicine Group, 2009–10
professor tilli tansey – professor of the history of modern medical sciences, 
Wellcome Trust Centre for the History of Medicine at UCL (WTCHM) and chair
dr sanjoy Bhattacharya – reader in the history of medicine, WTCHM
sir Christopher Booth – former director, Clinical Research Centre, 
Northwick Park Hospital, London
dr John Ford – retired general practitioner, Tonbridge
professor richard Himsworth – former director of the Institute of Health, 
University of Cambridge
professor mark Jackson – professor of the history of medicine and director, 
Centre for Medical History, Exeter
professor John pickstone – Wellcome research professor, University of Manchester
mrs lois reynolds – senior research assistant, WTCHM, and organizing secretary
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intrOdUCtiOn
As specialties go, clinical genetics has had a remarkably short history. Over the last 
30–40 years, it has grown from an isolated activity to a fully integrated clinical 
activity bridging clinical and laboratory functions. The complexity of issues it 
has been asked to manage in a clinical setting has also expanded dramatically 
in this short time frame, while the clinical load of patients who benefit from 
increasing scientific insights into human genetics has grown. Because of its 
short history and its impact on all aspects of medicine, it is a perfect subject for 
a Wellcome Witness Seminar. Many of the original ‘witnesses’ to the birth of 
this specialty are still alive and provide fascinating insights into how a very few 
individuals shaped this important clinical service.
Since its early gestation in a few centres, notably the Galton Laboratory, the 
Oxford MRC population genetics unit and the clinical labs at Great Ormond 
Street, Manchester, Guy’s and Newcastle, the specialty has fed off exciting 
advances in human genetics and applied these advances to improve human 
health. The early years were dominated by personalities such as Lionel Penrose, 
Alan Stevenson, John Fraser Roberts, Cedric Carter, Cyril Clarke, Paul Polani 
and others. This was an era when formal training was not established and the 
precise relationships between genetics and other disciplines were not defined. 
It was a time when the first laboratory function, cytogenetics, created the 
distinctive capabilities of the field that ultimately allowed the specialty to 
develop a unique position among the medical specialties. Clinical geneticists 
struggled with the longstanding associations with eugenics and were challenged 
by the limited opportunities to apply their growing science to patients, which 
eventually evolved to become a unique specialty, distinct but associated with 
established service functions in subjects such as paediatrics, neurology and 
general medicine.
The specialty confronted a range of challenges – recognition by the Royal College 
of Physicians and the Department of Health, the creation of an inclusive society 
to support its growth in the form of the British Society for Human Genetics, 
reconciliation between the laboratory and clinical functions of the service, and 
the need to evolve other paramedical capabilities such as genetic counselling. All 
these presented obstacles that were ultimately overcome as the isolated groups 
applying genetics to medicine came together as a professional body. Although 
small, the specialty has continued to have influence that far exceeds its size. This 
Witness Seminar clearly describes the formative years that created this entity, xx
influenced throughout by the great international figures of clinical genetics such 
as Victor McCusick.
This  story  is  crucial  to  a  modern  understanding  of  the  challenges  and 
opportunities confronting the specialty. The underpinning science has become 
one of the most important aspects of medical science and, through it, genetics 
has increasingly come of age, slowly but steadily infiltrating all specialties. The 
view of Cyril Clarke was particularly prescient, as it was he who encouraged 
the growth of genetics in general medicine and it is in this broader domain 
that clinical genetics is likely to eventually to end up. Genetics increasingly 
anchors our understanding of disease, and genetic diagnostics in the form of 
arrays and sequencing has now all but subsumed the laboratory functions that 
were developed 30 years ago. It seems unlikely that clinical genetics as it was 
originally conceived will be able to preserve its role in medicine. Molecular 
pathology  is  likely  to  assimilate  the  laboratory  functions  which  will  apply 
equally  to  haematology,  paediatrics,  neurology,  cardiology  and  oncology. 
Pharmacogenetics  is  already  becoming  an  important  tool  for  stratifying 
medicine. The clinical domain of clinical genetics will not disappear but the role 
of genetics in medicine will mean that both laboratory and clinical functions 
will be mainstreamed in the future.
The crucial roles played by the actors in this seminar in introducing genetics 
to the clinic must be remembered as they pioneered many of the practical and 
ethical issues that are likely to be revisited repeatedly as genetics finds its place 
in a wider arena.
sir John Bell
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professor tilli tansey: Good afternoon everyone and thank you very much for 
coming to this Witness Seminar on the history of clinical genetics in Britain. 
My name is Tilli Tansey and I’m the convenor of the History of Twentieth 
Century Medicine Group, which was established by the Wellcome Trust in 1990 
to bring together scientists, clinicians, historians and others who are interested 
in recent medical history – conventionally post-Second World War medical 
history – to find out what happened, when, why, who the drivers were and who 
the dissidents in certain fields were, and to record these reminiscences and to 
provide records to go into archives for the use of present and future historians.
This meeting was suggested by Peter Harper, professor of medical genetics at 
Cardiff University, who has, in addition to being a geneticist, also transformed 
himself into an historian, and he has just produced a book of nearly 580 pages, 
called A Short History of Medical Genetics.
1 Of course, it’s also very important 
to identify a chairman and we’re very grateful that Martin Bobrow, emeritus 
professor  of  medical  genetics  at  the  University  of  Cambridge  and  former 
governor of the Wellcome Trust, has agreed to undertake this onerous task and 
to keep you all in order during this afternoon. So, without further ado, I’ll hand 
over to Martin. 
professor martin Bobrow: So, now you all know why I am here: it’s to keep 
you in order. There certainly isn’t any other obvious reason why I should get 
picked out for this signal honour. However, as someone who doesn’t do history 
much, it is interesting to think about how clinical genetics over the time that 
I’ve known it – which I think is only a short time, because I’ve only just begun 
my career – and it has gone from next to nothing to a relatively mainstream 
bit of medicine, and is possibly on its way to becoming next to nothing again. 
I think it’s interesting to consider the origins of the subject and the way that 
it has developed as a separate specialty.
2 And if it becomes next to nothing, 
it won’t be because genetics becomes unimportant, it will be because it gets 
absorbed so much into the rest of medicine that it doesn’t have as strong a 
claim to a separate existence. That is one of the issues and tensions that has 
been present in clinical genetics since its inception: most of medicine is divided 
into territorial specialties – liver people have the liver and knee people have 
the knee – but genetics doesn’t quite have a territory; it stamps on everyone 
else’s territory. It’s not unique in that, but it is quite unusual and it leads to 
1  Harper (2008).
2  For example, see Christie and Tansey (eds) (2006) on the development of the field of medical physics.Clinical Genetics in Britain: Origins and development 
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certain tensions in structuring. Its scientific roots are very complex, I think. It’s 
easy to say: ‘It’s genetics’, but genetics is a separate body of knowledge, which 
differs from most of the laboratory techniques, that are themselves diverse and 
complex, that underpin genetic practice. It has strong roots in epidemiology 
and statistics, in counselling, whatever you wish to define that as, but certainly 
in talking as a means of getting through problems. It has always had a very 
strong basis in population science, both in terms of thinking of populations, 
as opposed to patients away from populations, and in terms of looking for 
prevention and screening as opposed to just thinking of treatment, because this 
is a non-prescribing specialty, to note another unusual feature. 
If one’s interested in curiosities in medical practice, it is quite an interesting 
topic to play around with. Within the UK, most of the people who made the 
early running are sitting in this room now. There are a few people that I wish 
were with us today who aren’t, some because they couldn’t make it, and some 
because they aren’t going to make any more meetings at all. But an awful lot of 
us, you, are sitting here. My job is just to keep you in order as we drift through 
a very loosely structured agenda (Table 1).
table 1: Outline programme for ‘Clinical Genetics in Britain: Origins and  
development’ Witness seminar
Origins and early development: the scientific roots of clinical genetics 
Lionel Penrose and the Galton Laboratory
Chromosomes and the need for clinical genetics
Alan Stevenson and the Oxford MRC unit
the first medical geneticists
John Fraser Roberts, Cedric Carter and the Institute of Child Health, London
Paul Polani and clinical genetics at Guy’s Hospital, London
Cyril Clarke and the Liverpool Institute
Wider development of the field in Britain 
Bodies involved in developing the field
Royal College of Physicians’ Clinical Genetics Committee and the special advisory committee 
Clinical Genetics Society and the British Society for Human Genetics
Department of Health
Other aspects
Dysmorphology and clinical genetics
Genetic counselling; the development of genetic nurses and genetic counsellors
The role of lay societies in the growth of genetic services
The ethical and social dimension in clinical geneticsClinical Genetics in Britain: Origins and development 
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The way I am going to play it, and this is not deeply rehearsed and is subject to 
change, is that as we go down this loose agenda, I’ve scribbled a name and I will 
look at someone to start the topic rolling, after which anyone who has anything 
to say may chip in. There are quite a few of us; we are covering roughly 40 years 
of work and we’ve got about three and a half hours. So a bit of mental arithmetic 
will tell you that half-hour speeches are not what we need this afternoon. Brevity 
and a few facts, and things that are interesting and illuminating, which is exactly 
what you are all so good at. So, lastly, it is a real pleasure to see so many people 
who have been part of my working life, some of whom I haven’t seen for years, 
and I’m looking forward to it. 
professor peter Harper: Over the past few years I started to think a lot about 
how clinical genetics began and then developed in the UK. But there are a good 
few points that I’m still very uncertain about and I think this Witness Seminar 
gives a good chance to discuss, and hopefully clarify, these; even though, as 
Martin said, some of the people who might have contributed most are no longer 
living. Of course, there has been a previous Witness Seminar, seven years ago, 
on genetic testing, but this was focused mainly on laboratory aspects.
3 So this is 
the first opportunity in a group setting for looking at the equally important field 
of clinical genetics. You’ll have seen that the first topic on today’s programme is 
the scientific origin of clinical genetics, but I think we also need to think about 
the origins from different fields of medicine: paediatrics, adult general medicine 
and ophthalmology, as examples. 
When did clinical genetics begin? I think most of us would probably put the 
date around the late 1950s when human genetics as a science was already 
reasonably  well  developed  and  human  chromosome  studies  had  provided 
medical genetics with a practical, laboratory basis, as well as a research basis. 
But, before the Second World War there were already people like Julia Bell 
(1879–1979) in the UK, and others like Madge Macklin (1893–1962) in the 
US and Canada, whose research was based on the combined clinical and genetic 
analysis of families.
4 I think that these and others like them should be regarded 
as forerunners of clinical geneticists, even though they did not actually practise 
3  The Witness Seminar was held in 2001 and published as Christie and Tansey (eds) (2003).
4  See, for example, Bell and Haldane (1937); Macklin (1933). For an evaluation of Julia Bell’s work, see 
Harper (2005); Bundey (1996); for details of human genetics in the US, see Reed (2005) and on medical 
genetics, see Leeming (2010) .Clinical Genetics in Britain: Origins and development 
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it as a medical specialty.
5 One such person who bridged these two periods was 
John Fraser Roberts and we’re very fortunate to have his widow, Margaret, here 
to tell us something about him and his work today. 
There’s one uncomfortable question that we need to ask and that is whether 
clinical genetics developed to any significant extent from the earlier field of 
eugenics. I’ve always felt this not to be the case, at least in this country, but some 
people consider the two to be directly linked, so I think it’s essential to look at 
how modern clinical genetics has developed what, in my view, is a very strong 
ethical dimension.
Once clinical genetics had become identifiable as a definite field of medicine, 
what were the factors that helped it to spread across the UK and become a 
flourishing specialty in its own right? Did the Department of Health and Social 
Security (DHSS) actively encourage it? Or was it the work and influence of 
just a few pioneers such as, for instance, Cedric Carter. After all, most of this 
development happened in the 1970s, when the economy wasn’t a whole lot better 
than it is today. And, how did clinical genetics become so well established in 
the Royal College of Physicians, with its own trainees and specialty committee?
6 
Then also how did it establish its own society, the Clinical Genetics Society 
(CGS)?
7 There are people here today who I think should throw some light 
on this. 
The final aspect that I hope we’ll be able to cover, although not nearly to the 
extent that it deserves, is the diversification of people working in clinical genetics, 
especially non-medical staff such as genetic nurses and genetic counsellors, and 
5  Professor George Fraser wrote: ‘One of these forerunners was Lionel Penrose, from 1931 when he initiated 
the Colchester survey (Penrose (1938)) onwards for more than four decades until his death in 1972. He was 
the first clinical geneticist and, at the Galton Laboratory, he passed on his knowledge and wisdom.’ Note on 
draft transcript, 28 February 2009; 2 March 2010. 
6  The Royal College of Physicians established the Clinical Genetics Committee in 1984 as a result of 
discussions in 1983 with Dr D A Pyke, the registrar of the college. Members were invited by the college, 
with Rodney Harris as the first chairman and Alan Johnston as honorary secretary. Among their reports 
are: Royal College of Physicians, Clinical Genetics Committee (1991a); Harper et al. (1996); Davies et al. 
(1998). See Appendix 1, page 84.
7  The Clinical Genetics Society was established in 1970 to bring together doctors and other professionals 
who were involved in the care of individuals and families with genetic disorders. It is one of the founding 
constituent groups in 1996 of the British Society for Human Genetics, which provides a forum for all 
professionals involved in genetics as a clinical service and for research. See www.clingensoc.org and www.
bshg.org.uk/society/about_us.htm (visited 7 January 2010).Clinical Genetics in Britain: Origins and development 
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the increasingly important role of lay societies in genetic developments. I think 
these are areas that would need a separate Witness Seminar to do them justice, 
but I’m glad we have some representatives here who can provide this kind of 
perspective. There is a project in progress trying to preserve and catalogue in 
detail the records of people in medical and clinical genetics, and Tim Powell, 
from  the  National  Cataloguing  Unit  for  the  Archives  of  Contemporary 
Scientists in Bath, is coordinating this.
8 He’s here at this meeting, so if any of 
you can think of key records that are buried somewhere that might be saveable, 
this is a good chance. 
I think I’ve said enough to get this seminar started, but I’d just like to end 
with a couple of definitions that might help us to avoid confusion: by ‘human 
genetics’ I mean the scientific study of heredity in humans, both normal and 
as in genetic diseases; whereas by ‘medical genetics’ I mean the study of genetic 
diseases in their own right, including applications in medical practice; and 
I’ve taken ‘clinical genetics’ to mean that part of medical genetics involving 
the direct clinical study of, and communication with, patients and families 
themselves. These three areas overlap extensively, but the third one hasn’t seen 
much attention in historical terms so far, so I hope that we can help to remedy 
this today.
Bobrow: The way Peter Harper has structured this – very helpfully, I think – 
is that you have three bullet points on your bit of paper (Table 1) on origins 
and early development, the first of which is Lionel Penrose and the Galton 
Laboratory at UCL.
9 We will go through those bullets one at a time just as 
discussion points with statements from anyone around who has anything to 
contribute on that topic. Before we launch into that, is there anything that Peter 
has said that people want to correct immediately, or violently disagree with? 
No, there’s nobody twitching to that extent? Let’s move on to Lionel Penrose   
(Figure 1) and the Galton Lab. I was hoping that Sue Povey would start.
professor sue povey: I feel very embarrassed to be representing Penrose and the 
Galton Lab, because I only started work at the Galton Lab in 1970, though I did 
8  For further information on the National Cataloguing Unit for the Archives of Contemporary Scientists, 
see www.bath.ac.uk/ncuacs/home.htm (visited 17 February 2010). The unit was closed at the end of 
December 2009 as part of university economies and will be reconstituted as part of the Science Museum in 
2010, but in the interim the Human Genetics Archiving Project is being continued at Cardiff University, 
funded by the Wellcome Trust. 
9  For further details about the work of the Galton Laboratory, see www.galtoninstitute.org.uk/Newsletters/
GINL9112/Galton_Laboratory_Today.htm (visited 19 February 2010).Clinical Genetics in Britain: Origins and development 
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visit it as a student and Penrose was there. And so, of course, being in the Galton 
Lab, one had a great awareness of Penrose’s contribution to the understanding 
of tuberous sclerosis (epiloia) in 1935 and phenylketonuria (PKU) just after 
the war.
10 My personal experience of him was that he had great concern for 
the patients. As far as I understand it, he had very ad hoc consultations with 
patients. I don’t think there was a standard genetic clinic at the time at UCL, 
but there are people here who were there at the time who could correct me on 
this. Penrose did once take me to see some Down syndrome twins who were 
supposed to be monozygotic, and one had Down’s and one did not. What I 
remember most clearly is that he was so distressed by the terrible state of the 
high-rise building and the mother who couldn’t get out. He was much more 
concerned with the welfare of the family than the science, which seemed to pale 
into insignificance compared with how this poor family were managing. 
Regarding the naming of the Galton Laboratory, it is my understanding that he 
did that by changing his notepaper when he became Galton professor, after the 
war. In 1955 he tried to change the name of the department from the department 
10  See Gunther and Penrose (1935); Penrose (1946); see also Harris (1974); Christie and Tansey (eds) 
(2003): 35, 40, 41.
Figure 1: professor lionel penrose, c. 1960. Clinical Genetics in Britain: Origins and development 
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of eugenics and the Annals of Eugenics to the Annals of Human Genetics, but 
UCL moved rather slowly, and it took about two years to do this, during which 
time he started using the name Galton Laboratory on his notepaper.
11 I may be 
corrected on that, but that is something that Bette Robson, Galton professor 
of eugenics at UCL (1978–93), said at the Penrose symposium I held for the 
centenary of his birth.
12 
My own memories of early clinical genetics, which you may well say was not 
early, are from 1967 when Dr Mary Lucas was appointed as a clinical geneticist 
at the Galton Laboratory (Figure 2),
13 and then the beginning of the MRC 
11    The  Francis  Galton  Laboratory  of  National  Eugenics  became  the  Galton  Laboratory  of  UCL’s 
department of human genetics and biometry in 1963 and part of the department of biology in 1996. The 
Annals of Eugenics was renamed the Annals of Human Genetics in September 1954 (volume 19 part 1). See 
Barnett (2004).
12  See Anon (1998). A detailed account of the Penrose symposium at UCL held on 12–13 March 1998 
(Povey and Press (1998)), including a summary of the papers presented, is available on the department 
of genetics, environment and evolution website at www.ucl.ac.uk/gee/about/penrose_symposium. A list 
of sources of biographical information on Lionel Penrose provided by Professor George Fraser will be 
deposited, along with the other records of this meeting, in archives and manuscripts, Wellcome Library, 
London, at GC/253. For further details of the Galton Laboratory, see note 9. See also Laxova (1998). 
13  See, for example, Lucas et al. (1972).
Figure 2: dr mary lucas explains a poster to the University of london’s  
Chancellor, princess anne, October 1981.Clinical Genetics in Britain: Origins and development 
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unit, when Gerald Corney (Figure 5) ran a clinic at which the notable things, I 
think, were that he accepted patients who referred themselves and always wrote 
to them afterwards, using great detail about what had happened and what the 
conversation had been. He did a great deal of background work on the diagnosis 
before ever agreeing to see the patients. I thought that I would mention Gerald, 
because people, perhaps, forget that particular clinic.
14 
professor Ursula mittwoch: I don’t know the definition of a genetics clinic, but 
I do remember that every so often on a Saturday morning Lionel Penrose would 
see a child with Down syndrome and his or her parent, usually the mother, and 
he would advise them. He took palm prints of the child and the parents and I 
was called in to make blood films to study the polymorphonuclear leucocytes.
15
professor Joy delhanty: I came to work at the Galton Laboratory to do my 
PhD in 1959. It was in 1959 when the first case of a chromosomal anomaly 
had been described and that was in a case of mongolism (Down syndrome).
16 
My supervisor in genetics, John Maynard Smith, said he wondered whether 
Lionel Penrose would be interested, in view of that finding, in taking on a PhD 
student. That’s how I came to work at the Galton Lab, and I went for a week to 
study with David Harnden at Harwell (MRC radiobiology unit, Atomic Energy 
Research Establishment) to learn the essence of tissue culture and how to grow 
skin biopsies.
17 I remember the excitement over the next couple of years, because 
Lionel was so interested in the families that he’d accumulated, particularly those 
where there were siblings with Down syndrome. In one of those, the early ones, 
we were able to demonstrate that there was an inheritance of a Robertsonian 
translocation, which was responsible for the recurrent Down syndrome. This 
was the first demonstration of that (Figure 3a and b).
18 
14  See, for example, Crosse and Corney (1961). For biographical note, see page 117.
15  Professor Ursula Mittwoch wrote: ‘The leucocyte investigation was based on the finding by Turpin and 
Bernyer (1947) that the polymorphonuclear lobe count in patients with Down syndrome was lower than 
in unaffected individuals. The problem was that there were no controls for the patients visiting Professor 
Penrose. Dr Valerie Cowie kindly solved this problem by introducing me to the Fountain Hospital, Tooting, 
London, where the physician superintendent and staff were extremely helpful in selecting Down syndrome 
patients and appropriate controls, and facilitating the technical procedures. The results of the investigations 
on lobe counts and the incidence of drumsticks gave rise to several publications between 1955 and 1958. 
See for example Mittwoch (1958a and b).’ E-mail to Professor Tilli Tansey, 29 September 2008.
16  Lejeune et al. (1959); Jacobs et al. (1959); Harnden et al. (1960).
17  See, for example, Harnden (1960, 1979, 1996).
18  Penrose and Delhanty (1961); see also Penrose et al. (1960).Clinical Genetics in Britain: Origins and development 
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(b): Family pedigree, showing three generations with inherited translocation  
(marked with t). penrose and delhanty (1961).
Figure 3(a): the karyotype of a phenotypically normal woman (no. 110 in 2nd row in b) who 
gave birth to four children (3rd row in b), two of whom had langdon down syndrome anomaly 
(nos. 160 and 183 in 3b), all of whom exhibit a fusion between chromosomes 15 and 21.  
(a)
(b)Clinical Genetics in Britain: Origins and development 
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He was so interested he couldn’t keep away from the lab and the microscope. He 
was always coming and saying, ‘What have you found today?’ And sometimes 
it was to do with Down’s and sometimes it was looking at miscarriages, and we 
did find the first two examples of triploidy in humans at that time. So it was a 
very exciting time.
professor  George  Fraser:  I should like to acknowledge my personal debt 
to Lionel Penrose, whom I first met 52 years ago and who was my teacher, 
my mentor and my friend. He was a pioneer in clinical genetics and medical 
genetics as well as in human genetics; in the years since our first meeting, I have 
not met anyone working in any of these overlapping fields whom I admire and 
respect as much.
19 
He was a man, take him for all in all, 
I shall not look upon his like again.
20
 
At the time when I arrived at the Galton Laboratory at UCL in October 1957 
as a PhD student, Sylvia Lawler, a long-time associate of the Galton Laboratory 
had said: ‘Anyone who managed to get a PhD in the Galton Laboratory had to 
have a streak of originality. There was no spoon-feeding. Penrose would take 
people in, shut them in a room, and let them get on with it.’
21 In my own 
experience, this was indeed so. During my second year at the Galton Laboratory, 
in April 1959, I told Lionel that I would not be staying for a third year. Lionel 
said that it was a pity that I had not written a PhD thesis. ‘But, Professor,’ I 
said, ‘I am writing a thesis and you shall have it before I leave in October.’ 
Lionel was not in the least taken aback; he wanted to know what the topic of 
the thesis was. I told him that the topic was a clinical and genetical study of 
the Pendred syndrome of deafness with goitre in collaboration with a physician 
across the road at University College Hospital, Dr W R Trotter. The mention 
19  Professor George Fraser wrote: ‘His son, Professor Oliver Penrose, wrote of Lionel’s tenure of the Galton 
chair at UCL between 1945 and 1965: “In particular, he was the first clinical geneticist, that is to say 
he advised patients who already had one mentally handicapped child what the chances were, if they had 
another child, that the new one would have the same affliction” (Penrose (1998): 12–13). Apart from these 
informal Saturday morning genetic counselling sessions at the Galton Laboratory, Lionel had long-standing 
contacts in the field of clinical genetics with colleagues at the neighbouring University College Hospital 
throughout his tenure of the Galton chair; towards the end of his tenure, in the 1960s, these contacts were 
formalized by a joint appointment in the field of clinical genetics.’ Note on draft transcript, 28 February 
2009; 2 March 2010. See also Professor Ursula Mittwoch on page 10. 
20   Thompson and Taylor (eds) (2006): Act 1, Scene 2, lines 186–7, page 182.
21  Kevles (2007): 45; Robson (1996). Clinical Genetics in Britain: Origins and development 
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of Dr Trotter brings to mind the multi-faceted diversity of Lionel’s intellectual 
interests, in that in 1952, in his role as a psychologist, he published a book 
called On the Objective Study of Crowd Behaviour, based to a substantial extent 
on the book Instincts of the Herd in Peace and War written in 1916 by Wilfred 
Trotter, the father of my collaborator. 
22
Of Lionel’s many other talents, I shall not go into detail about his wooden self-
replicating machines.
23 He was also an excellent chess player and delighted in 
the composition of chess problems. Lionel was a founder member and chairman 
of the Medical Association for Prevention of War. In a letter to the Lancet, 
adducing a scientific basis for the struggle for peace, he and six others wrote: 
Doctors have a social responsibility as well as a personal one to their 
patients; they have an ethical tradition and an international allegiance. 
War is a symptom of mental ill health. Its results include wounds and 
disease. Doctors are, therefore, properly concerned in preventing it. An 
‘epidemic of trauma’ requires prophylactic treatment as much as any 
other epidemic.
24 
Lionel was brought up in a Quaker household and his aversion to war was 
already developed during his childhood, when he wrote a little poem:
We are under one king
Let our flag be peace.
Let us take our swords off
And let the bloodshed cease.
25 
During the First World War, he served in the Friends’ ambulance train of the 
British Red Cross in France.
26 
22  Penrose (1952); Trotter (1916).
23  Clarke (1974): 246. A list of Professor Penrose’s articles on his machines has been provided by Professor 
George Fraser and will be deposited along with other records of this meeting in archives and manuscripts, 
Wellcome Library, London, at GC/253.
24  Doll et al. (1951).
25  Professor George Fraser wrote: ‘This poem was written by Lionel at the age of eight years (Smith (n.d., 
c. 1999): 6).’ Note on draft transcript, 2 March 2010. 
26  Professor Lionel Penrose served in the Friends’ no. 5 ambulance train of the British Red Cross in France 
in 1918. For further details, see Smith  (n.d., c. 1999): 7.Clinical Genetics in Britain: Origins and development 
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An extract from the last section entitled ‘positive eugenics’ that he added to the 
fourth, new revised edition of his classic book, The Biology of Mental Defect, 
published in 1972, the year of his death, is revealing with regard to Lionel’s 
views concerning the eugenics movement: 
It has been one intention throughout this book, to explore the broad 
problems of eugenics and to show that they cannot be solved until the 
mode of action of natural selection on the human race is much more 
fully understood than it is at present. It may be relatively easy to point 
to genes which appear altogether bad; for example, those which make 
their possessor victims of epiloia or of Huntington’s chorea. Even these 
may not be unfavourable in all circumstances. Carriers of ‘bad’ genes 
may sometimes have compensating advantages….The position is quite 
different when we try to identify ‘good’ genes. The human types which 
are accepted by eugenists as desirable can be specified to some extent….
Nothing is known, however, about the actual genes which might form 
the basis of such qualities.
27
I started my tribute to Lionel Penrose, pioneer of clinical genetics as well as of 
human genetics, with a quotation from Shakespeare and I will end with one 
from Osler: 
The great possession of any university is its great names. It is not the 
pride, pomp and circumstance of an institution which bring honour, 
nor its wealth, nor the number of its schools, nor the students that 
throng its halls, but the men who have trodden in its service the thorny 
road through toil, even through hate, to the serene abode of fame, 
climbing like stars to their appointed heights.
28 
I think both Shakespeare and Osler could have been thinking of Lionel when 
they wrote these words. 
Bobrow: George, thank you very much indeed. And could I formally thank 
Professor Emery for helping with that presentation [Fraser dropped his papers 
during his contribution, Emery gathered them up and held them for Fraser to 
read].
27  Penrose (1972): 293.
28  Osler (1904): 10–11.Clinical Genetics in Britain: Origins and development 
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professor shirley Hodgson: I never actually worked with Lionel Penrose, but 
as he was my father, I knew him for a long time! I want to make a couple of 
brief points. An important influence on Lionel was what George Fraser has very 
eloquently mentioned, his Quaker upbringing. And I know JBS Haldane used 
to say that Lionel was deeply Quaker in all his beliefs except for the theology, 
and that thread went through much of his thinking. As Sue Povey said about 
the Galton Laboratory, he did try very hard to change its name, and he said 
from the beginning that he found it a continual embarrassment to be associated 
with the stigma of eugenics. According to the obituary from Harry Harris: 
‘The long delay [in changing the name of the chair] had been because of legal 
problems connected with the original wording of Galton’s will.’
29 I know he very 
soon changed the name of the Annals of Eugenics. Its subtitle was ‘a journal for 
the scientific study of racial problems’ in 1926, and it was changed to ‘a journal 
devoted to the genetic study of human populations’ by Sir Ronald Aylmer Fisher 
in 1933, and Lionel changed the title to Annals of Human Genetics.
30 So he was 
constantly trying to change the emphasis and was very concerned about any 
association between what the laboratory was doing and any eugenic theories or 
associations. I would also endorse what Sue said about his enjoyment of being 
with people who had mental retardation. There was a lovely story he used to tell 
about how he was talking to a man with Down syndrome, which, of course, was 
called mongolism then, in the grounds of the hospital, and the chap with Down 
syndrome said: ‘Oh, there’s a mongol. There’s another mongol. They must be 
digols’. I’ll leave it there. 
Harper: Could I just come in at this point and throw a question out to everybody, 
but particularly those people who had direct connections with the Galton: I’m 
always puzzled as to, with Penrose’s particularly clinical approach and the fact that 
people came from all over the world to work at the Galton, many of whom would 
later be founders of medical genetics in their own countries, why did the Galton 
not become a centre of clinical genetics?
31 Because it didn’t and from the 1970s 
on it looked at basic science, very distinguished basic science, but it wasn’t a place 
that people looked to if they were developing clinical genetics. I’m not quite sure 
29  Harris (1973): 538.
30  The journal was founded in 1926 by Karl Pearson, Galton professor of eugenics at UCL, who was 
succeeded by R A Fisher in 1933, followed by Lionel Penrose in 1945. See Clarke (1974); Li (2000); see 
also note 11.
31  Professor Sue Povey wrote: ‘The Galton Laboratory at UCL flourished, but the genetic clinic was not a 
major feature.’ Note on draft transcript, 2 March 2009. See pages 16–17. Clinical Genetics in Britain: Origins and development 
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whether that came about because Harry Harris succeeded Lionel Penrose, or for 
other reasons, but I’d be interested to know if people can throw light on this. 
professor marcus pembrey: May I first give a second-hand comment about 
Lionel  Penrose?  I  talked  at  length  to  Laurie  Smith  down  in  Colchester,  a 
laboratory technician (1937–85) who used to help with the genetic clinics there 
and was appointed by Lionel in 1937 at the Eastern Counties Hospital (Royal 
Eastern Counties Institution, Colchester, Essex), as part of his MRC-funded 
work on mental retardation.
32 He used to be responsible for doing the urine 
tests for the new PKU test and I specifically asked him, I remember, and he 
said that Lionel did talk to the families before the war, where the nature of the 
inheritance was understood, PKU being one. Lionel then gave up the Eastern 
Counties activity and clinic to John Fraser Roberts.
33 
The other thing about why the Galton never flourished – if by the Galton you 
mean not the Kennedy-Galton (Northwick Park and St Mark’s, London) but 
32  Professor George Fraser wrote: ‘Lionel practised clinical genetics long before he took up the Galton chair. 
Thus he exercised the same functions in advising patients, as described by his son Oliver (Penrose (1998)), 
even during the Colchester survey of 1280 cases of mental defect, which he carried out between 1931 and 
1938.’ Note on draft transcript, 10 November 2009. See note 19. 
33  See Pembrey (1987); Polani (1987) and Fraser Roberts’ biographical note on page 120. 
Figure 4: Gu Wen-xiang, professor Bette robson, Galton professor of human genetics,  
dr david Hopkinson (Hoppy), director of the mrC human biochemical genetics unit,  
and dr Joy delhanty in the staffroom of the Galton laboratory, 1981.Clinical Genetics in Britain: Origins and development 
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the Galton Laboratory at UCL – was, I think, principally because John Fraser 
Roberts, Cedric Carter and people at the Institute of Child Health had already 
established a very active clinical genetic service in that region.
34 Also, the people 
who took over from Lionel, I think Harry Harris and Bette Robson (Figure 4), in 
particular, didn’t welcome clinicians, if we put it bluntly. She said: ‘We’re proper 
doctors here’, implying that the clinicians weren’t. So I think that it was the style 
that led to it not being fought for, and there were adequate genetic services around.
Fraser:  Lionel was a great man, and that’s why he welcomed ‘proper’ (i.e. 
those with a PhD) doctors and ‘improper’ doctors (i.e. medical) to the Galton 
Laboratory. There is a great deal of biographical information available about his 
scientific activities both in human and in clinical genetics. His inaugural lecture 
as Galton professor in 1946 is very well known, and I had hoped that copies 
would be distributed to the participants at this seminar; I regret that this has 
not proved possible.
35 
Bobrow: I think that is right, but what we’re trying to dig at is the history of the 
Galton Laboratory and its contribution to clinical genetics because there is a lot 
known about Lionel’s own background.
Fraser: Then I’ll restrict myself to one sentence from his inaugural lecture. He 
was talking about phenylketonuria, and he says: ‘A sterilization programme to 
control phenylketonuria confined to the so-called Aryans would hardly have 
appealed to the recently overthrown government of Germany.’ He didn’t, in fact, 
know at that time what had happened in Germany. But this was a comment on 
the fact that phenylketonuria had not been found among Jews and Negroes.
36 
Bobrow: Extraordinary. I’m sure people will come back to get details from you.
professor John Burn: Briefly on Gerald Corney (Figure 5) with whom I worked 
for several years, who is often forgotten.
37 He was a very gentle, very wonderful 
34  See pages 21 and 26–9. 
35  Penrose (1946). Professor George Fraser wrote: ‘This lecture has been reprinted in the Annals of Human 
Genetics more than half a century after its first publication (Penrose (1998)).’ Note on draft transcript, 
28 February 2009. A copy will be deposited along with other records of this meeting in archives and 
manuscripts,  Wellcome  Library,  London,  at  GC/253  and  is  available  at  www.ncbi.nlm.nih.gov/
pubmed/9803263 (visited 8 March 2010). 
36  Professor George Fraser wrote: ‘So much wisdom condensed into a single sentence – the infallible mark 
of a truly great man. And he wrote this at a time when very little was known of the excesses of the Nazi new 
order in Europe.’ Note on draft transcript, 28 February 2009.
37  See, for example, Burn and Corney (1984); see also note 14.Clinical Genetics in Britain: Origins and development 
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doctor who did the most amazing pedigrees. He’s the only person I ever saw 
who did a separate pedigree for each side of the family in his clinic. He had a 
considerable indirect influence: he was a great mentor to me for several years, 
and to both Peter Farndon and Robin Winter.
38 Many of us would go and sit 
and chat with him for hours. I think he had quite a lot of influence on our early 
development.
professor  dian  donnai:  Before ever I got into genetics, I was training in 
paediatrics in London, and I went to Northwick Park Hospital as it first opened 
in 1970. Lionel Penrose was at Harperbury Hospital for mental defectives, 
Shenley, Hertfordshire, at that time and I remember having him as the visiting 
consultant coming to our ward.
39 I’ve still got photographs of a patient with 
Rubinstein Taybi syndrome that he saw in 1970; and a patient with tuberous 
38  See, for example, Donnai (n.d., c. 2004). Professor Robin Winter developed the London dysmorphology 
database series with Professor Michael Baraitser, distributed from the mid-1980s and then published by 
OUP in 1990, followed closely by the neurogenetics database in 1991 (see www.lmdatabases.com/ (visited 
19 January 2010); see also his biographical note on page 131.
39  See Watt (2000).
Figure 5: dr Gerald Corney and mrs nona parry-Jones, chief technician,  
Galton laboratory, c. 1981.Clinical Genetics in Britain: Origins and development 
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sclerosis. My interest in genetics as a career was probably awakened by that 
contact. He used to bring a lot of people who seemed to be middle-European, 
who took fingerprints of everybody and looked in great detail at that, and there 
was Mike Ridler, the cytogeneticist, who was a lovely man and worked with 
Lionel.
40 But I have to say that I feel very privileged to have met Lionel at the 
end of his clinical career.
Bobrow: Let’s move our way down the list. The next bullet is ‘chromosomes and 
the need for clinical genetics’. I think when this was put down, there was a hope 
that there would be a small coterie of other cytogeneticists in the room who 
would speak to it.
41 I’m going to ask Joy Delhanty whether she has anything 
to say, and if not, I’ve got about two sentences and we might make up a lot of 
time on this. 
delhanty: I think I’ve already said my bit, so you can carry on with your 
two sentences.
Bobrow: Good enough. I think the point that I would want to make is that 
the development of clinical genetics at that time, in my view, was critically 
dependent on the discovery of the chromosomal abnormalities and methods 
for diagnosing them, because that, I think, gave a clinical need to see patients 
who were outside of the specialties of other major medical groupings. This was 
the territory that genetics then stamped out for itself: interpreting laboratory 
results, some of which were rather complex, and even pretty good paediatricians 
– they were all paediatric at that time – found it relatively hard to get to grips 
with the technology quickly. I think that theme has continued and expanded as 
the laboratory components of genetics, about which we are not to speak today, 
have become more and more complex.
42 The clinical geneticists have, in general, 
come to be an interface between the real world and laboratory results in a way 
that, so far, has required skilled interpretation. So each of the major centres at 
which clinical genetics developed and spread is associated with significant early 
contributors to the development of laboratory techniques. The two are, I think, 
absolutely interwoven. We’ve already heard about that for the Galton, but the 
40    Dr  Michael  Ridler  was  head  of  the  Kennedy-Galton  cytogenetics  laboratory  and  co-chair  of 
the  Association  of  Clinical  Cytogeneticists  (ACC)  with  Dr  Maggie  Fitchett.  See,  for  example,   
Mutton et al. (1996).
41  For a history of cytogenetics and medical genetics, see Ferguson-Smith (2008). 
42  For the annotated and edited transcript of the 2001 meeting on genetic testing, see Christie and 
Tansey (eds) (2003). Clinical Genetics in Britain: Origins and development 
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same will, I think, be true for all of the other major centres. The labs and the 
clinics grew up together, tightly interwoven. 
mittwoch: Chromosome studies themselves were preceded by the discovery of 
sex chromatin bodies, and sex chromatin that is present in females and not in 
males. That gave rise to the discovery that patients with Klinefelter syndrome 
had the Barr body and therefore might have been females, and conversely 
patients with Turner syndrome lacked the Barr body. So, when chromosome 
techniques became available, they were the patients that were singled out for 
chromosome investigations.
43
Harper: I suppose I’d better justify why I put this down in the first place. 
It’s exactly what Martin Bobrow has said, that somehow there was interplay 
between the laboratory and the clinical side, and the two together were the main 
stimulus for clinical genetics developing from being something very small-scale 
to something much larger. I think it’s worth remembering a quotation from 
Victor McKusick: ‘Until the advent of clinical cytogenetics, our specialty was 
not yet born. We were dependent, like the fetus, but clinical cytogenetics gave 
us our own organ.’ Actually, about six months ago, I quoted this in my book, 
and I thought I’d better find the source.
44 I couldn’t find it anywhere, so I wrote 
to Victor saying, ‘Where did you actually say this? It must be in one of your 
reviews,’ knowing Victor, with his encyclopaedic memory, would definitely be 
able to find it. He wrote back to say that actually, he couldn’t quite remember 
either, but I’m sure he did say it – maybe somebody can pinpoint that? 
What Ursula has said reminded me of a fascinating experience I had a couple 
of years ago now, in recording an interview with Mike Bertram, who discovered 
the sex chromatin body with Murray Barr. He is now in his eighties, living 
in Toronto, Canada, and gave a vivid account of this discovery, as if it might 
have been yesterday. A blow-by-blow account, and you know, that was in 1948, 
published in 1949, but it’s amazingly vivid.
45 
dr alan Johnston: If I could throw a little light on Peter’s problem, because in 
1960 I had just come back from spending over a year with Victor McKusick. 
I was full of enthusiasm, but there was no funding for clinical work by the 
43  Jacobs and Strong (1959); Ford et al. (1959a and b).
44  Harper (2008): 282. See note 47.
45  Barr and Bertram (1949). See Professor Peter Harper’s interview with Ewart Bertram on ‘Interviews with 
Pioneers of Human Cytogenetics’, track two at www.genmedhist.info/Interviews/ (visited 26 January 2010).Clinical Genetics in Britain: Origins and development 
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authorities for me to become a clinical geneticist at UCH. I was told to go back 
to work as a senior medical registrar, which is what I did, and continued to do 
so until the end of my working life. There was definitely a financial element: 
laboratory work could be funded but not clinical work.
pembrey:  I  would  like  to  disagree  a  little  with  the  complete  emphasis  on 
the cytogenetics and the origin of clinical genetics thereafter. I think there 
is another point to make regarding the province of clinical geneticists, not 
just in interpreting genetic-related tests, but pedigree analysis. And I think 
that the origins of the clinic at Great Ormond Street in 1946 by John Fraser 
Roberts and so on, first were based on pedigree analysis and then empirical risk 
figures.
46 He already had those for mental retardation at various levels from his 
work in Bristol, and with Cedric Carter this was then extended to congenital 
abnormalities of various sorts. So that was all occurring before the chromosomal 
abnormalities. So there was a need and pedigree analysis is still one of the things 
that is particularly the province of the clinical geneticist. 
Bobrow: Point well taken. Should we move on to the Oxford unit and Alan 
Stevenson? 
dr Clare davison: I’d like to tell you a bit about the background to this. Alan 
Stevenson was a professor of social and preventive medicine at the Queen’s 
University Belfast in Northern Ireland, and I well remember as a student having 
these very peculiar lectures on genetics. We all thought them rather peculiar but 
we had to put up with it if we were to get that pass as part of our final exams. 
He was, at that time, very interested in looking at populations and population 
studies, and Northern Ireland in those days was a very captive area. All he had 
to do was to write to the clergy and say, ‘I wish to carry out a study on such 
and such’ and it would be announced at church and not a single member who 
went to church would refuse to take part in the study. A very good one was on 
myotonic dystrophy.
47 He then was appointed director of the MRC population 
46  Mrs Margaret Fraser Roberts wrote: ‘It was 1946 when Sir Wilfred Sheldon, senior consultant paediatrician 
at the Hospital for Sick Children, Great Ormond Street, London, invited my husband to provide a clinic 
for genetic advice there.’ Letter to Mrs Lois Reynolds, 18 March 2010. Professor Paul Polani’s obituary of 
Dr John Fraser Roberts stated that ‘in 1946, he established a genetic counselling clinic at the Hospital for 
Sick Children, Great Ormond Street, London (and later at the Children’s Hospital, Bristol), the first ever 
organized clinic in Britain and Europe and the third in the world (the others being the Heredity Clinic, 
University of Michigan, and Dight Institute, University of Minnesota). In the same year he was appointed 
lecturer in medical genetics at the London School of Hygiene and Tropical Medicine.’ Polani (1987): 309. 
47  Stevenson (1953).Clinical Genetics in Britain: Origins and development 
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genetics research unit in Oxford in 1958, and he was the only director there until 
his retirement in 1974. At the beginning there was a cytogenetics laboratory set 
up under Marco Fraccaro and the other medics at that time included George 
Fraser, of whom you’ve already heard, and John Edwards. Around that time 
the WHO did a worldwide study of congenital malformations under Alan’s 
auspices. It was a great big, thick book, published in 1966.
48 
As well as the cytogenetics laboratory, there were two invaluable health visitors 
appointed  then  too.  And,  horror  of  horrors,  there  were  Saturday  morning 
clinics in the outlying hospitals and patients were also seen in local hospitals. 
The  reason  that  they  were  Saturday  morning  clinics  was  that  nobody  else 
would have a clinic on a Saturday morning. I know a little bit more about what 
happened from 1962 because that’s when a lot of us joined the unit. I could 
give you a list of some of the names of the people who worked at that unit from 
1962 onwards, all those who were on the staff, whether they were MRC staff or 
whether they were visiting fellows from here, there, and everywhere – we’d lots 
of them – all set up departments, either clinical departments under the NHS or 
whatever the equivalent was in their own countries, or university departments. 
Some of them unfortunately are deceased: Charles Kerr, R S Wells, familiarly 
known as Charles, who was a dermatologist who came up to St John’s here; 
I was there, Ian Shine, Martin Bobrow, Dick Lindenbaum, Derek Roberts, 
Denis Bartlett, Peter Pearson and Norman Nevin. My apologies to anyone   
I’ve forgotten. 
I would like to mention some of the population work that Alan Stevenson was 
particularly interested in – he got his staff to do the work. His name may have 
gone on that paper at the end, but he made certain we did most of the work. 
One of the studies that I’d particularly like to mention was Charles Kerr’s work 
on X-linked conditions in Oxford.
49 Charles was given the happy job of finding 
out in which families there were two or more males affected with something. 
He did his DPhil on that and, because he discovered that there were a whole 
lot of families with males with severe mental retardation, as it was known in 
those days, Charles went back to Sydney and he got Gillian Turner to do such a 
study,
50 whereas I did my MD on that in Oxford. 
48  Stevenson et al. (1966).
49  Kerr (1968).
50  Turner et al. (1970).Clinical Genetics in Britain: Origins and development 
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Another was Charles Wells’s work as a dermatologist, using ichthyosis, one of 
the first papers with the delineation of the genetics, histology, clinical features 
etc. Charles enabled clinicians to assign the mode of inheritance based on the 
different clinical features of ichthyosis, and he was able to say, ‘Ah yes, this is the 
mode of inheritance of the different types of ichthyosis’.
51 
I forgot to mention, and I think I’m right in saying, I can see that people were kind 
enough to say it was the first book – I don’t know whether it was, Peter Harper is 
nodding in agreement – on genetic counselling. I looked at it the other day and I 
was horrified to find just how cheap it was. No wonder people were able to buy it 
and put it in their pockets and take it to clinics. It was published in 1970 by Alan 
and me.
52 We did another edition in 1976 and then, of course, there was Peter 
Harper’s book, Practical Genetic Counselling, afterwards.
53 At that time, when I 
was in Oxford, we had population studies, Mendelian inheritance, empiric risks, 
and what I think is vital to all geneticists: intuition, because we frequently saw 
families where things occurred more than once, and what was very interesting 
was that a lot of those guesses, which were intuition, were subsequently proved 
correct by studies carried out by others. Alan did a lot for quite a lot of us, and 
the cytogenetics lab was set up with the main reason that we could persuade the 
doctors to let us see their patients. It was tit for tat: they referred patients to us 
and we saw the patients and did chromosome studies for them.
Bobrow:  My  recollection,  subject  to  correction  from  people  with  better 
memories or bits of paper, is that the other name associated with that unit – the 
one you left out – is Jim Renwick, who I think never worked there. He signed 
up and was on staff for quite a long time, but didn’t take up his appointment 
and took another job before he ever got around to starting. Still – interesting. 
Two other comments about that unit where I spent my early years as well. One 
of the things that we had was a jolly good library and Alan was fanatical about 
getting every journal that one could conceivably get, saying that whatever needed 
to be read was there to be read on site. Secondly, he was extremely good at 
ensuring that everyone had a place in which they all had coffee together, and that 
kept the clinical staff of the doctors and the nurses and the lab staff all in touch 
with one another in a very convivial atmosphere, occasionally punctuated by a 
very aggressive atmosphere, but at least there was always an atmosphere that we 
51  Wells and Kerr (1965).
52  Stevenson et al. (1970).
53  Harper (1981, 2004). Clinical Genetics in Britain: Origins and development 
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were sharing. It was an interesting experience. That was an MRC unit built in the 
grounds of a hospital trying to interface with the 1970s NHS.
54 I suspect that it 
was a bit of a laboratory for both the MRC and the NHS. It wasn’t unique, there 
were other places like that, but it was an interesting breeding ground for trying to 
work out how the interface between research, genetic service and clinical practice 
would work. There were health visitors working there from my earliest memory, 
which would be early 1960s, 1963, I think, or 1964. 
Fraser: They were there in 1961.
Bobrow: They were there in 1961, so they weren’t genetic counsellors, not only 
in name. I think – and we can get into this later – there were some differences 
in the way people were treated, but the concepts and the origins were there 
from a very early stage, there and elsewhere. The unit was closed by the MRC 
when Stevenson retired in 1974 and the people who were there, largely stayed. 
They largely stayed, with one or two exceptions. They stayed as either NHS or 
university employees. 
Harper: Martin, you mentioned the library; you may be interested to know that 
about four years ago now I received a rather plaintive phone call from someone 
in the Oxford unit to say that there was no space to keep books any more so 
they were all going to be disposed of. This was actually the origin of our current 
Human Genetics Historical Library at Cardiff because I went over with my 
fairly capacious car and returned with around 300 books. It was only when I 
got back that I realized that many of them went right back into the 1950s and 
1960s and had originated from the Stevenson time, and so I think the Oxford 
people and I were all very happy that this collection has now been preserved. 
That library’s catalogues are available on the internet and so you can see exactly 
what it consisted of.
55 
Might  I  be  allowed  a  question  for  Clare  Davison? You’re  absolutely  right, 
Clare, yours was the first book on genetic counselling from the UK, although 
we mustn’t forget Sheldon Reed’s from the US.
56 But I’m always intrigued to 
know about the origins of the chapter in it on Bayesian risks, which I’d been 
54  Harper and Pierce (2010).
55  The Human Genetics Historical Library was established in 2002 at the Institute of Medical Genetics, 
Cardiff University, supported by funding from the Wellcome Trust, and is now part of Cardiff University’s 
special collections and had over 3000 volumes in 2010. See www.genmedhist.info/HumanHistLib/ (visited 
29 April 2009).
56  Reed (1955).Clinical Genetics in Britain: Origins and development 
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brought up with in Baltimore from Tony Murphy.
57 Was this something that 
Alan Stevenson or you derived, so to speak, de novo, or did you get it mainly 
from reading Tony Murphy’s papers on Bayesian risk estimates?
davison: Alan did most of that. I remember Alan doing the risks and he asked 
round the rest of us whether we agreed or not. We also had a statistician on the 
staff at that time and he was sourced to vet it. Actually, there are two different 
ways of working out the risks: there’s the way that you did it and the way that 
Alan did it. And if you actually do the same thing twice, one way and then 
the other, the risks come out the same. I’m not sure that it was all that easy for 
people to understand. Most of the doctors that I met said, ‘We skip that out; 
we go to the other more interesting chapters.’ Martin Bobrow will probably put 
me right on that.
Bobrow: No, I can’t actually. I certainly know that Alan was doing Bayesian 
calculations and that he loved them. He showed me how to do them, and I have 
to say I didn’t love them that much. But I don’t know whether he worked it out 
for himself or read it in one of his books.
57  See, for example, Murphy and Mutalik (1969); Bayes (1763).
Figure 6: dr John Fraser roberts at the time of his election as a  
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davison: I think before he came to Queen’s University, Belfast, he worked for 
some time under the auspices of R A Fisher.
58 I may be wrong on that, but he 
certainly worked for someone in this.
Bobrow: There’s no question that he was highly numerate; he was a public 
health epidemiologist by training. He didn’t have trouble with statistics. What 
I don’t know is whether he took the idea of Bayesian risk calculations from 
Murphy or not, but he did them, undoubtedly, in vast quantities. Let’s move 
on to John Fraser Roberts (Figure 6), Cedric Carter (Figure 7) and the Institute 
of Child Health.
pembrey: I’m delighted to have Margaret Fraser Roberts next to me and I’m 
sure she can fill in some of the details. I knew John Fraser Roberts well because 
I spent a decade, many days a week, going through editions of his book, a first 
edition of which I have here, the Introduction to Medical Genetics, 1940.
59 This 
in fact is quite interesting – the archivists might be interested: John’s book, in 
which he pencilled in all the changes he was going to make for the 1959 edition, 
which was the second edition. There was a lot in this book that actually spelled 
out pedigree analysis in particular and the tools of the clinical geneticist. But 
it wasn’t until the 1959 edition that there was an actual section on the clinic, 
talking to patients and so on. But I think it’s well known, and Margaret can 
fill in the details here, that while he was working at the London School of 
Hygiene and Tropical Medicine he was asked to start a genetic clinic at Great 
Ormond Street in 1946 and he did so.
60 Fairly soon afterwards, certainly by the 
late 1940s, he was joined by Cedric Carter, who was a research fellow there, 
focusing on congenital malformations. That clinic continued and then in 1957 
John Fraser Roberts moved with his team to the Institute of Child Health at 
UCL to become the first director of the new MRC unit for clinical genetics 
58  See, for example, Stevenson (1954). Dr Clare Davison wrote: ‘I think it might have been Bradford Hill 
(1897–1991) rather than R A Fisher (1890–1962), but I am not certain.’ Note on draft transcript, 13 
February 2009. No mention was made in the Royal Society biographical note of either. 
59  Fraser Roberts (1940). See his biographical note on page 120.
60  Great Ormond Street Hospital had a tradition in this field. Mr Nick Baldwin, GOS archivist, wrote: ‘Sir 
Archibald Garrod (1857–1936), generally considered to be the founder of modern genetics research, was a 
senior physician at Great Ormond Street. We have 29 volumes of his patient casenotes from 1899–1913. 
Among other things, these contain the first recorded case of alkaptonuria in 1904, and there may well be 
other “firsts”. The volumes under 100 years old still have restricted access to external researchers on data 
protection grounds, but the others are open to bona fide researchers.’ E-mail to Mrs Lois Reynolds, 10 
March 2010. See also notes 4 and 46.Clinical Genetics in Britain: Origins and development 
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there.
61 Margaret will, I think, enlarge on something that’s interested me about 
clinical genetics: the origin of the sort of weekly meeting, or the way in which 
the information was gathered in advance of going to the clinic. And also the 
generation of separate genetic notes, which is something we’ve retained. I know 
in my time we were struggling to maintain that separateness, because we saw 
not just one person but the whole family. The notes go back, I think, to the 
practice at Great Ormond Street and the Institute of Child Health in the late 
1940s and 1950s. 
The research into the genetic counselling, fairly directly, was first instigated 
by John Fraser Roberts and then Cedric Carter, establishing the consecutive 
case series from Great Ormond Street, where they looked at recurrent risks 
by diagnosis. That gradually became the basis on which they gave genetic 
counselling to families where there wasn’t a clear inheritance pattern. John 
moved to Guy’s Hospital, London, in 1964, and the thing that I particularly 
remember about his period there, apart from collaborating on the book and 
getting to know him very well, was his evidence-based medicine, as it would 
now be called. He was funded to do follow-up studies by the MRC. And so 
there were a series of follow-up studies, the results from which were published, 
in which he found out what the families did after coming for genetic counselling 
and relating it to what they were told.
62 Now Cedric carried on or cooperated 
in those studies, and in fact, interestingly, it was a result of those follow-up 
investigations about what people actually did in relation to what they were 
told at the clinic, that I remember and quite definitely changed Cedric’s way 
of counselling.
63 I remember him telling me, and I remember discussing with 
Martin Bobrow and Michael Baraitser, that he became concerned that the way 
the counselling had been done in the past was putting too many people off 
having babies and so he tempered it with a qualifying phrase: ‘We regard this as 
a very low risk’ or something like that. This actually came from the follow-up.
John came from Stoke Park Hospital, Bristol, so he maintained his outlying clinic 
there and also he took over from Lionel Penrose at Colchester. So certainly John 
was doing at least those two regular outlying clinics from London and I think 
there were others for a short time in Plymouth and Taunton, and one or two 
others. As far as I know, but I don’t have this very firmly, Cedric Carter didn’t 
61  Pembrey (1987). See also page 21 and note 46.
62  See, for example, Carter et al. (1971).
63  See, for example, Dennis et al. (1976). Clinical Genetics in Britain: Origins and development 
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do many outlying clinics. I may be wrong, but what I can glean from talking 
to people is that Cedric was basically based at the Institute of Child Health 
and used to do clinics at Great Ormond Street and the National Hospital for 
Nervous Diseases, Queen Square, London.
I’ve been interested in the fact that John would tell me quite often that he only 
qualified in medicine in order to study humans, to do medical genetics, and the 
day he qualified he hung up his stethoscope. I can remember him saying that 
repeatedly. He therefore made it quite clear that he wasn’t going to be diagnosing 
patients and that he gathered together good evidence of the diagnosis and said 
that clinical genetics always had to be practised in a place where you could get 
expert diagnostic skills. I wondered whether that might have been the origin of 
this tradition, at least at Great Ormond Street, of the weekly meeting at which 
everything was gathered together. But I do think that at least in Great Ormond 
Street, the origin lies much more with Margaret Fraser Roberts and the way she 
wrote out a format for the clinic for visiting doctors to follow. I leave that for 
Margaret to say. 
With regard to the assistance of the genetic counsellors or others, fairly early on 
in the 1950s, Kathleen (Kath) Evans, who was an almoner at Great Ormond 
Figure 7: l to r: mrs Kathleen evans, dr nick dennis and  
professor Cedric Carter, 1981.Clinical Genetics in Britain: Origins and development 
29
Street Hospital
64 when Cedric was setting up things there with John Fraser 
Roberts, volunteered to go into the genetics side. So, that was from the social 
work area, and she gradually took on a role preparing information before the 
clinic and then talking to the families before they went to see Cedric, and quite 
often, because of Cedric’s rather perfunctory style, talking to them afterwards 
as well. I think Kath teamed up with someone named Anne, from Victor 
McKusick’s outfit, who used to come over from Johns Hopkins. 
Cedric carried on this style of clinical, empirical risk figures, meticulous family 
studies with the assistance of family visiting personnel, health visitors or people 
with social work backgrounds at the clinic at Great Ormond Street. But he did 
a lot to encourage the formal recognition of clinical genetics as a specialty, and 
I remember as clear as day, the day clinical genetics was on the Department of 
Health’s list of clinical specialties. I think it was 1980. And he came through from 
his room into the library, waving it, saying: ‘We’re in! We’re in!’ (or something 
along those lines). So he was very keen to get clinical genetics recognized. And 
of course he was instrumental, along with Dr Sarah Bundey and others, in 
setting up the Clinical Genetics Society.
65
mrs margaret Fraser roberts: Marcus Pembrey very kindly referred to a bit of 
help that I used to produce before my husband’s clinics for genetic advice. He 
only needed brief details of a case. I used to produce notes for him so he knew 
what sort of conditions were coming up, in case he wanted to look anything 
up beforehand. At Great Ormond Street Hospital and at Guy’s Hospital in 
particular, he started having visiting doctors from other countries. Very often 
there was a language problem, so I just expanded my bare-bones notes a bit so 
that there was a little précis about each family or patient who was going to be 
seen, and that seems to have gone down quite well, I think.
dr nick dennis: I joined Cedric Carter as what I think was probably the first 
registrar in clinical genetics in the country in 1972 and stayed until 1976. It 
was an MRC unit, as has been said, headed by Cedric. As well as Kath Evans, 
there were people like Jean Heath, Becky Coffey and later, Joan Warren. They 
were primarily employed for research purposes, because the main function of 
this unit was research. They all went out and gathered family data on whatever 
abnormality was being studied. So, the clinic was run rather as a sideline and 
it’s true that Kath Evans did attend those clinics, but coming in as registrar, 
64  An almoner is a medical social worker. See Baraclough (1996); Bell (1961); see also pages 30 and 71.
65  See note 7; see also Burn (1983).Clinical Genetics in Britain: Origins and development 
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my main job was to look at all the referral letters that came in and do the 
background reading so I knew what cases were coming to the clinic. But I don’t 
ever remember sitting down with Cedric before the clinic and having any sort of 
meeting to discuss what was going to be said. In three-and-a-half years I think 
I probably sat down and spoke to a family less than six times, so my training 
was very much as a fly on the wall. The reading round was very helpful, but 
I had no real hands-on experience. There was a weekly clinic, which I think 
was on Thursday afternoons, and there would be a list of eight families. So 
they were given about 20 minutes each and Kath Evans and I would sit in and 
occasionally there would be another visitor sitting in. Cedric was fairly brief, 
but very focused. I only remember perhaps three or four times that Kath Evans 
had to rush out and comfort somebody in the corridor because they were visibly 
upset. So although her presence there was comforting, she didn’t have a formal 
role, as far as I can remember, either seeing people before or after the clinic. 
Other points worth mentioning: in this unit of perhaps a dozen or 15 people, 
there was also Joan Slack, who had a rather separate existence running a lipid 
research laboratory carrying out population studies and she was collaborating 
with Northwick Park at the time.
66 Everybody got together for tea and coffee 
at ten o’clock in the morning and three o’clock in the afternoon for ten or 15 
minutes and that was a three-line whip; you didn’t miss that. I found it very 
helpful. Everybody would down tools for ten or 15 minutes, and go to the library 
to talk. Michael Baraitser turned up about half way through my time there. He’d 
come over from South Africa where he was a neurologist and he’d developed a 
neurogenetics interest and I think he took off some of the Huntington’s disease 
families to see at Queen Square. The main sort of case mix was the congenital 
malformations, where Cedric was very much on his home territory, giving an 
empirical recurrence risk. Then what we later started calling ‘query syndrome’ 
cases. I remember those as being pretty much a snap judgement on Cedric’s part 
without a very prolonged clinical examination. Then came the chromosomal 
abnormalities and then Huntington’s disease.
67 Anne Child was there before me, 
so perhaps I wasn’t the first registrar. I think Cedric regarded her as his registrar 
as well, and I was succeeded by Anita Harding and then John Burn. 
Burn: I was the last clinical scientific officer – I think that was my official 
title – before Carter retired. And it’s worth pointing out the distinction 
66  See for example, Slack et al. (1977); see also Reynolds and Tansey (eds) (2006): 28–30.
67  See discussion on page 76. Clinical Genetics in Britain: Origins and development 
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between  genetic  consultation  and  counselling.  Cedric  wasn’t  a  genetic 
counsellor; he did genetic consultation. I always tell people in Newcastle 
that he only gave them 12 minutes, whether they needed it or not. But 
the point was that he didn’t see it as his job to explain in detail. He would 
give his opinion and then write to their doctors and it wasn’t in any sense 
that he wasn’t being a good doctor, he just didn’t have very much time. His 
perception was that he should give his expert opinion and then pass it back 
to the patients’ own doctors. So I think that was, in a sense, a distinction 
from what we now perceive to be our task, explaining it in words of one 
syllable to the doctor and to the patients.
Bobrow: That’s a very interesting distinction. I wonder what was going on 
elsewhere. My training was to be told to do the Swindon clinic one Saturday 
morning a month and I got a bunch of notes, and I read what I could, I got on 
my motorbike – I had a wonderful red Honda four-cylinder bike at the time 
– and I went to Swindon once a month and saw people. Bear in mind that I 
had never studied genetics or anything much else – I was a junior registrar in 
surgery before I made this lateral move. Then I rode back to Oxford and tried 
to sort out the mess afterwards. Alan Stevenson was always available if there 
was something I wanted to talk about, but usually I would start with Clare 
Davison and progress to him if the need arose, and he would spend as much 
time as it took to talk through individual cases. But there was no question 
of structured training at all in that sense. I would say that we were definitely 
groping our way in terms of counselling. We saw our job as trying to ensure 
that the patient understood the diagnosis so that they could explain it to   
the doctor. 
mrs lauren Kerzin-storrar: I want to add something to Marcus Pembrey’s 
comments about the follow-up studies that were done to see what reproductive 
choices patients made after attending genetic counselling clinics. I think that 
the discrepancy between what the risk figures might predict about behaviour 
and what families actually chose to do led Cedric Carter to engage a psychiatrist 
called John Pearn. Nick (Dennis), was that when you were at Great Ormond 
Street? Is it right that John Pearn was a psychiatrist?
dennis: I think he was a paediatrician – he did the work on spinal muscular 
atrophy (SMA), didn’t he?
68
68  See, for example, Pearn (1973b); Pearn et al. (1978). Clinical Genetics in Britain: Origins and development 
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Kerzin-storrar: I didn’t know that, but he wrote a seminal paper on psychological 
mechanisms influencing interpretation of risk that is regarded as salient today.
69 
I understood that that study initially came out of an interest in understanding 
why patients weren’t doing what the doctors thought they were telling them to 
do and therefore was the first step, perhaps, towards developing a non-directive 
ethos in genetic counselling practice. 
pembrey: Yes, I can confirm that John Pearn was involved. In fact, I remember 
taking him off to the Long Lane antique market (Bermondsey, London) very 
early one morning, because that was one of his interests as well. And I think 
that’s probably right, the paper came out of that discussion.
Harper: A point about Cedric Carter and eugenics: Cedric was, I think it’s 
fair to say, one of very few and possibly the only practising clinical geneticist 
who had quite strong eugenic inclinations, at least in recent years. People may 
disagree, but I think it’s fair to say that most of us felt distinctly uneasy about 
that. But Cedric didn’t bring eugenics into his regular practice; he had these 
views, and I think most of us realized he did have them, and most of us, I think, 
agreed to differ on it. Is that a fair perception?
dennis: Well, I remember Cedric saying once that there was an article he was 
going to write for The Times, but he’d have to have been retired before he wrote 
it – I’m not sure it ever appeared. But Cedric regarded himself as a ‘positive 
eugenicist’; he was interested in increasing the intelligence of the population, 
so he thought all of the more intelligent people should have a lot of children. 
He had seven.
70 He once asked me how many children I had, and I said: ‘Two.’ 
He looked a bit thoughtful and said: ‘Hmm, I think you should have another.’ 
Bobrow: That’s nice: he thought well of you. 
dennis: He certainly never tried to discourage people in the clinic from having 
children. He was very non-directive, I always felt. Another thing I would like 
to say about him personally is that although he wasn’t a very talkative character 
– he was always rather terse – his door was always open and you never felt any 
sort of bar to going in and sitting down with him and he would always give you 
as much of his time as you needed. 
69  Pearn (1973a).
70  Dr Nick Dennis wrote: ‘He thought that if contraception was readily available, the less intelligent would 
voluntarily curtail their own fertility. He did not believe in any form of coercion or overt discouragement.’ 
Note on draft transcript, 15 February 2009. Clinical Genetics in Britain: Origins and development 
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Fraser: In this connection there is a paper written by Cedric Carter and a 
gentleman called Kenneth Hutton, who taught me chemistry at Winchester 
College in the late 1940s.
71 They were both scholars at Winchester College and I 
71  Professor George Fraser wrote: ‘The paper was read at a meeting of the Eugenics Society on 18 November 
1952, at a time when Cedric Carter was secretary. His influence was acknowledged in the publication as 
follows: “A large number of other friends and colleagues have assisted…and I should like to thank them 
all very much, but most especially our secretary, Dr Cedric Carter, who has provided the driving force 
and encouragement necessary to get this paper produced.’’ (Hutton (1953): 215). As stated, both Cedric 
Carter and Kenneth Hutton had been scholars of Winchester College, a group characterized in the paper 
as “an extremely intelligent section of the community (page 215)…exceedingly few of them not being in 
the top 1 per cent of the population, with respect to Cattell IQ (above 160 or 170).” (Hutton (1953): 
207). The importance of the inquiry was stated as follows: “It appears probable that the intelligence of the 
nation is declining but there is little or no direct evidence in this country of how many children people 
of high intelligence have.…Here in ex-pupils of Winchester College I have a sample of high intelligence 
and I have found out how many children they have.” (Hutton (1953): 205). The number of the other 
scholars’ children was slightly lower than the number of children born to males in the general population. 
Nevertheless, the paper ended on an upbeat note: “The most encouraging sign is that among the scholars – 
who cover a 20-year range – there is evidence of a steady increase in family size so that it may be expected 
that the 1921–25 group, (i.e. those born in 1908–13) will have not merely more children than the average 
of the population but even just enough for replacement.” (Hutton (1953): 215).’ Selection from a note on 
draft transcript, 19 September 2009; e-mail to Mrs Lois Reynolds, 2 March 2010. The complete version 
will be deposited along with other records of the meeting in archives and manuscripts, Wellcome Library, 
London, at GC/253.
Figure 8: professor paul polani in Cameron House, Guy’s Hospital, initial  
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don’t know where this paper was published, it may be in the Winchester College 
magazine. They were very enthusiastic about counting the number of children 
the scholars of Winchester had, and obviously they were keen that they should 
have as many as possible. As you say, Cedric Carter had seven; Kenneth Hutton 
had four. I’m not sure that the other scholars kept up with them.
72
Bobrow: Should we move down our agenda to Guy’s? I’ll ask Caroline Berry to 
begin. 
dr Caroline Berry: Paul Polani was the leading spirit at Guy’s and he was a real 
polymath.
73 If it hadn’t been for the Second World War, I think he’d have been a 
neurologist and stayed in Italy. As it was, he joined the British merchant navy, he 
was interned in the Isle of Man and spent the rest of the war as a surgeon in the 
Blitz at the Evelina Children’s Hospital.
74 Then, in 1948 he was for some reason 
persuaded to become a physician and he became a quite a leading paediatrician 
at Guy’s. But he was interested in the origins of children’s conditions. He used 
to work with the children’s cardiologist Maurice Campbell,
75 and they noted, 
I suspect it was Polani who noted, that the girls with Turner syndrome had 
coarctation (narrowing of the aorta), but coarctation was a condition that was 
more common in males. Therefore they questioned whether Turner’s was some 
kind of pseudosexual anomaly. Then, of course, came the finding of the Barr 
bodies, which confirmed the suspicion, and then chromosome analysis.
76 So, he 
led straight from paediatrics into genetics because it seemed to show the origins 
of the disorders. 
Polani’s curiosity and enthusiasms were in a way rewarded because in 1960 
what was then called the Spastics Society (Scope since 1994) endowed the 
Prince Philip chair of paediatric research at Guy’s. They must have put a lot 
of money into the paediatric research unit, which was housed in a warehouse 
at the back of Guy’s. Polani became its director and this gave him full rein to 
72  See also Carter (1956, 1966). 
73  See Harper (2007); see also Christie and Tansey (eds) (2003): 6–12, 15–20, 26, 50, 100; Figure 8. 
74  The Evelina Hospital, London, founded by Baron Ferdinand de Rothschild in 1869 in memory of 
his wife who died in childbirth, was amalgamated with the children’s unit at Guy’s Hospital in 1947 and 
moved into a new building at St Thomas’ Hospital in 2005. See www.guysandstthomas.nhs.uk/services/
managednetworks/childrens/evelina/about/history.aspx (visited 13 January 2010).
75  Silverman (2003).
76  Polani et al. (1954, 1956); Ford et al. (1959b).Clinical Genetics in Britain: Origins and development 
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pursue his research interests. There were chromosome labs, others where he had 
Philip Benson doing biochemistry and Mary Seller doing embryology. He had 
a brilliant library so that people didn’t waste time going to the Guy’s library. 
Then, when John Fraser Roberts left Great Ormond Street, Polani inveigled 
him to join so that there was also a clinical aspect. 
Polani was an excellent paediatrician and he continued to see children mostly 
– he was an early syndromologist and he was very skilled. If I’m allowed one 
anecdote: I remember being rather shocked when we were seeing a family where 
there were two children with heart disease, one of whom had died, and he said 
to the mother: ‘Would you remove your clothes?’ She duly did, and she was 
covered in lentigines, freckle-like spots. Polani had noticed that she was a little 
deaf, and this was an early family with what we used to call Leopard syndrome 
(now called multiple lentigines syndrome).
77 
However, what happened then was that the prenatal diagnosis scene burst upon 
us. At Lewisham they were doing amniocentesis for Rhesus, so the Guy’s cyto lab 
got the samples and found it could karyotype amniotic fluid cells, and therefore 
prenatal diagnosis became possible.
78 Not long afterwards David Brock found 
alpha-fetoprotein (AFP). I can remember sitting at the kitchen table reading 
the exciting paper and thinking: ‘Wow, if this is something, this is big news.’
79 
Then, just down the road we had Stuart Campbell using ultrasound to see 
fetuses in utero.
80 This was all burgeoning and becoming more clinical than 
Polani wanted, so he took on board, first of all, Jack Donald Singer, and then 
I joined the team and, quite unlike Nick Dennis, I was funded to see patients 
from the word go. Although Polani continued to see the difficult paediatric 
cases in the clinic, a big clinic developed. We did a lot of prenatal work, a kind 
of overflow from the John Fraser Roberts clinic. Again, all this was on soft 
research money; I was a research assistant. There was no NHS money and there 
77  Lassonde et al. (1970); Blieden et al. (1981); Shamsadini et al. (1999).
78  Santesson et al. (1969); Christie and Tansey (eds) (2003): 16–19. See also Medical Research Council, 
Working  Party  on  Amniocentesis  (1978).  Dr  Caroline  Berry  wrote:  ‘Rhesus  sensitization  was  being 
monitored by amniocentesis by the late 1960s, so I expect this was when it started at Lewisham. Sadly the 
obstetrician responsible, Mary Anderson, died a few years ago. The first chromosomal diagnosis on amniotic 
fluid done at Guy’s was in 1972, and they would have needed at least a year to develop the technique.’ 
E-mail to Mrs Lois Reynolds, 1 March 2010.
79  Brock and Sutcliffe (1972).
80  Tansey and Christie (eds) (2000): 30, 43–4, 54–5; see also Campbell and Kohorn (1968).Clinical Genetics in Britain: Origins and development 
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was a constant struggle to get clinical recognition. So, that was how it all started 
at Guy’s.
81 
Bobrow: Who else remembers Guy’s at that time? I went to Guy’s in 1983 – 
that’s so recent it’s not history! 
Harper: Might I ask Caroline Berry a question? At what point did the regional 
development of clinical genetics services start to happen? Because I always see 
Guy’s, perhaps along with Manchester, as having pioneered the concept of 
covering the whole region, rather than just thinking in terms of one central 
focus.
Berry: I think it must have been about 1978. I remember going with Paul Polani 
to the NHS regional offices in Croydon and talking to them there to persuade 
them. It was interesting because an evening television programme at that time 
ran a feature on prenatal diagnosis, which was very exciting. I was there and was 
interviewed on that programme and the chap we saw at the Croydon office had 
seen it and obviously realized that this was not going to go away. So, something 
probably came out of that in the late 1970s. 
pembrey: Actually, the origins of the regional side at Guy’s came from a research 
study that was aiming to identify all trisomies in the south-east region.
82 In fact, 
the nurse appointed to do the family visits and take blood was Dottie Garrett 
and that began in the 1960s. So, it was on the back of that research project that 
all the regional links were established and the flow of clinical samples started. I 
think that is probably why it was seen as very early in terms of being organized 
regionally. That was in the 1960s and 1970s.
davison: Surely Oxford was one of the first ones for this, because in 1974 the 
NHS took over the MRC unit, and at the same time in Cambridge, under the 
East Anglian regional health authority, genetics and cytogenetics laboratories 
were established, as were clinics, in three of the district hospitals.
83
Bobrow: Well, they are two separate things. When were regional clinics being 
done? It was organized on a hub-and-spoke basis and Oxford was certainly 
81  Polani et al. (1979). 
82  The paediatric research unit was established at Guy’s Hospital, London, in 1960, the Supraregional 
Laboratory for Tissue Enzymes in 1973 and the South-east Thames regional genetics centre in the unit in 
1976 (Polani et al. (1979)). See Hamerton et al. (1965); see also Polani et al. (1960). 
83  Dr Clare Davison wrote: ‘Peterborough, Norwich and Ipswich district hosptials.’ Note on draft transcript, 
27 February 2010.Clinical Genetics in Britain: Origins and development 
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running regional clinics regularly in 1964/5. There was a whole ring of peripheral 
hospitals that people visited regularly. When it was taken over by the NHS it 
was all done on MRC money – only moderately appropriately – and when the 
unit closed in 1974 it was formally taken over as an NHS commitment. 
davison: The East Anglian regional genetics service was set up in 1974.
Bobrow: Should we move down our list to Cyril Clarke and the Liverpool 
Institute?
professor sir david Weatherall: It’s always difficult to talk about Cyril Clarke 
(Figure 9). It’s like travelling in Ireland, when you ask the way, they say: ‘Well, 
you can’t start from here.’ I think many of you know Cyril’s background: he 
came to Liverpool in the early 1950s as a straightforward consultant physician, 
building up a private practice and with a major interest in asthma. There was 
no hint of things to come. But from his early childhood he had had a profound 
interest in butterflies and, later, genetics. He was breeding butterflies furiously by 
the early 1950s and got fascinated with mimicry. Purely by chance, through an 
Figure 9: sir Cyril Clarke.Clinical Genetics in Britain: Origins and development 
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advertisement for samples of butterflies, he met Phillip Sheppard from Oxford, 
who was one of E B Ford’s protégés and they became very close friends. 
Cyril told me, and I think he told several people, that it was while walking on the 
Broads that Phillip said to him: ‘Doesn’t all this genetics have any applications 
to medicine?’ They threw this thought around and Phillip said: ‘The only thing 
that can be easily studied at the moment is blood group genetics.’ This was 
around the time that Ian Aird from the Hammersmith Hospital had produced 
his preliminary data on the relationship between blood group A and gastric 
cancer.
84 So, they started work in the field of blood group associations, working 
with duodenal ulcer and secretor status. Along the way they became interested in 
Rhesus, and put a young chap called Ronnie Finn to work on a rather mundane 
kind of problem for his thesis: to try to confirm previous work suggesting 
that ABO incompatibility might protect women against Rhesus sensitization. 
I do not need to expand on that story any further because you dealt with 
how it led to the prevention of Rhesus disease very thoroughly in a previous   
Witness Seminar.
85
When I was Cyril Clarke’s houseman in 1956, medical genetics was just starting 
to zoom, lots of excitement, everybody rushing around the hospital spitting 
into  tubes  and  smelling  their  urine,  and  lots  of  very  bright  young  people 
coming along for research projects. After I left for my national service, Cyril 
established a connection with the Moore Clinic at Johns Hopkins Hospital 
in Baltimore with Victor McKusick.
86 David Price Evans went from Liverpool 
as the first of the Moore Clinic fellows and did some rather beautiful work on 
pharmacogenetics.
87 I followed David to the clinic as the next fellow when I 
came out of the army. Meanwhile, at Liverpool, a number of other registrars 
were coming along with bright ideas and new projects, and because of the 
84  In 1935, Professor R A Fisher and Dr G L Taylor at the Galton Laboratory started a genetic study of 
blood groups, with a Rockefeller Foundation grant and MRC support, later constituted by the MRC as the 
blood group research unit in 1946 at the Lister Institute, directed by Dr R R Race (Thomson (1975): 150). 
See Aird et al. (1954); Clarke et al. (1956); see also Weatherall et al. (1985).
85  See Zallen et al. (eds) (2004): 28–30; see also Finn et al. (1961).
86  The Moore Clinic at Johns Hopkins Hospital was endowed by Dr J Earle Moore as a chronic disease 
clinic in 1952 and became Dr Victor McKusick’s clinic for the new division of medical genetics in the 
department of medicine in 1957. See McKusick (2001). For an interview with Professor Victor McKusick 
and his wife Dr Anne McKusick by Andrea Maestrejuan for the oral history for the medical genetics project 
at UCLA in 2001, see also www.socgen.ucla.edu/hgp/mckusick_interview.html (visited 17 February 2010).
87  Price Evans (1962). Clinical Genetics in Britain: Origins and development 
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connections with E B Ford and the Nuffield Foundation, it was decided to 
support Cyril in building the Nuffield Institute of Medical Genetics.
88 So, by 
the mid-1960s when I came back from the US, the building was almost ready 
and we were able to have a complete floor to develop haemoglobin genetics. 
David Price Evans was there and there was a cytogenetics group led by Stanley 
Walker on the top floor. Above this, on the roof, there was a large butterfly 
breeding facility. My own team was greatly strengthened by the arrival of John 
Clegg from the Laboratory of Molecular Biology in Cambridge and together 
we were able to evolve a strong team which carried out some of the early work 
on haemoglobin synthesis in thalassaemia, the pattern of fetal haemoglobin 
production during early development, and a programme which laid the way for 
the first description at the DNA level of a deletion as the cause of a common 
genetic disease.
89
There was also some excellent work going on in the department of medicine 
at that time with a major focus on genetics. For example, immunogenetics was 
particularly strong through John Woodrow’s work on the human leukocyte 
antigen (HLA), diabetes and rheumatoid disease.
90 If you look at the history 
of the development of HLA-related disease genetics, Woodrow’s early work is 
often overlooked, but it was absolutely seminal in developing a solid basis for 
the HLA relationship with type-1 diabetes.
91
Some of you in this room will ask, as many others have, why the Nuffield 
Institute was never established as a more formal clinical genetics centre.
92 I 
think the answer is clear when seen in the light of Liverpool medicine’s view on 
specialization during the postwar period. I remember Cyril Clarke’s predecessor, 
Lord Cohen, asking me what I was doing with my career and when I told him 
I wanted to do haematology he looked at me as though I had just crawled out 
from under a stone. ‘A specialist is a person who knows everything about his 
field except its relative importance’, he added. Most of the clinical basis for 
genetic work in Liverpool during Cyril’s time came from clinics in related fields. 
Our haematology clinic where I saw patients with inherited blood diseases 
88  See Anon (1963); see also Zallen et al. (eds) (2004): 46; Harper (1985).
89  Clegg et al. (1968); Ottolenghi et al. (1974); see also Weatherall (2001).
90  Cudworth and Woodrow (1974); Woodrow (1975, 1985, 1988); see also Zallen et al. (eds) (2004): 23–8, 
30–6, 41–5. 
91  See, for example, Gale (2001).
92  See earlier discussion on the Galton Laboratory on pages 15 and 17. Clinical Genetics in Britain: Origins and development 
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was one. The genetics of rheumatic disease came from John Woodrow’s big 
clinical practice in rheumatology and all of Cyril’s work on tylosis and cancer 
of the oesophagus was based on work in the gastroenterology department at 
Broadgreen Hospital, Liverpool.
93 I do not think that Cyril ever believed that 
genetics should become a separate specialty from the rest of medicine. Rather, 
and I think this was his enormous strength, he felt that genetics had relevance 
to every aspect of medicine and it should stay like that. It was only when we had 
all left Liverpool that clinical genetics per se developed. But, apart from his own 
wonderful work on Rhesus disease,
94 Cyril’s great contribution was to inspire 
groups of extremely talented young people – some of whom are in this room by 
the way – about the importance of genetics in medicine, but without trying to 
formalize the association in any way.
Bobrow: He actually went on doing that for a long time. I never worked there, 
but I met him at the Royal College of Physicians (RCP) and other places. He 
was inspirational. 
professor alan emery: Coming from the north of England, I have to reply. 
My boss, Sir Robert Platt,
95 and David’s boss, Cyril Clarke (Figure 9), were very 
good friends. It was Robert Platt who encouraged me to do genetics. But I think 
we have to remember what it was like then. In a weak moment before coming to 
this meeting, I found my inaugural address when I went to Edinburgh in 1968, 
and I got a quotation from the Lancet in 1966 that says: ‘Medical geneticists 
able to speak with equal authority among both pure geneticists and consultant 
physicians are, not unexpectedly, as rare as astronomers who can navigate a 
liner.’
96 One tends to forget where you’re coming from: if you’re in inner London 
and you’ve been with all these very famous people, of course the scene is set, but 
if you were outside it was very different. 
I came into medical genetics much later in life because I’d been in the army, and 
then taught for several years before studying medicine. So when I qualified and 
completed junior hospital jobs, I was 33, nearly 34. What are you going to do 
then? My boss said: ‘Go to see Cyril Clarke and talk about medical genetics.’ 
That was an eye opener because there were all these very famous people doing 
93  Howel-Evans et al. (1958).
94  Clarke and Sheppard (1965).
95  Platt (1963, 1972). 
96  Emery (1968a): 12. Clinical Genetics in Britain: Origins and development 
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various aspects of genetics, which encouraged me. But it was a long time before 
the experts got hold of this. And it was people like Cyril and Robert Platt who, 
I think, did it more than anyone else. 
Cyril Clarke convened a meeting at the Royal College of Physicians of London 
when  he  was  president  (1972–77),  for  people  who  wanted  to  do  medical 
genetics. There are perhaps several people in this room who were at the meeting. 
He took a current textbook on medical genetics and waved it in the air: ‘All you 
need to do is read this, but get your Membership first.’
97 I think in those days we 
were trying to get people to be card-carrying physicians or surgeons and then to 
become geneticists. Of course, the picture has changed now, but that was how 
it was in the early 1960s (Figure 10). I owe a great deal to Cyril, even though he 
got me carting those damned great boxes about from Liverpool to Manchester 
to collect Biston betularia (the peppered moth).
98 I never found any of the black 
ones, because I lived in the suburbs and there wasn’t any atmospheric pollution. 
Apart from that, we owe a lot to Cyril Clarke and to Robert Platt, who got it 
going at a clinical level.
97  Professor Alan Emery wrote: ‘This was Emery’s Elements of Medical Genetics (Emery (1968b)), now in its 
fortieth year in 2008 and 13th edition), which was awarded the BMA best medical student textbook prize 
in 2008.’ Note on draft transcript, 16 January 2009. 
98  See, for example, Kettlewell (1956).
Figure 10: total number of published papers on human genetics, 1946–67.
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donnai: In looking through the archives of medical genetics in Manchester, 
I came across a letter dated 22 November 1958 and signed by Robert Platt, 
regarding the formation of a group for the study of human genetics (Figure 
11). He talked about it being his intention to do this, and he said that as he was 
shortly to give up the chair of medicine, he hoped to have more time to devote 
to this kind of work, and that his appointment as chairman of the recently 
constituted MRC committee on human genetics should enable him to keep 
in touch. There were quite a lot of people at the Paterson Institute attached to 
the Christie Hospital involved in early cytogenetics. I’ve also found the medical 
board records when Alan Emery asked to set up a Wednesday clinic in clinical 
genetics in 1964. In fact, when I joined Rodney Harris we still had that clinic 
in the Manchester Royal Infirmary. The group for the study of human genetics 
was formed and was very healthy until at least 1969/70 and had very eminent 
people speaking at it. Alan Emery fostered the group for a while and then 
Rodney Harris took it over in 1968 with enthusiasm. I found quite a lot of 
Rodney’s records of all of the people whom he had put a great deal of effort into 
inviting to speak there. So, I think Manchester has a history almost as long as 
Liverpool’s, spearheaded by Alan and then Rodney. 
professor rodney Harris: When I told Cyril Clarke that I might be leaving 
Liverpool to go to Manchester, he said to me: ‘You’d be a mug if you go to 
Manchester.’ 
Bobrow: Was he right? No. Let’s roll seamlessly into Manchester: how did it all 
happen in Manchester? Who set what up?
emery: I have an anecdote about Rodney Harris I would like to relate. When 
he came to take over my job in Manchester he found a bottle of magnesium 
trisilicate (for indigestion) in my drawer and said: ‘My God, is this a difficult 
job then?’ But it was Cyril Clarke and Robert Platt who got it going. Robert 
published  quite  a  bit  on  the  genetics  of  hypertension  and  he  had  this 
multifunctional debate in the literature of the time, ‘Platt vs. Pickering’, as to 
whether the distribution of hypertension was multifactorial or unifactorial.
99 
That encouraged a lot of people. But I have to emphasize, going to Manchester 
in the 1960s after I had spent some period at Johns Hopkins, the funny thing 
was that there wasn’t a lot of interest. I could talk at a meeting and half of 
the consultants would be asleep! But they have no excuse now for doing that, 
whereas they probably did then. 
99  Swales (ed.) (1985); see also Ness et al. (eds) (2002): 37, 66.Clinical Genetics in Britain: Origins and development 
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Figure 11. invitation to discuss the formation of a group for the study of  
human genetics, 1958. Clinical Genetics in Britain: Origins and development 
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We appointed John Timson to study chromosomes.
100 I believe this was the first 
centre outside of London that was a proper medical genetics centre. We had two 
technicians doing biochemistry, measuring creatine kinase, which I developed 
when I was in the US, then the Boehringer Chemical Company took it over 
commercially, otherwise I wouldn’t be here now, I’d be in the Bahamas! This 
became our way of doing it, and counselling became terribly important. I went to 
see Cedric Carter, who was very helpful to patients. Victor McKusick was, as I say, 
in the US, and talked a lot to patients and that came over very strongly. It wasn’t just 
a question of diagnosing the condition, though this had its own specialties, and, 
of course, needing material from other laboratory sites in order to help. The main 
thing was to converse with the patient. People, even senior medical students in 
Oxford, still ask me now what to say if the patients are a Catholic family and you’ve 
got to talk about prenatal diagnosis. These are the questions that we started to look 
at in Manchester, as we had to deal with that problem with a lot of Catholics there. 
There were also a lot of orthodox Jewish people who also couldn’t consider many 
things like this and I learnt an awful lot from that maelstrom, that multifaceted 
society in Manchester, which maybe I would have got in London too. 
I went up to Edinburgh in 1968 and that was when the university got together 
with the health service, the Southeast Health Board in Scotland and the MRC, 
to fund a proper department doing nothing but human genetics – medical 
genetics. Someone’s mentioned David Brock’s AFP test
101 that took off then and 
John Scrimgeour’s fetoscopy.
102 We were all going into this new world of what it 
meant to patients with genetic diseases. Looking at the inaugural lecture I wrote 
in 1968 – I found by chance a couple of days ago – which shows how much 
we depended on people in London.
103 Nearly all of my references had to do 
with Paul Polani, John Hamerton and people like this, who did so much work 
to give clinical genetics a scientific basis. And, of course, we shouldn’t forget 
Harry Harris, because he got inborn errors off the ground, which I thought was 
terribly important.
104
Harper: Could I just reinforce the point that David Weatherall made about 
Cyril Clarke? I think it has been very fundamental and long-lasting. Cyril 
100  See, for example, Harris et al. (1969).
101  See, for example, Brock (1979).
102  Scrimgeour (1978).
103  Emery (1968a). 
104  See, for example, Harris (1970).Clinical Genetics in Britain: Origins and development 
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genuinely saw genetics as part of everybody’s job in medicine, and yet, to be 
honest, I think most of the people in Liverpool and elsewhere – most of the 
other physicians – didn’t know what he was talking about, and didn’t care too 
much. In a way, he was absolutely right, but he was 40 years too early. I’d go 
one stage further and say that of the various people that Cyril was instrumental 
in training, very often in conjunction with Victor McKusick – most of us went 
into medical genetics as a specialty – retaining a greater or lesser connection 
with general medicine. David himself, in Oxford, has been the only one who 
has been able to put Cyril Clarke’s vision into practice. I don’t honestly think 
that would have been possible anywhere other than in Oxford, simply because 
you needed to have an array of talent across the board, which just about every 
other centre didn’t have. It is only now that Cyril’s original vision is becoming 
generally accepted. That’s how I feel anyway.
Harris: I’m quite embarrassed about this bit of discussion because I ended up in 
Manchester under completely false pretences. I’d never been trained in genetics 
and I was offered a job in Manchester to do tissue typing in support of the 
renal transplant unit. It was at that point that Cyril Clarke said that I’d be 
a mug to go to Manchester and that if I’d stayed in Liverpool I could have 
been a physician. However I did go, and attached to my tissue typing job was, 
I think, one Saturday morning clinic on genetic counselling, which I didn’t 
understand at all. I did that, but it grew and grew and I can only say that my 
connection with medical genetics was entirely accidental, but very entertaining. 
Incidentally, you (Martin Bobrow) may have had a four-cylinder Honda – I had 
a two-cylinder horizontally opposed BMW – a much better bike!
Bobrow: I agree to that. 
donnai: I think the department in Manchester grew a great deal under Rodney 
Harris’s influence. Rodney got to know everybody in the region and he worked 
enormously hard to build up a credible clinical service with NHS funding, 
recognizing that anything that was on short-term funding would be a disaster. 
We also began the regional genetic register service in Manchester and Lauren 
Kerzin-Storrar was one of the early appointees to develop that service.
105 Rodney 
also fought very hard to establish one of the first properly and permanently 
funded NHS senior registrar posts. There were two others in the country: one 
was in Cardiff, to which Ian Young was appointed, and the other was at the 
Kennedy-Galton Centre and Robin Winter (Figure 12) was appointed to that. 
105  Manchester’s genetic register service was established in 1980. See also Kerzin-Storrar (1996). Clinical Genetics in Britain: Origins and development 
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I’m pleased to say that Rodney appointed me to the third proper training post 
in 1978, although at that time there was no formal curriculum or anything. You 
still got sets of notes that you learnt from and you also learnt from the patients. 
I think the diagnostic laboratory and molecular laboratory services were built 
upon various initiatives that may be mentioned a bit later today.
106 Rodney was 
always very enthusiastic about the regional service and from very early on there 
were clinics set up in peripheral centres and because Manchester is in the south 
of the northwest region we went up as far as Lancaster until we strayed on to 
the Newcastle territory. 
Burn:  Derek Roberts, of course, who we heard mentioned earlier, moved to 
Newcastle in, I think, 1969, as a lecturer in child health, and became the first 
lecturer in human genetics. Very early, with Surinder Papiha in particular, he 
started to expand into medical genetic laboratory work and could see that as a 
way of funding the service.
107 Val Davison, now lab head in Birmingham, started 
her career as a cytogeneticist in the department. Derek was very much a research-
orientated population geneticist, having previously been a geographer, but he 
developed a clinical service with the help of Rosemary Boon, the wife of Tom 
106  See, for example, Harris et al. (1989).
107  Papiha and Roberts (1972); Lanchbury et al. (1990).
Figure 12: professor robin Winter, c. 1992/3.Clinical Genetics in Britain: Origins and development 
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Boon, then a leading physician.
108 They took on two part-time health visitors, Jean 
le Gassicke and Dorothy Gibson, to set up peripheral clinics. Derek continued to 
do genetic counselling until his retirement.
109 I gradually eased his fingers off the 
handlebars because he hadn’t done any medical training at all and, in fact, he was a 
little nervous of the medico–legal issues, so he tended to be hesitant about making 
a clear diagnostic statement. But, nevertheless, he was very influential in getting 
us going, getting the clinical service working and properly resourced, and getting 
us a small terraced house in which to be based. I joined him as a medical student 
back in 1972 to do a degree in genetics and then went to Victor McKusick in 
1974 and decided to announce that I would be a clinical geneticist. About that 
time the university offered George Fraser the job – and I thanked George many 
years later because George chose not to turn up; he decided to stay in Ottowa 
instead. They were so annoyed at this that they decided to wait until I qualified in 
1984, and gave me the job. I thank you again, George. 
Bobrow: There is a big institute of neurology in Newcastle, which was doing 
an awful lot of stuff to do with genetic disease. Was there any contact, until 
recently, I mean? – I know there is now, but in those days were these just two 
separate entities?
Burn: Yes, I think they were. John Walton, now Lord Walton of Detchant, 
obviously got heavily into Duchenne dystrophy and did that himself, establishing 
a local reputation for muscle genetics which persists to this day.
110 Derek Roberts 
undoubtedly had some involvement, but he was mostly seeing referrals from 
paediatrics. One small interesting anecdote was that I inadvertently distressed 
Rosemary Boon enormously when I returned from London, because she had 
always assumed that the diagnosis she was given by the paediatrician was the 
one she should counsel to. I told her that we didn’t believe anything anyone 
said when they referred patients to our clinic and we almost always changed the 
diagnosis. I think I hastened her early retirement by telling her that. 
The only legal case I have ever faced originated in the team’s willingness to 
accept diagnoses; I told a lady that she had pseudo-achondroplasia, a type of 
short-limb dwarfism, and that it was autosomal dominant, which was why she 
had an affected child. It turned out that many years earlier she had been told 
108  Boon and Roberts (1970).
109  See, for example, Roberts (1968). 
110  See, for example, Bobrow et al. (1988); Christie and Tansey (eds) (2003): 10, 33–4, 41. For Lord 
Walton’s biographical note, see page 130. Clinical Genetics in Britain: Origins and development 
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by Derek Roberts on the basis of paediatric diagnosis, that she had Morquio 
syndrome, a rare type of dwarfism with serious consequences, and it wouldn’t 
recur. When she did have a recurrence, she went on to sue the hospital. But, 
since I’d taken over as head of the service, I was the one who was named. I 
decided that God was punishing me. For the record, the court ruled the case to 
be inadmissible, because the doctors had done the best they could at the time.
Bobrow: Let us move on to bodies that were involved in the field, the first of which 
was the Royal College of Physicians genetics committee and the Special Advisory 
Committee (SAC). There are several people here who know all about that. 
Johnston: I’m not quite sure how it all started, but the Clinical Genetics Society 
produced quite a number of reports in the 1970s.
111 One of the things discussed 
was the question of accreditation of the specialty. The Joint Committee for 
Higher Medical Training (JCHMT, replaced by the Joint Royal Colleges of 
Physicians Training Board in 2007) was pretty well ruling the roost in terms 
of training, in allocating training posts. And they had set up these various 
committees. I remember very well having Paul Polani at one of the meetings 
discussing these reports and I was unwise enough to say that I was expecting to 
see Sir John Crofton the following week in connection with general medicine. 
Paul Polani immediately picked this up and said: ‘Can you go and talk to him 
about clinical genetics?’ So, I ended up having coffee after breakfast with Sir 
John in the Station Hotel in Aberdeen and that was the basis of the SACs. I 
talked to Sir John and he was very supportive until we came to the question 
of having our own SAC. He explained that the whole JCHMT had taken 
a policy decision to restrict the number of SACs and to reduce the number 
of those involved as far as possible. From that point on, we were stuck with 
the problem of supervision of accreditation and that wasn’t solved during my 
professional lifetime. Things have changed quite a lot now, I understand, but it 
presented us with all sorts of problems in trying to supervise training schemes of 
senior registrars in clinical genetics.
112 And just for the record, the second senior 
registrar for clinical genetics in Scotland came to Aberdeen. 
emery: The first approved specialist registrar in genetics was in Edinburgh. 
Harris: (getting the microphone) Thank you very much indeed. I thought you’d 
cut me off because I said my bike was better than yours. 
111  Dr Alan Johnston wrote: ‘Initially at Cyril Clarke’s request.’ Note on draft transcript, 18 February 2009.
112  For details of current training arrangements, see www.jrcptb.org.uk/Specialty/Pages/ClinicalGenetics.
aspx (visited 20 January 2010).Clinical Genetics in Britain: Origins and development 
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Bobrow: No, I admire you for having a better bike. I couldn’t afford one; MRC 
rates, you know.
Harris: It was quite an expensive bike, especially when I broke it. Alan Johnston 
was a marvellous guy to work with on the RCP committee on clinical genetics. He 
was very good indeed. What we did was to push the registrar of the RCP, David 
Pyke. Well, that was the SAC, and there wasn’t an SAC, as you’ve explained, 
until we had finished and moved on. What we did was to turn up regularly at 
the JCHMT, which I think must have been the most boring part of anybody’s 
work – it was not the most imaginative. However, it was good because it would 
get senior registrars coming into the specialty and there was an increasingly good 
training structure. They didn’t play around and hope for the best.
113 
I think the most important single event at that time was when it was agreed at the 
King’s Fund forum that there should be a single representative body for clinical 
genetics, including clinicians and laboratory people, and nurses and others of 
that ilk. That is actually published and the reference to that is on one of the bits 
of paper on your seats there.
114 What followed after the Clinical Genetics Society 
was the British Society for Human Genetics (BSHG). That was wonderful 
because it got all of the different specialties on equal terms, exactly as the King’s 
Fund had envisaged. Another thing that exercised us a great deal at that time was 
the question of getting clinicians and laboratory people to work closely together. 
It’s hard to believe now, but there was quite a lot of struggle going on over who 
controlled laboratories. The idea of it all being ‘under one roof’ took hold. Now, 
it was not literally under one roof, but it was spiritually under one roof.
115 
113  Professor Rodney Harris wrote: ‘Other initiatives at that time included successful lobbying of the 
NHS chief scientist to establish genetic associates as integral members of the NHS regional clinical genetic 
teams. The need for a British association for genetic medicine was stressed to include genetic associates as 
well as genetic nurses, medics, scientists and laity in a single representative body. See Harris (1988). This 
heralded the British Society for Human Genetics.’ Note on draft transcript, 23 February 2009. See also   
Appendix 1, page 84.
114  Harris (1988). 
115  Professor Rodney Harris wrote: ‘Close collaboration between cytogenetic laboratories and clinicians had 
not always been the case so we encouraged the organization of clinical and laboratory genetic services “under 
one roof” to promote better management of patients and their families and training and research. The 
artificial separation of medical genetics from medicine, paediatrics, obstetrics, pathology and other fields has 
also been diminished and the committee on clinical genetics surveyed the education and training of clinical 
geneticists. See Royal College of Physicians, Clinical Genetics Committee, Working Party (1990).’ Note on 
draft transcript, 23 February 2009. See Appendix 1, page 84. Clinical Genetics in Britain: Origins and development 
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Another thing that was extremely good and rewarding was the dialogue that 
we had with the ministers about genetic associates. Derek Roberts says that at 
that time he told genetic associates that they didn’t have a pay structure except 
what they had to find themselves, like nursing. That was the beginning of 
getting genetic associates put on the same salary scale as laboratory scientists. 
That was quite a pleasing thing. Another development that was also a result 
of a lot of discussions with ministers was the establishment of ‘special medical 
development’, which was NHS funding for DNA labs in the health service.
116 As 
a result of that, three centres – Cardiff, the Institute of Child Health, London, 
and Manchester – were set up officially with NHS funding and that took off.
117 
I think the next thing is to go from things that were referred to as a medical-
genetics sort of specialty to an idea that a lot of us have had, and I think I felt 
very strongly about coming from a department of medicine, being a physician 
by  training,  that  medical  students  needed  to  be  taught  genetics. The  RCP 
established a survey of all medical schools.
118 Each dean was written to and asked 
what genetic teaching was going on in their school. I can remember at the time, 
somebody at the college – I can’t remember who it was – saying: ‘Oh, we’ve never 
been involved in teaching.’ But we did it. And it was very successful; whether it 
actually improved teaching, I don’t know. People will know that better than I do. 
Alan Johnston himself took on postgraduate medical genetic teaching as well.
119 
The business of people other than geneticists doing genetics is, of course, a 
very  real  and  fundamentally  important  activity.  So  we  set  up  a  National 
Confidential Enquiry into counselling for genetic disorders by non-geneticists. 
The most important observation that came out of it was that hospital records in 
paediatrics, obstetrics and other specialties were so bad we couldn’t find out.
120 
116  Department of Health and Social Security (1987). 
117  Professor Rodney Harris wrote: ‘During the 1980s and 1990s my colleagues and I shared specific 
concerns about medical genetics in the UK and the EC generally. Although DNA methods were becoming 
important in clinical genetics, adequate resources were not yet available in the NHS and an application 
was therefore made for NHS Special Medical Development funding to pilot NHS DNA laboratories in 
Manchester, Cardiff and London, see Harris et al. (1989).’ Note on draft transcript, 23 February 2009.
118  Royal College of Physicians, Clinical Genetics Committee, Working Party (1990).
119  See, for example, Johnston (1978, 1979); Anon (1983); Griffiths (2006).
120  Professor Rodney Harris wrote: ‘Subsequently in a series of NHS funded confidential enquiries we 
audited the quality of genetic counselling and prenatal diagnosis, the most striking finding of which was 
the poor clinical records of genetic management in obstetrics and other specialities that limited audit. The 
subsequent wide dissemination of these reports was aimed to draw the attention of professionals to these 
deficiencies. See Harris et al. (1999).’ Note on draft transcript, 23 February 2009.Clinical Genetics in Britain: Origins and development 
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However, certain very good things did follow from that: one was the question 
of  prenatal  screening,  and  one  of  the  things  we  looked  at  was  screening 
for  haemoglobin  disorders,  and  one  of  the  great  things  that  followed  on 
from  that  was  NHS  screening  programmes  for  haemoglobin  disorders
121 
(haemoglobinopathies, common inherited blood conditions affecting people 
whose origins are from Africa, the Caribbean, the Middle East, Asia and the 
Mediterranean, but are also found in the northern European population). 
The final thing was getting out into Europe. We established a concerted action 
on genetic services in Europe, which contacted all 31 European countries, to 
find out how they did it. Did they recognize genetics as a specialty? What was 
going on? That produced a report, and I’m told by European colleagues it is 
now widely used.
122 
Johnston: I mentioned earlier that we had produced a series of reports on 
training and staffing by the Clinical Genetics Society. This culminated in a big 
meeting at the college in May 1976, where there were representatives of the 
various health departments and the professors of medical genetics, and so on.
123 
It validated our reports of the Clinical Genetics Society to substantiate this 
steady involvement of other departments. So we particularly wanted to be sure 
that everyone who was at that meeting accepted all that was being asked of us.
121  The NHS Sickle Cell and Thalassaemia Screening Programme was set up in England in 2001 following 
Government commitment in the NHS Plan (Department of Health (2000): 109) to the world’s first linked 
antenatal and newborn screening programme. See http://sct.screening.nhs.uk/; and www.library.nhs.uk/
SCREENING/ViewResource.aspx?resID=268964 (both visited 21 January 2010). See also: Thein and 
Weatherall (1987); Lane et al. (2001).
122  Professor Rodney Harris wrote: ‘Medical genetics was recognized as a specialty in the UK in 1980 
thanks to the efforts of Dr C O (Cedric) Carter. I endeavoured to extend this recognition and was able, 
with European colleagues, to obtain EC funding for a concerted action on genetic services in Europe, a 
comparative study of medical genetics in 31 countries. (Harris (ed.) (1997)). This set up a network of 
clinical geneticists to stimulate recognition of medical genetics in all European countries and to investigate 
the structure, workloads and quality of genetic services and the different responses made in each country to 
the new opportunities and challenges of clinical genetics.’ Note on draft transcript, 23 February 2009. See 
also Appendix 1, page 85; CGS Working Party (1983); Figure 14.
123  Speakers at the half-day conference on 13 May 1976 were: Sir Cyril Clarke, Professors C O Carter, 
A E H Emery, J H Hutchison (chair), M A Ferguson-Smith, Drs A W Johnston, D F Roberts and H Soltan. 
Dr Alan Johnston donated his papers relating to the preparation and organization of the 1976 meeting 
and other documents on the training and function of medical geneticists, both nationally and in Scotland 
(1973–97). These will be deposited along with other records from the meeting in archives and manuscripts, 
Wellcome Library, London, at GC/253.Clinical Genetics in Britain: Origins and development 
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Harris: Ian Lister Cheese is in the audience somewhere and I have to say that 
our relations with the Department of Health were superb, partly at least because 
he was such a good intermediary. 
Bobrow: Now, the next item on our list is the Clinical Genetics Society that 
then morphed into the British Society for Human Genetics. We’re going to start 
with Michael Laurence, please. 
professor michael laurence: The CGS started off as a clinical genetics society 
at an informal ad hoc meeting in Edinburgh. We all came up to Edinburgh, sat 
round a table and, in fact, we decided to have a secretary. Cedric Carter was 
going to be the leading secretary and he had some guidelines, I think, of some 
society based in each of the main centres. To some extent, we were having to 
cater for the surrounding districts as part of the NHS, not as part of the MRC or 
some other body. And this was enthusiastically received and supported. I think 
if we hadn’t done that we would still be in a mess today. The NHS supported 
us quite fully on that. 
Bobrow: Who was at that first meeting?
laurence: Rodney Harris (Figure 14), Cedric Carter (Figure 7), Alan Johnston, 
myself (and I think there may have been Norman Nevin from Northern Ireland). 
It wasn’t a large meeting.
Bobrow: And Sarah Bundey? Yes: Peter’s just whispered ‘Sarah Bundey’. That’s 
very helpful, thank you. Does anyone have anything to say about the CGS in 
its early days, because I then want to move onto the BSHG and the transition?
pembrey: I have an anecdote about accreditation.
124 I think it’s worth recording 
here that the CGS produced a number of early documents.
125 One was the 
Provision of Services for Prenatal Diagnosis of Fetal Abnormality in the UK; and 
then The Provision of Regional Genetic Services in 1978; Provision of Regional 
Genetic Services in the UK in 1982 (Figure 13); and then in 1983 Report of the 
124  Professor Marcus Pembrey wrote: ‘When accreditation was being considered in 1976/7, Sir Cyril Clarke 
was president of the Royal College of Physicians and he advised me to get accredited in general medicine and 
in medical genetics rather than seek dispensation as an established medical geneticist. This went smoothly 
and I was accredited in both subjects in 1977. In 1978 I received a letter from the college saying something 
like: “We are planning accreditation in medical genetics and have discovered, to our surprise, that you are 
already accredited. It would help us in our deliberations, if you could you give us details of your training.”’ 
E-mail to Mrs Lois Reynolds, 4 March 2010.
125  Dr Alan Johnston wrote: ‘Chaired by different people.’ Note on draft transcript, 18 February 2009.Clinical Genetics in Britain: Origins and development 
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Working Party on the Role and Training of Clinical Geneticists.
126 Another reason 
for flagging it up is that these were reported in supplements of the Bulletin of 
the Eugenics Society and I think that, going back to the earlier discussion, this is 
often a little bit of a surprise for people who didn’t understand that the Eugenics 
Society at that time was a natural assistant to getting these things published and 
so on. And that I think people sometimes overinterpret the fact that these early 
documents were published as a supplement – it was just a way of getting them 
published. There were a lot of people in both organizations. 
Harper: Just to follow up on what Marcus Pembrey has said: I was on the council 
of the CGS at that time, and I think I’m right in saying that the main reason for 
the Eugenics Society publishing things was that the CGS had no money at all 
in its early years, and the Eugenics Society had lots of money and didn’t know 
what to do with it; it was a very pragmatic decision. But those reports, and 
likewise the series of reports from the RCP Clinical Genetics Committee, were 
very influential right across the world, especially in continental Europe, not just 
in Britain. And, I think it is important a complete collection is made, which 
is something we are trying to do with the Human Genetics Historical Library. 
So, if any of you have got copies of those old reports, again, check the index on 
the library website to see if it is in the library, because these are just the kind of 
publications that get lost sight of, in comparison with conventional books.
127 
126  Clinical Genetics Society, Working Party (1983).
127  See note 55.
Figure 13: report of the Clinical Genetics society’s Working party, 1982. Clinical Genetics in Britain: Origins and development 
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professor Heather skirton: I’d like to make a comment before we move on to 
the BSHG, about the huge support the CGS gave to genetic nurses in the early 
days.
128 We did have our own very small society but the CGS gave us a lot of 
moral support and also practical support. We used to hold our own scientific 
meetings under the auspices of the CGS, I can’t remember whether it was the 
first day of CGS, or the last. And through our clinical genetics colleagues we got 
a huge amount of support that helped us to move forward as well. 
Bobrow: My recollection – and I was never a big player – is that it was a very well-
meaning and well-intentioned organization. From quite early on, personally I 
was not greatly drawn to an organization that made quite as much distinction 
between clinical and laboratory and other professions as the CGS was bound to 
do by its structure. I guess a lot of people felt that way, which is where the drive 
came from to slowly move forward to the BSHG. I don’t know who’s going to 
talk about BSHG in its early days, but John Burn seems a good person to start. 
Burn: Yes, I’d like to speak about this because it’s probably the only true historical 
contribution I can make. 
Bobrow: You’re too young, that’s the trouble.
Burn: When I was made secretary of the Clinical Genetics Society by Alan 
Johnston and a cartel of senior colleagues in 1989, I don’t remember being 
given the chance to vote on the decision, but I did say that I needed Peter 
Farndon to be my colleague as treasurer, so we split the job in two. I immediately 
thought – and Peter and I can’t quite remember how this came about, but we 
agreed – that we needed a joint conference, and I think it was my idea to go 
for creating a joint society. I remember suggesting it to Peter at a ceilidh at 
one of the meetings, I think in Cardiff, and he said: ‘Well, that’s a good idea if 
you can pull it off’, or something to that effect. I set about trying to persuade 
the other societies. The CGS and the nurses and counsellors were all fine, but 
the Association of Clinical Cytogeneticists (ACC) proved to be a harder nut 
to crack, but eventually they came on board.
129 In fact, the plan was to merge 
completely, but the ACC reneged and said they wanted to stand apart because 
they were a friendly society. So we created the federation model, and in fact, to 
give him credit, my colleague in Newcastle, John Wolstenholme, representing 
the ACC in discussions, pointed out that linguistically it should not be the 
128  See Appendix 2, pages 87–8.
129  Professor Sir John Burn wrote: ‘The cytogeneticists were always less likely to agree. They were fiercely 
independent.’ E-mail to Mrs Lois Reynolds, 8 March 2010.Clinical Genetics in Britain: Origins and development 
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British Society of Human Genetics, but the British Society for Human Genetics. 
So we stand apart from the Americans and the Europeans on that point. We 
started in 1996, which is when I finished my tenure as secretary. 
donnai: I think we should, in this regard, pay credit to Andrew Read, who was 
the first chairman of the British Society for Human Genetics.
130 I remember 
having a talk with Martin Bobrow, probably in a bar somewhere, and as we were 
talking about the formation of this new British Society for Human Genetics, 
Martin said, in his very decisive way: ‘The only person that can be the first 
chairman is Andrew Read.’ And I think he was absolutely right, because Andrew 
130  Professor Dian Donnai wrote: ‘Andrew Read joined the Manchester department as lecturer in 1978. 
He made major contributions to early studies on prevention of neural tube defects by folic acid and 
multivitamin supplementation and to the development of prenatal diagnostic testing. He was instrumental 
in setting up the research and diagnostic molecular genetics laboratory in Manchester from 1982 and his 
group discovered PAX3 mutations in Waardenburg syndrome (Tassabehji et al. (1992)). He established 
collaborations with clinicians and scientists internationally and is widely recognized as a brilliant teacher. 
He was a founder member and then chairman of the Clinical Molecular Genetics Society and the founder 
chairman of BSHG. Human Molecular Genetics (Strachan and Read (1996)), now in its 4th edition in 2010, 
has become a major text in its field and New Clinical Genetics (Read and Donnai (2007) is in its 2nd edition 
in 2010.’ Note on draft transcript, 5 March 2010.
Figure 14: dr Hilary and professor rodney Harris, 2006.Clinical Genetics in Britain: Origins and development 
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commanded the respect of all the constituent societies and everyone, and I 
think that was an inspired choice. So much so that he insisted on being called 
‘chairman’ and not ‘president’, and didn’t have any regalia to go with it either. 
Bobrow: Yup, and you’re right: it is respect that does it. 
pembrey: I think another influence, about that time or just before, was Pat 
Jacobs, who was president of the Clinical Genetics Society.
131 She wasn’t a 
physician and that helped as well. I think that was important. 
Bobrow: Right, we can move on from that. So the next thing on the list is 
labelled ‘Department of Health’ and I think what we’re trying to get at is the 
relationship that several people have referred to already, between the department, 
whose face was often Ian Lister Cheese, but none of us understood what was 
going on behind you, Ian, and this developing society, or societies, all of whom 
were somewhat jockeying for position. And some of us, I guess, were slightly 
naive about how things work in the real world as well. We thought it would be 
interesting to hear how this looked from the other side of the fence. To give notice 
to others, I’d quite like, under this heading, because it doesn’t come in anywhere 
else, to touch a little on screening, in a general sense, for genetic disease. I know 
that Bernadette Modell covered a lot of that in the other meeting.
132 I’d just like 
to get a few words on the screening programmes because they came out of the 
same stable. Ian, how did it look from the Department of Health? Why did 
anyone let us get away with setting up an operation of this nature?
dr ian lister Cheese: Having been invited as a non-specialist and non-expert – 
and here by false pretences, as so many other geneticists are, of course – you might 
wish to know that people like me came to the Department of Health at a mature 
age, often with a good deal of clinical experience (I’d been in general practice in 
Wantage in Oxfordshire, a tutor and trainer in general practice, and had a small 
role in management in the cottage hospitals around Oxfordshire). One of the 
things that was very vivid – I think Hilary Harris will know what I mean – is 
that when you have responsibility for something like 1600 or 2000 patients in a 
market town and village community, you don’t attend 1600 patients, you attend 
100 or 200 families. You know their dispositions, their diatheses, as the Victorian 
physicians used to say. In a sense I’ve always had that feeling, as it were, for the 
genetics of the population – the disposition of the population. 
131  See, for example, Jacobs et al. (1959); Jacobs and Strong (1959).
132  Christie and Tansey (eds) (2003): 48–9; see, for example, Modell B (1997); Modell M et al. (1998).Clinical Genetics in Britain: Origins and development 
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So I came into the Department not as an expert, but as a generalist when Donald 
Acheson became Chief Medical Officer (CMO, 1983–91).
133 After the usual sort 
of induction that new civil servants have to undertake in rather run-down country 
houses to be taught how not to embarrass their ministers and the like, he asked 
me to take over the policy job that covered children in hospital, the newborn and 
genetics, and to become secretary of the Standing Medical Advisory Committee. 
So genetics was obviously a very small part of what I was asked to do. 
I read into the subject, as one must; there wasn’t very much within the Department. 
The Standing Medical Advisory Committee had, in 1972, produced a very small 
booklet on genetics.
134 It was a description of Mendelian genetics with a few 
pictures of chromosomes, and a little paragraph about genetic counselling.
135 I 
thought at first, since it was produced in 1972, that Cyril Clarke, who had become 
president of his college at that time, might have produced it. Now I know there 
was no possibility whatever of him having written that document. The point was 
this: there was very little by way of a policy statement, very little indeed. And it 
didn’t matter, because the work of the professional bodies, the RCP, the Clinical 
Genetics Society, and of individuals – many of them – had led to a series of 
authoritative documents which laid down clearly what a clinical genetics service 
should comprise. They set out its purpose, its function, and all the elements that 
make up an effective clinical genetics service. They described its educational and 
research roles and they had investigated the ethical aspects of genetics. There was 
a sense in which one didn’t have to do anything. The ground had been laid. 
This was very important in another way. When the time came, as Rodney Harris 
has described, to undertake what was called a ‘special medical development’ 
(SMD) to explore the application of new genetic probes in the service context, 
it became obvious that that organization of genetic centres – regional genetic 
centres as they’re called – was not only fitting but necessary to do that kind of 
work. It was a wonderful confirmation of the ripeness of what had evolved.
136
133  Sir Donald Acheson (1926–2010) was chief medical officer, Department of Health (1983–91). See 
Dean (2010) and biographical note on page 113.
134  Department of Health and Social Security, Scottish Home and Health Department, Welsh Office, 
Standing Advisory Committee (1972).
135  For an earlier volume on genetic counselling, see Fuhrmann and Vogel (1969).
136  Dr Ian Lister Cheese wrote: ‘SMD was led by Professors Peter Harper, Rodney Harris and Marcus 
Pembrey, and included Drs (now Professors) Angus Clarke and Dian Donnai and Drs Helen Hughes, Helen 
Kingston and Maurice Super.’ Note on draft transcript, 19 August 2009; see also note 117.Clinical Genetics in Britain: Origins and development 
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I think throughout those years in the DHSS, much of our attempt to do 
rather more in respect of the NHS and its support for clinical genetics was 
overshadowed by a general unease about abortion.
137 Ministers have always 
adopted, as you know, ‘a neutral stance’ over abortion. And it’s unfortunate 
that genetics, indeed the very word, was always closely linked with abortion. 
But fortunately there was another aspect. A number of people have spoken 
about the link of genetics and paediatrics and the origins of many geneticists as 
paediatricians, and it was easy to look at genetics in the context of reproductive 
health and the health of children, and in doing so to put it into a public health 
context. You recall that every year the CMO would produce a report on the 
state of the public health to the Secretary of State. This allowed us to insert, as 
it were, current preoccupations, current issues and if not actually to give them 
wide publicity, at least to put them on the record.
138 
Towards the end of the 1980s were a number of profound changes, all of which 
would have touched you. One, of course, was the establishment of the Human 
Fertilization and Embryology Authority.
139 That was immensely sensitive. In 
fact, it was so sensitive, I remember, that the work we were trying to do under 
137  Dr Ian Lister Cheese wrote in 1997: ‘The development of policy in this field was shadowed by the 
continuing  political  and  public  controversy  that  abortion  arouses….Even  the  clarification  of  desired 
outcomes; for example, to restore reproductive confidence, a phrase coined, I believe, by Marcus Pembrey, 
has not deflected that sensitivity. It cannot be too often stated that it is not the primary aim of genetics 
practice to reduce the birth prevalence of inherited disease, although there is good evidence that it is a 
consequence of informed decisions that individuals and couples make.’ Lister Cheese (1997) unpublished: 
page 3, which will be deposited along with other records from the meeting in archives and manuscripts, 
Wellcome Library, at GC/253. See also, for example, Polkinghorne (1989). 
138  See, for example, Department of Health (1989, 1992a, 1993).
139  The Human Fertilization and Embryology Authority (HFEA) was created in 1991 as a statutory body 
under the Human Fertilization and Embryology Act 1990 to license and monitor UK clinics that offer in 
vitro fertilization and donor insemination treatments, and all UK-based research into human embryos, as 
well as regulating the storage of eggs, sperm and embryos, including a database of every IVF treatment and 
one of every egg and sperm donor. See www.hfea.gov.uk/25.html (visited 21 January 2010). Department of 
Health advice on the disposal of human tissue from pregnancy loss before 24 weeks’ gestation was contained 
in HSG(91)19 (Health Service Guidelines – Disposal of Fetal Tissue (12 November 1991)), replaced by the 
HFEA’s Code of Practice, and subsequently the Human Tissue Act 2004 (for England, Wales and Northern 
Ireland only), which set out a new legal framework for the storage and use of tissue from the living and for 
the removal, storage and use of tissue and organs from the dead. This includes tissue following clinical and 
diagnostic procedures.Clinical Genetics in Britain: Origins and development 
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David Weatherall’s prompting, to set up a gene therapy advisory committee
140 
was objected to in the department because it might get in the way.
141 It was as 
sensitive as that. However, there were a number of helpful opportunities that 
came our way almost coincidentally. Again, Rodney has mentioned one: clinical 
audit. Medical audit first, clinical audit later, became the fashion. Money was 
made available. Rodney took the opportunity to set up what he called CEGEN, 
the National Confidential Enquiry into counselling for genetic disorders by non-
geneticists.
142 In a sense, it wasn’t an audit, it was a way of setting standards in 
retrospect. It did a number of necessary things to put a clinical service and those 
who practised it onto the most secure footing possible. Another opportunity 
arose in 1990. The Health Select Committee looked at maternity services and 
childbirth.
143 One of the items they considered was preconception care.
Opportunities like that in the department allowed one to declare an interest and 
to bring in the evolving, or evolved services, in a way that was pertinent to the 
interests of the committee.
144 And when the Select Committee says something, 
makes a recommendation or a comment, it can’t be ignored. You know that 
very  well  from  recent  experiences  with  the  Lord’s  Science  and Technology 
140  The Gene Therapy Advisory Committee (GTAC) was established in 1993, following the recommendations 
of the 1992 Clothier committee report on the ethics of gene therapy (Department of Health (1992b), Sir 
Cecil  Clothier  QC,  chair;  see  also  www.galtoninstitute.org.uk/Newsletters/GINL9306/ethics_of_gene_
therapy.htm; Taylor and Lloyd (1995)). All gene therapy is considered as research, and recruitment of 
patients into research trials is covered by strict rules set out by the GTAC. The primary concern is whether 
the research proposal meets accepted ethical criteria for research on human subjects. The GTAC reviews 
take account of the scientific merits of the research, and its potential benefits and risks. The safety and 
welfare of patients is of paramount importance. See http://genome.wellcome.ac.uk/doc_WTD021011.
html (visited 21 January 2010). 
141  Professor Sir David Weatherall wrote: ‘My guess is that one or two areas in this meeting will come 
over quite well, but others, like ethics and like issues will probably need an awful lot of work at your end. 
I suspect that some of these topics could well do for a Witness Seminar on its own. I was thinking of 
bioethics because there was no time to mention all the fascinating events that led up to the Government 
recommendations on gene therapy and later on embryo research and so on. Although I hate to say it, but 
I think this country has done better than almost any other in finding its way through the complexities of 
modern biology and it might be quite a good topic for you in the future.’ E-mail to Professor Tilli Tansey, 
29 September 2008. See, for example, Human Genetics Commission (2006).
142  Harris and Harris (1999); Harris et al. (1999). 
143  House of Commons, Health Committee (1991). 
144  Department of Health (1992c).Clinical Genetics in Britain: Origins and development 
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Committee.
145 So once again we were able to draw the attention of the NHS to 
the importance of clinical genetics services in the context of preconception care 
and maternal health and so on. 
There was another inhibition, another restriction. At that time, the Department 
refrained from giving any kind of specific instructions to the NHS. However, 
the CMO was able to write a Professional Letter on clinical genetics services, and 
to draw the attention of people to their importance in the developing NHS.
146 
I needn’t go on beyond that but, as you know, genetics gradually became, more 
and more, a public issue, and in many ways a threatening issue. Those of us 
who served the Clothier Committee will remember phrases like ‘Frankenstein’s 
monster’ being used. It was a most absurd state of affairs, but that was the 
atmosphere at the time. I think that has passed now.
I’d like to go back to one thing – I’m just recalling it. After the Special Medical 
Development, which I think ended in about 1986/7, it seemed sensible to 
produce an interim report before the full evaluation of the development had 
taken place.
147 It was actually rather a good thing to do because the final report 
didn’t appear for another four or five years.
148 But I remember speaking with 
Rodney, and to you, Martin, and to Peter Harper and Marcus Pembrey, to see 
145  House of Lords, Science and Technology Committee (2009).
146  Department of Health, CMO and CNO (1993). 
147  Dr Ian Lister Cheese wrote: ‘The interim report (Department of Health and Social Security (1987)) 
was not published formally but was made available to participants. Copies were lodged with the Legal 
Deposit Libraries. In evidence to the Science and Technology Committee in 1995, the CMO outlined 
action being taken by the Department of Health in relation to education and training for clinical practice. 
As a first step the Department drew the attention of NHS education advisers to an educational video 
“Chance to Choice”, supplemented by a booklet, prepared by the Institute of Child Health, London, under 
the leadership of Professor Marcus Pembrey. A personal view from the Department of Health was contained 
in an appreciation given by me at a Festschrift to mark the retirement of Professor Rodney Harris in 1997. 
Many aspects of this personal recognition apply no less to the other leading figures in this field.’ Note 
on draft transcript, 19 August 2009. A copy of the Interim Report, the professional letters and Dr Lister 
Cheese’s appreciation will be deposited along with other records of the meeting in archives and manuscripts, 
Wellcome Library, London, at GC/253.
148  Beech et al. (1994); House of Commons, Science and Technology Committee (1995, 1996); see note 
120; Brock (1990). Four Scottish university medical genetics centres formed a consortium in 1985 to 
provide a DNA-based service in prenatal diagnosis, carrier detection and predictive testing for a range of 
Mendelian disorders. Members were: A W Johnston, N Haites, K Kelly, W J Harris, C Clark (Aberdeen); 
M W Faed, M Boxer (Dundee); A Curtis, L Strain, L Barron, M Mennie, J A Raeburn (Edinburgh);   
M Connor, M A Ferguson-Smith, G Lanyon, S Loughlin, E O’Hare (Glasgow). See also Kelly (2002).Clinical Genetics in Britain: Origins and development 
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what lessons we could draw from it that were persuasive. There were two that 
I remember now; there were certainly others. The first was, of course, that the 
new probes allowed much more informative data to be given to patients in 
counselling. It had one important consequence – that people who would not 
have risked pregnancy became more confident to do so. I don’t think enough 
was made of that at the time. The other thing that came out of it was the way 
people sought counselling. I can’t remember whether it was part of the SMD 
or not. It was something like this: 200–300 people at primary risk were written 
to and offered counselling.
149 A small minority responded in the first instance, 
and yet over the succeeding weeks or months a majority self-referred or sought 
advice. The point was that there was a growing awareness of what was on offer. 
And it brought the prospect of a huge demand for genetic services of the kind 
you deliver as the possibilities of advice, of information, grew. That presented 
a real problem. Could genetic services grow in such a way and fast enough to 
meet that potential demand? I think it was a very important issue because it 
meant that one had to capture the interest of the patient bodies of that time and 
say to them: ‘Don’t ask for too much too soon.’ It couldn’t be delivered.
150 There 
are many more aspects, though.
Bobrow:  Extremely  helpful.  I  think  we  were  very  fortunate  to  have  an 
understanding ear within the DHSS at the time to translate what was going 
on into terms that were suitable for internal consumption. I think many of 
us knew that at the time, but you’ve confirmed it. Are there other questions 
or comments on that? I wonder if I could pick up briefly the question of how 
screening services were developing in parallel with this. And by screening I’d 
like to include not only the haemoglobinopathies,
151 but also the Down’s and 
neural tube screening.
152 Do you think that those developments would have gone 
ahead anyway much as they did if there had not been a growing subspecialty, 
later becoming the specialty, of clinical genetics? Or did the two feed off each 
other? Nobody knows.
149  See data provided in unpublished interim report (Department of Health and Social Security (1987): 
Appendices A and B), which will be deposited along with other records of the meeting in archives and 
manuscripts, Wellcome Library, London, at GC/253.
150  Dr Ian Lister Cheese wrote: ‘The Genetics Interest Group (GIG), an umbrella organization newly 
formed in 1989, understood the position and pressed its interests and concerns keenly but responsibly.’ 
Note on draft transcript, 19 August 2009.
151  See note 121.
152  Spencer et al. (1993); Wald et al. (1998); Harris et al. (1999); Ferguson-Smith (2008).Clinical Genetics in Britain: Origins and development 
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Harris: I don’t know either. I think the thing that is striking is that in the survey 
of 31 European countries, the UK and a few others like Holland stood out 
because these sorts of things went ahead, because there were clinical genetics 
(and scientists working with them) to push them.
153 
skirton: Could I make a comment from working within an NHS trust at the 
time when screening for Down syndrome was introduced? The genetic services 
– the regional genetic service – and genetics per se, I think, had very little to do 
with that, and it was pressure from women who were saying: ‘My sister went 
to Bart’s and she had a test, and we want it.’ And so it was introduced in a 
rather unthought-about way – I know this for sure in Somerset, at least. So, I 
would have said – and actually what happened – is that the genetic services were 
brought in afterwards to pick up some of the pieces, because it was introduced 
in a very haphazard way. That’s my experience.
dennis: I was the regional clinical geneticist in Southampton, covering Wessex, 
in the late 1970s and early 1980s when a lot of screening developments were 
taking place. I think I felt that I had a lot to say about screening but nobody 
was asking me, and it took a lot of pushing from the genetics people to get 
a voice. With the help of Pat Jacobs, we had a regional committee convened 
eventually to discuss Down’s screening. And the obstetricians and other people 
involved in actually delivering screening didn’t seem inclined to look to their 
local geneticists for help. 
Burn: I think this is a good illustration of how things can go different ways in 
different places. Derek Roberts set up an AFP testing service for spina bifida in 
one of our district hospitals back in the early 1980s. In fact, we came across the 
association of hCG independently of Bart’s, and so in 1986 we started doing 
double testing for Down’s ourselves.
154 I decided to take it over, because then I 
could incorporate the cytogenetic costs into the price of the biochemistry. So we 
introduced a regionalized service, but, in fact, it was for only half of the health 
districts. We negotiated district by district. It was £14.20 a test, I remember it 
vividly. We actually controlled Down’s screening all the way through until it 
became a national screening test run by our regional screening lab around 2004.
153  See note 122. 
154  Professor Sir John Burn wrote: ‘The discovery came out of our NHS scientist Irene White working 
under our senior lecturer in human genetics with whom I worked. The former had little interest in academic 
publication and the latter failed to understand the urgency, so the work was not submitted to a journal, but 
we deployed it quickly into our clinical practice.  By the time we had more data on its relevance, the “Barts 
test” had been released.’ E-mail to Mrs Lois Reynolds, 22 March 2010; see Wald et al. (2003).Clinical Genetics in Britain: Origins and development 
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Berry:   Guy’s was rather the other way round from Southampton, in that we 
very much controlled the screenings, certainly for Down’s, because we could 
only handle a certain number of samples each week and there were strict 
criteria that obstetricians had to fit in with. The actual AFP assay was all done 
at Guy’s. Certainly we would see the obstetricians, who were always relieved 
to hand over any difficult counselling or difficult results or anything. So it 
was very much a partnership, and I think probably the Guy’s group drove the 
service to some extent. 
emery: I think in Scotland in the late 1960s–early 1970s we had three screening 
programmes going on. They were screening for phenylketonuria in Glasgow in 
newborns (1967) (this was nothing to do with genetics; this was, I think, by 
the Public Health Department).
155 We took it up later using the same technique 
when  screening  newborns  for  Duchenne  muscular  dystrophy.
156  But  it  was 
David Brock who started AFP screening in Edinburgh, and then it spread all 
over.
157 So two tasks were stimulated by geneticists, CPK and AFP, and one 
stimulated by the Health Board with PKU.
158 
Bobrow: I guess, for completeness, from my memory, Nick Wald was in Oxford 
and did much of the basic work.
159 This came out of a collaboration between 
genetics and Nick Wald and was driven clinically from the Oxford genetics 
department. It wasn’t all done there, but it was controlled there. So, quite a 
mixed pattern across the country. Now, dysmorphology.
donnai: We didn’t invent dysmorphology (the study of malformation). You have 
to remember that within pathology and anatomy, there had been many scholarly 
descriptions of syndromes in the old literature that we now recognize. In the 
UK, when I first began in genetics, people like Cedric Carter were undertaking 
epidemiological studies about individual malformations like cleft palate and 
Hirschsprung disease, etc., and deriving risk figures which are very good and still 
155  Consultant Paediatricians and Medical Officers of Health, South-East Scotland Hospital Region (1968).
156  Duchenne muscular dystrophy (DMD) affects 1 in 3500 newborn males, causing progressive weakness 
of the muscles. The test involves the measurement of an enzyme (CPK) using the neonatal blood spot 
collected  for  the  phenylketonuria  test,  part  of  the  routine  newborn  bloodspot  screening.  A  newborn 
screening programme for DMD has been running in Wales since 1990, evaluated (1990–98) and health 
authority-funded from 1998. Bradley et al. (1993).
157  Brock (1990); see note 152.
158  National Medical Consultative Committee, Working Group (1986).
159  See note 154.Clinical Genetics in Britain: Origins and development 
64
Figure 15: dysmorphology Club meeting invitation, 1982.Clinical Genetics in Britain: Origins and development 
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in use today. But in terms of the individual syndromes, I don’t think that was 
Cedric’s focus. The term dysmorphology was probably coined by David Smith 
in Seattle, who was working in the 1970s.
160 In the US there were a series of 
conferences supported by the Teratology Society and the March of Dimes.
161 
David Smith was an excellent teacher and had quite a lot of fellows. He died 
tragically early in 1981 and his ex-fellows set up a series of conferences that are still 
going on, the David Smith workshops on malformations and morphogenesis.
162 I 
was the first person from the UK to attend this meeting in 1984. 
But things were going on in the UK as well and indeed in 1984 I began the 
biennial series of Manchester birth defects conferences, called the Manchester 
Dysmorphology Conferences from 2008, which are still hugely oversubscribed 
and very international now. This is something that has been one focus of 
dysmorphology in the UK. But dysmorphology in the UK was built on the 
interest and enthusiasm of a number of individuals, and foremost among these 
were Michael Baraitser and Robin Winter, initially of the Kennedy-Galton 
Centre and then at Great Ormond Street. People forget that Robin worked for 
a long time at the Kennedy-Galton. I remember Michael, Robin and I standing 
in corners at CGS meetings with slides looking at pictures of patients in the late 
1970s. The Dysmorphology Club, which is still held three times a year at Great 
Ormond Street, began as a lunchtime meeting when Cedric was still there, 
in the library, I think in 1980. I travelled all the way down from Manchester, 
which was quite a long journey in those days, three hours plus, for this one-hour 
lunchtime meeting and then went all the way back. I eventually persuaded them 
that it should be at least half-a-day. So in 1981, I think, when John Burn was 
there, we had this half-day meeting and wider participation from other centres 
was encouraged. By 1982 it was so popular that this was a whole-day meeting 
and I’ve got records of John’s invitation to the meeting asking for £1 from all 
participants for tea, coffee, biscuits and photocopying (Figure 15).
That tells you how long ago that was. I think the Dysmorphology Club, as well 
as being useful for the diagnosis of individual patients, was extremely important 
in defining new syndromes by people being extremely collaborative, setting up 
research collaborations, and in fact some of the major studies that have been 
160  Smith (1966, 1977).
161  See www.teratology.org (visited 6 May 2009) and for details of past annual meetings of the Teratology 
Society, see www.teratology.org/archivedMeetings.asp (visited 6 May 2009). See also www.marchofdimes.
com (visited 6 May 2009).
162  See http://dwsmith.org/ (visited 6 May 2009).Clinical Genetics in Britain: Origins and development 
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Figure 16: Contents of the first issue of Clinical Dysmorphology, 1992. Clinical Genetics in Britain: Origins and development 
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done on individual syndromes were started from that group. I think it’s the 
perfect example of a cooperative. It only cost £1; it wasn’t official in any way, 
and it still isn’t official in any way, yet it’s enormously popular. 
Robin and Michael, meanwhile, were working on another major contribution to 
dysmorphology, that is the dysmorphology database, and the prototype of that 
was distributed informally from about the mid-1980s and then published by 
Oxford University Press in 1990. It’s a tool for experts and it’s in use worldwide 
still. Following Robin’s death in 2004, Michael has continued to ensure that 
this is up to date and that excellent standards are maintained. He renamed 
it the Winter-Baraitser Dysmorphology Database and this is now distributed 
by Michael.
163 There’s also the journal, Clinical Dysmorphology, which is in 
the colour that Robin chose and we always used to call ‘dysmorphology pink’ 
(Figure 16). After Robin died, Jill Clayton-Smith joined me, so Jill and I are the 
editors now, although Michael still supports us. 
I think there have been a number of centres in the UK that have trained people in 
dysmorphology and have populated many other centres as well: London, Great 
Ormond Street and Guy’s being the main ones; and then there’s Manchester; 
and then in Cardiff, Helen Hughes was recruited by Peter Harper in about 
1986. Obviously John Burn went from Great Ormond Street to Newcastle and 
Judith Goodship joined him there. Those have been the main centres where 
there has been a lot of dysmorphology research as well as training. 
The last point I’d like to make focuses on the patient cohorts that have been 
built up over the years that are national patient cohorts, and have been often 
in  collaboration  with  patient  groups. There  has  been  incredible  progress  in 
identifying the genetic mechanisms underlying many of these syndromes that 
we’ve always recognized as families of syndromes linked by phenotypic similarity. 
It’s very gratifying that by understanding the pathways in which the genes that 
are mutated operate that our clinical ‘eyes’ are now being given some credence. 
We’re even, for some of these disorders, beginning to look at the possibility of 
modifying the disease process and even treatment. So, I think dysmorphology has 
moved on from when I first went into genetics. I remember somebody saying to 
me: ‘What does dropping out of real medicine feel like?’ I feel that we’ve all been 
very privileged to be able to be involved in the delineation of disease, the study 
of natural history, and then understanding of the mechanisms and beginning to 
look forward to the treatment of some of the most intractable and rarest diseases.
163  See www.lmdatabases.com/about_lmd.html (visited 6 May 2009).Clinical Genetics in Britain: Origins and development 
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Burn:  Apart from saying that Dian Donnai has been absolutely influential 
throughout the last 20 years in keeping dysmorphology focused as a clinical 
aspect of our specialty, I think it is worth noting historically that the beginning 
of the 1980s was a very important time for the specialty because that was when 
we grabbed hold of paediatrics again. I joined having completed a paediatric 
training.  People  like  Peter  Harper  had  established  our  presence  in  general 
medicine, but we hadn’t secured our base as a paediatric subspecialty. It gave 
us an area that we as a group of clinical consultants could genuinely own. We 
could go to any city, any hospital within the country and we walked tall because 
we could recognize Rubinstein Taybi syndrome and they couldn’t. That still 
is an asset to clinical geneticists and it’s one of the reasons why we won’t die 
out, I suspect, because you need someone who focuses on doing rare problems 
enough so that they can get their eye in and keep it in, and you can’t actually 
get rid of that. I should say that Michael Baraitser was a source of encyclopaedic 
knowledge and was the most wonderful man to work with, but he was an adult 
neurologist. I remember having to teach him how to examine children; he 
thought they always cried when you examined them. I showed him how to do 
it without actually making the child cry and it was a great illumination to him.
pembrey: I think we’ve illustrated how clinical dysmorphology took off from 
that first meeting in 1980, but there were some real politics behind the scenes, 
which largely fell to Michael Baraitser and me. When we said we were going 
to do that meeting, every single paediatrician in Great Ormond Street felt they 
should be invited. We only had a small space, and they all came and wanted 
to know why we couldn’t change the time because it clashed with their clinics 
and so on. So, the paediatricians realized what was happening and we had to 
decide how we were going to deal with it. We didn’t want it to be elitist, by 
invitation only, so we decided we would talk dysmorphology in fine detail 
with no concessions for people who didn’t know what we were talking about. 
That continued, and after three meetings, all the general paediatricians stopped 
coming. It defined the subspecialty, and it worked a treat.
Bobrow: Yes. This is the secret of much good government. Excellent. Let’s 
go from that to the subject of how the counselling side of genetic counselling 
developed. 
skirton: We have less history, I think, but nevertheless it’s very much entwined 
with the history of medical genetics and our medical colleagues. As we’ve heard, 
in the early days – even in the 1960s but certainly in the 1970s – there were 
a few health visitors or social workers who were working as part of a clinical Clinical Genetics in Britain: Origins and development 
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genetics team or alongside medical geneticists. But we date our profession from 
1980 when the association was formed with nine nurses and one social worker: 
it was named the Genetic Nurses and Social Workers Association (GNSWA) 
and that name stuck until we joined the BSHG and took the opportunity to 
change our name, partly because we’d sat in meetings with John Burn for many 
years while he laughed at the name. So we had wanted to change the name for 
some time. During the 1980s the association gradually grew from the original 
ten members to roughly 100 members in about 1990. It’s true to say that there 
were some initiatives that helped the growth of the genetic nurses and later 
genetic counsellors. One of those was the course established by Mary Rogers 
in Cardiff under the Welsh Nursing Board, which was a module in genetics 
nursing that was the key to many people developing the skills they needed to 
work more autonomously in the field. Up to that time, we had all worked and 
learned on the job, by a process of osmosis, working alongside our very skilled 
medical genetics colleagues. But that course defined a new type of skill for 
genetic nurses, alongside those we already had. As I mentioned, we had a lot of 
support from the Clinical Genetics Society and we started a scientific meeting 
in the late 1980s. At the time there was no such thing as a genetic counsellor 
and there is someone sitting to my right – Lauren Kerzin-Storrar – who is 
virtually responsible for single-handedly introducing that breed of person to the 
UK. Lauren trained in the US, came to Manchester and was very innovative. 
She introduced a Masters’ degree in genetic counselling that has since trained 
many counsellors. 
At that time there were changes in nursing which meant that nursing was 
becoming  more  professionalized,  and  nursing  practitioners  were  becoming 
more autonomous. There were also these counsellors who had a Masters in 
genetic  counselling  but  no  other  professional  background,  and  we  started 
to think about regulating this new profession. Nurses had their professional 
statutory guidance, but the genetic counsellors who had done the Masters did 
not. We felt that there were concerns about setting standards for patient care. 
During the 1990s, Penny Guilbert, who’s not here today but has had a huge 
part in this, started an education group, which I chaired for a long time. And 
we started to look at education, the role and the scope of working of genetic 
nurses and counsellors. We four here – Chris Barnes, Ann Kershaw, Lauren and 
myself – were in the education working group and first we did a study where all 
the genetics nurses and counsellors and the medical geneticists in the UK were Clinical Genetics in Britain: Origins and development 
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asked what they thought the role and scope of practice for genetic nurses was.
164 
That was quite powerful, because not only did we have the views of nurses, we 
had those of our medical colleagues. We did this study in 1996 and I have to say, 
it was wonderful to get the responses from our colleagues who demonstrated 
their faith in the way that we were working and developing. It was the impetus 
for us to go on and develop more autonomous roles. At that time, most of us 
were seeing some patients on our own, as well as doing pre- and post-clinical 
work with our colleagues. There were occasional pockets where nurses were 
still getting the doctors’ coffee and changing the sheets on the examination 
table – and that is true – but this study helped us to change those outliers. We 
did publish a couple of papers on our role and the educational standards, and 
we started to think about registration.
165 In 2001 the Association of Genetic 
Nurses and Counsellors voted to have a registration system, a voluntary system, 
whereby  people  demonstrated  their  competence  through  a  portfolio. That 
system has been highly successful to the point where now we are actually one 
of the professions applying for registration through the Health Professions 
Council, and we hope that next year (2009) that will become a reality for us, 
and it won’t be a voluntary system any more, but one that truly establishes our 
profession among the big boys.
166 
Bobrow: Lauren, do you want to say anything?
Kerzin-storrar: Not so much in the historical sense or about the evolution of 
the profession, but something about the kind of ethos and scope of non-medical 
colleagues in the clinical genetics team. We’ve talked about some of the very 
early pioneers like Kathleen Evans at Great Ormond Street and Audrey Tyler in 
Cardiff, who were from social work backgrounds. But I think it’s fair to say that 
in the early days those individuals and other health visitors were often employed 
on research money with the aim of gathering extended pedigree information 
and to obtain research samples. It started out in that way. The role then moved 
to  encompass  provision  of  psychological  support  around  pregnancy  issues 
and diagnoses, and now it has evolved to a combined role which includes the 
previous roles, but also autonomous genetic counselling for individuals where the 
diagnosis is established. It now includes discussion of the genetics and decision- 
making around testing with patients and their families. That is important to say. 
164  Skirton et al. (1997, 1998).
165  Fine et al. (1996).
166  See Appendix 2, pages 87–8.Clinical Genetics in Britain: Origins and development 
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The issue about the term ‘genetic counsellors’ has been something interesting, 
because I’ve worked now for nearly 30 years in the UK in this field, and 
for a long time – I’m looking at Peter Harper because we have had a lot of 
discussions about this over the years – for a non-medical geneticist to call 
themselves a genetic counsellor was a difficult issue. And my sense was that 
when you as medical geneticists were still establishing yourselves as a recognized 
subspecialty, you rightly thought you were doing genetic counselling – and you 
do do genetic counselling – and that’s what you, in many ways, saw yourselves 
as, in addition to being diagnosticians. But as you’ve become more established, 
I think people became more comfortable to call a different group of individuals 
‘genetic counsellors’. In past editions of your Practical Genetic Counselling, 
Peter, there was always a little paragraph – and I used to go and look at it with 
each edition to see where you were up to in your thinking – and it’s evolved 
quite a lot.
167 
skirton: May I add to that? Virtually every genetic nurse or counsellor I have 
ever known has confessed that, for the first two or three years of their practice, 
they didn’t let Peter Harper’s book out of their sight for more than about five 
minutes because we relied on it so much. 
May I share one anecdote that reflects the naivety of the Genetic Nurses and 
Social Workers Association in the early days? We didn’t know what we were 
doing and it was decided that a constitution should be established for this new 
association. But no-one had ever done that before and one of the members of 
the group was a member of a sailing club and she went and got the constitution 
for the sailing club and they crossed out ‘sailing’ and put ‘genetic nursing’. We 
lived with that constitution until the BSHG was formed.
mrs ann Kershaw: There are two people here that have certainly had a huge 
effect on my career in genetics, and the reason I’m in genetics is because, as a 
health visitor, one day I went to a talk and there was somebody called Clare 
Davison there who was so enthusiastic about this thing I had never heard of 
called ‘clinical genetics’, that I thought, ‘I have got to do this.’ So after many 
years working in the department of genetics in Cambridge and enjoying my 
role, but feeling that we perhaps hadn’t quite developed, Martin Bobrow came 
along and I remember him sitting down and talking to me, and we sat in a clinic 
and he said: ‘I think you’re all far too well qualified to be sitting in a corner. 
167  See the section on ‘The genetic counselling clinic’ in Harper (1981): 114–15 and Harper (2004): 138–9.Clinical Genetics in Britain: Origins and development 
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Go out and see patients.’ And that’s what we started to do. Counsellors in our 
department now see 40 per cent of referrals and work very happily alongside 
our medical colleagues; the thing that has grown is the mutual respect that 
we have for each other, and that’s something that I value and I think benefits   
our patients.
ms Chris Barnes: I’m the fourth member of our merry band and I want to 
acknowledge the Department of Health. In the 2003 Genetics White Paper,
168 
it was acknowledged officially that a training scheme for genetic counsellors 
was needed, something that the four of us, together with our other colleagues, 
had striven very hard to establish. The funding for that scheme enabled us 
to appoint 43 trainees, who have either graduated from that scheme or are 
still in training, and this has been an enormous help. We have had many 
productive conversations with the Department of Health about the importance 
of training genetic counsellors and the future of genetic counselling. Without 
the Department of Health’s help we wouldn’t have the strong position that we 
do now.
professor angus  Clarke:  I think it is interesting to think about what has 
happened in the UK and compare that with what’s happened in European 
countries, where the role of genetic counsellor is hugely varied; in some countries 
it is very well developed, but in others it scarcely exists. In some countries the 
one or two genetic counsellors there have to develop the role against a rather 
hostile bunch of medical practitioners. It would be interesting to think through 
the factors that have led to those differences.
Harper: Thanks to Heather Skirton and others for being so charitable. I look 
back  at  the  early  editions  of  my  own Genetic  Counselling  book  sometimes 
and think: ‘Good heavens, did I write that?’
169 I have to say my attitudes have 
changed a lot. I am particularly interested and heartened by what Heather has 
said, because I myself have always felt that the links between genetic counsellors 
and nurses, and the clinical geneticists have always been strong and mutually 
supportive. But, then I wondered: ‘Well, is it just me thinking that?’ I started 
reading quite recently about the experience in the US, where there was a very 
bitter division in the late 1970s. I hadn’t realized how bitter until I read about 
it; a very exclusionary – mutually exclusionary – attitude was taken up by both 
168  Department of Health (2003). The White Paper covered arrangements in England, with those in Wales, 
Scotland and Northern Ireland outlined in an appendix.
169  See page 71. Clinical Genetics in Britain: Origins and development 
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camps. I hadn’t realized this had even happened and I thought: ‘My god, I’m 
sure we didn’t have that same problem in the UK’. So, I am relieved to hear 
Heather say that we didn’t. 
May I put in a plug for records? I think the early records of groups like the 
Association  of  Genetic  Nurses  and  Social Workers  and  these  other  groups 
are important, particularly those from the stages before they got big or too 
formalized. The Dysmorphology Club, again I hope people will make an effort 
to preserve these records.
Hodgson: I’d like to bring in cancer genetics here, because it doesn’t get a 
heading, as I’ve noticed, but it is something which has become a very large 
part of clinical genetics in the last 20 years or so. Certainly, in the 1990s cancer 
genetics was hardly known, and then people like Bruce Ponder
170 and Joan 
Slack
171 started clinics and then it mushroomed, as everybody knows. Of course, 
I was interested in what Angus Clarke said because I did a survey of cancer 
genetics services in different European countries and the services were very 
much enhanced in the countries where nurses were able to practise and help 
with the service, because it’s the sort of service where you need a lot of people 
and certainly nurses and other non-medical people can play an enormously 
important part in developing this kind of service.
172 So I would say that that’s 
been very important in this major development in clinical genetics.
skirton: That’s very interesting, Shirley, and I was going to mention that, in 
the survey we did in 1996, we asked medical colleagues and nurses where they 
thought development of genetic nursing would lie, and cancer, which was just 
looming on the horizon as a very big task, was cited as an area where genetic 
nurses could play a major role. 
I want to go back to what Peter Harper said because I think when we oldies sit 
around and talk about how our careers have developed, we always go back to 
the central component of the development of a trusting relationship between 
individuals, between a doctor and a nurse working in a department that enabled 
that person to develop and go on to become a leader in the profession. I think 
perhaps that is what differs in Europe and some other countries, but it is 
certainly true for us in the UK. 
170  Ponder (1987, 1991).
171  See, for example, Murday and Slack (1989); Iselius et al. (1991); Houlston et al. (1991, 1992). 
172  Hodgson et al. (1999); Hodgson (1999).Clinical Genetics in Britain: Origins and development 
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Bobrow: Peter, you were going to explain why cancer genetics is not on the 
agenda.
Harper: We didn’t forget about cancer genetics, but felt that not only was it 
pretty recent but that it was a very big topic and that to cover it would require 
a completely different community and set of people. So we thought we’d leave 
that for Shirley Hodgson or somebody to suggest as a separate Witness Seminar.
donnai: Angus Clarke raised the issue as to the reason why genetic counsellors 
and clinical geneticists and most of us work in relative harmony most of the 
time. Firstly, I think that is because we have a socialized healthcare system, 
and secondly we have regional genetic services. One of the few other countries 
where this exists is the Netherlands and I think services have similarly thrived. 
Whereas in the US, of course, there are pockets of great brilliance in genetics 
and genetic research, but many of my colleagues in genetics in the US are 
one-man bands. People there call themselves dysmorphologists and have no 
connection whatever with genetics. I never call myself a dysmorphologist, I 
call myself a clinical geneticist, because that is the family to which we belong 
and I subspecialize in that particular area. Even in France, although there are 
attempts to try to look at things country-wide – they’ve got excellent services for 
people with rare diseases and investment in research into rare genetic disorders 
– they still haven’t got the same approach to regional genetic services. In the 
UK, there is cooperation between centres, and collaboration in research studies, 
a willingness to let other people have your patients and samples from your 
patients or to be part of a multicentre study – these are part of the reason that 
UK genetics has been so successful. 
Bobrow: Interesting comment with which I will not argue just yet. What did 
I mean? That’s not fair, is it? I think there are lots of examples within the NHS 
of other parts of the medical profession who still today regard anyone who 
doesn’t have a medical degree as pretty subservient. I think we got over that as a 
community a couple of decades ago and I think that we were ahead of the game. 
I am going to go back to the agenda. We are going to skip the role of lay 
societies, with some regret, because as it turns out, although several people were 
invited and slightly fewer agreed they would be here and on the day – for one 
reason or another – there aren’t any attending. So we will note, and I don’t 
think there’s any argument about it, that there’s been a lot of interplay between 
the professions and lay societies in the field of inherited diseases. They’ve been 
extremely active and incredibly helpful; it’s been a very productive relationship Clinical Genetics in Britain: Origins and development 
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and we all know who should have been here to talk about it, and you’ll try to 
somehow or other to work it in when you write, about the ethical and social 
dimension in clinical genetics.
173
Clarke: It is usually the ethical and social bits that drop off the end of the 
agenda. Obviously, in a sense, it would need a much bigger group of people to 
try to represent what has been discussed regarding the social and ethical issues 
surrounding genetics, because it has involved so many more people than those 
within the profession. I will try to mention three or four themes or issues that 
have cropped up and come out with a few statements relating to each and 
people can carry on discussing it over a glass of wine afterwards. The areas I’m 
going to think about are: reproduction, very generally; testing individuals with 
an individual focus, that’s another area; family issues, that’s a third area; and 
then the transition between research and service, as a fourth. There are a lot of 
other ways one could do it. 
There are a lot of issues around reproduction – I feel I came into this halfway 
through – but as I remember, if you look at some of the literature in the 1970s 
and 1980s, there were a lot of papers about reproductive population screening 
which focused very much on population outcomes, cost of screening versus 
cost of care and things like that, which I think caused quite a bit of offence 
outside the medical community and made quite a few people within it uneasy.
174 
There was an effort to shift terminology away from cost rationales for screening 
through into individual and informed choice, and to some extent that has been 
a cosmetic operation. I think that it’s not only cosmetic, but there has been quite 
a significant shift in how services are delivered, if you look back 20 or 30 years. 
But there was quite a lot of debate, I think, particularly in this service, and the 
disability rights groups were quite vocal in discussing these topics in a very broad 
public agenda. I think professionally that led into a desire to emphasize non-
directiveness as a way of distancing ourselves from the more public-health driven 
screening programmes. One can see how that shift towards non-directiveness 
was a way of preserving one’s dignity as a profession and was, I think, synergistic 
along with the development of the genetic counselling community. I think, 
173  See, for example, note 141.
174  Professor Angus Clarke wrote: ‘For the use of “cost of screening is less than lifetime cost of care” as 
justification of antenatal screening, see Hagard and Carter (1976), which raised the important questions 
and called for a debate that then failed to happen. See also Boston (1981); Wald et al. (1992); Anon. (1992); 
Shackley et al. (1993); Piggott et al. (1994); Clarke (1997a).’ E-mails to Mrs Lois Reynolds, 11 and 15 
March 2010. Clinical Genetics in Britain: Origins and development 
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to some extent, those things were happening at the same time. Following on 
from that battle, because it is more or less won, I think the individual focus on 
reproduction has carried on in other ways: there have been discussions about 
terminations of pregnancy for less serious conditions, preimplantation genetic 
diagnosis and for what conditions termination is acceptable. Those things have 
come along more recently and they’ve had a much greater focus on what the 
individual family or woman wants to do, and negotiating that outcome with 
the professionals rather than stepping back to the population perspective. 
Moving on to testing individuals and how that has developed, or been thought 
about, while I was just beginning to get into genetics – from the beginning 
as far as I was concerned – there was a very cautious approach to predictive 
testing, particularly as the early testing for Huntington’s disease served as a 
paradigm for this.
175 This very cautious approach of ‘Let’s go very gently, see 
what happens’ and to develop the service in that way again fitted in with the 
genetic counselling perspective. I can see one or two factors that led into that: 
one was the involvement of the patient support groups and family federations 
in the mid-1980s. I don’t know how big a factor this is, but I think it might 
be relevant that the clinicians involved in predictive testing for Huntington’s 
disease often came out of a research base where they had tracked families, got on 
their bikes and gone around and met a lot of family members, collecting blood 
samples to do linkage studies that were an essential preliminary before this 
could happen. So, there were a lot of clinicians who had met and got to know a 
lot of affected, at-risk, and unaffected and married-in spouse members of these 
extended families. That helped, and I think, perhaps, the relationship with the 
family support groups reinforced this very calm decision to have a very cautious, 
measured approach to things. Maybe I’m reading too much into the personal 
experiences of the clinicians, I don’t know. This strand of being cautious has 
developed since then as well; an obvious example that I’ve been involved with 
is genetic testing in children. That was at the Clinical Genetics Society working 
group reporting the early 1990s, which Lauren Kerzin-Storrar contributed to 
and that is a topic that still bubbles away on the back burner and hasn’t quite 
gone away.
176 But that’s another area where this has carried on, and I suppose 
175  See, for example, Craufurd and Harris (1989); World Federation of Neurology (1989, 1993); Tyler et al. 
(1992); Harper and Clarke (1990); Harper (1997); see also Harper et al. (1981). 
176  Professor Angus Clarke wrote: ‘There were protests by disability rights activists, such as one in London 
aimed at prominent medical researchers enthusiastic about antenatal screening, carried on by the group of 
adults affected by Down syndrome, People First.’ E-mail to Mrs Lois Reynolds, 11 March 2010. See also 
Hubbard (1997); Parens and Asch (2000). Clinical Genetics in Britain: Origins and development 
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you can see it in our collective response – not quite a collective response, but 
the collection of our individual levels of distress – in relation to some of the 
inappropriate offers of susceptibility screening and the commercialized medical 
testing that one sees now.
177 I’m not sure that as a profession we’ve done very 
much about that, we’ve done little bits. But this measured approach to trying to 
help think through with families when a test is helpful and when it isn’t stems 
back to the mid-1980s. 
On to the family dimension, I’m thinking about privacy and confidentiality 
issues. There were quite a lot of fears and statements in Nuffield Council and 
RCP committees about how to deal with individuals in families who do not 
pass on genetic information to their relatives when we think they should.
178 This 
prompted quite a lot of ethical and legal soul-searching, and there’s been quite a 
lot of discussion about that, some fairly academic, but I don’t think it involved 
the profession and beyond half as much as it should have. But there’s been quite 
a lot of academic work on that and it’s been a theme that has cropped up in the 
Wellcome Trust biomedical ethics research programmes. There have been several 
projects they have funded on that.
179 One of the responses to that set of issues and 
concerns has been empirical studies of ‘how do family members actually handle 
communication and pass information on to one another?’, which has been a very 
productive response to tackle the difficult issues, rather than the profession, in 
deciding to introduce a set policy on forced disclosure and drawing up detailed 
statements about when to drive round to tell someone that a family member 
hadn’t passed information to them. A different route has emerged there. 
Regarding  research  into  service  transitions,  there  are  quite  a  few  that  one 
could touch on and several have been mentioned already: cancer genetics is 
one; the role of the genetic counsellor is another, so many of the early proto-
genetic counsellors being research funded.
180 Another is the legacy research 
177  Professor Angus Clarke wrote: ‘Numerous offers of commercial testing for genetic susceptibility to the 
complex disorders are available through the internet or face-to-face. These are of dubious worth and the 
evidence of any clinical utility is minimal or absent.’ Note on draft transcript, 11 March 2010. See also   
Rafi et al. (2009); www.hgc.gov.uk/client/Content.asp?ContentId=752 (visited 16 April 2010). 
178  Royal College of Physicians, Committees on Ethical Issues in Medicine and Clinical Genetics (1991b); 
Nuffield Council on Bioethics (1993); Clarke (1997c); British Medical Association (1998). 
179  Featherstone et al. (2006); see also, for example, Forrest et al. (2003). See 2004 feature on family 
communication by Karen Forrest at http://genome.wellcome.ac.uk/doc_WTD022305.html (visited 22 
January 2010).
180  For genetic counsellors, see pages 35, 68–72.Clinical Genetics in Britain: Origins and development 
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results generated in a project that then ceases, and you go back and look at 
the workbooks of people and wonder what to do with those results when a 
family or family member comes along. Also, the drive to proper laboratory 
accreditation has been quite an important transition. I think the cohorts of 
families who have been studied for research, particularly the big linkage families 
(the muscular dystrophies, Huntington’s disease and some of the cancers, in the 
linkage phase of the work), there were often management clinics or at least some 
sort of management bonus that the families involved got from participation 
in the research. As that phase of research has gone away, a lot of those clinical 
structures have lingered on, which I think is quite appropriate.
181 Then we 
come up against NHS definitions about what counts as a genetic service, to 
what extent provision of practical support is appropriate for a genetic service, 
and it shades into coordinating surveillance for those at risk of cancers. A lot 
of areas, particularly multi-organ cancers, are accepting the coordination of 
surveillance for people at risk of those conditions. Probably fewer want to take 
on coordination and surveillance for those at risk of maybe one tissue being 
involved, and leaving that to the surgeons or whoever. When it comes to the 
non-cancers, I think we’re in disarray and areas are very different and I think we 
should be working something out. I’ll be very interested in people’s comments, 
and I hope I’ve provoked a few people.
Bobrow: Is anyone provoked? Shirley is provoked.
Hodgson: Yes, I have a quick comment about the role in terms of surveillance 
for people with cancer-predisposing conditions. It’s interesting, because I did 
a survey of the management of people with hereditary non-polyposis colon 
cancer in the London regions. We wrote to a lot of GPs and gastroenterologists 
at  genetics  centres  and  asked  who  they  thought  was  responsible  for  the 
maintenance of the follow-up surveillance for these people, and everybody said 
it was somebody else. Basically nobody thought it was them. I thought that was 
quite interesting. There were one or two genetic centres that were beginning to 
think their registers could be used to help with this, but there were an awful lot 
that didn’t feel that the actual responsibility for sending out the appointments 
for surveillance was their responsibility. It was quite informative.
182
pembrey: I think it would be right to mention Gordon Dunstan in this because 
181    Professor  Angus  Clarke  wrote:  ‘These  clinics  arise  and  continue  or  cease  for  multiple,  complex, 
interacting reasons.’ E-mail to Mrs Lois Reynolds, 18 March 2010.
182  Geary et al. (2008).Clinical Genetics in Britain: Origins and development 
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from his base at King’s College London, as the holder of the first F D Maurice 
chair of moral and social theology, he was engaged fully with the Association of 
Paediatrics and the Clinical Genetics Society in various ways and was immensely 
helpful in the discussions.
183 I certainly felt so. 
The other thing that I want to flag up is that we’ve skipped over the Special 
Medical Development that the Department of Health funded, or we talked 
about it but perhaps have not drawn out as much as we might have from it. 
That funding went over three or four years and was then extended and grouped 
together in a very practical way, while we were working out how we were going 
to apply these DNA probes, what we should tell, what about the error rates, 
and so on. Certainly for me, I thought it was the groups getting together and 
thrashing out things like the objectives of what we were doing. I remember 
travelling back from Cardiff with Bernadette Modell and trying to find a phrase 
that countered the pro-lifers’ ‘search and destroy’ tag that they were giving the 
use of prenatal diagnoses using probes and so on.
184 Modell’s beautiful work on 
the succession of what happened in the Cypriot families with b-thalassaemia, if 
they didn’t know anything, they just went on having lots of children, some of 
whom would be affected.
185 When they had the counselling but not the prenatal 
diagnosis, they stopped having babies. But with the offer of prenatal diagnosis 
the number of pregnancies was restored to the level when they were ignorant of 
the genetic risk. This idea of restoring reproductive confidence, thinking that 
through – it’s all very obvious now – it was a way of presenting an objective 
for what we were doing then, among others, which I think was very helpful in 
moving things forward. 
Bobrow: I don’t see anyone else rising strongly. It suggests that what you’re 
saying sounds less revolutionary than it might have done a year or two ago. It 
was an extremely fair summary, I thought. If I move on from the ethical issues, 
we’ve heard nothing yet about the interface with primary care. We happen to 
have one former GP, self-confessed – although I hadn’t known about Ian Lister 
Cheese – and two others, Hilary Harris and Michael Modell. 
professor michael modell: Very briefly: I have tried to get primary care engaged 
in genetics since about 1990. My aim has been to encourage health professionals 
183  See, for example, Shotter (2004); Reynolds and Tansey (eds.) (2007): especially 17, 45–7, 75–6, 107–8, 
175–6.
184  See, for example, Christie and Tansey (eds) (2003): 70.
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to view genetics as part of mainstream clinical and reproductive medicine. Until 
recently, I suspect most family doctors considered clinical genetics to be a very 
specialized subject, only affecting a few of their patients and therefore of limited 
interest. GPs have little contact with clinical geneticists. They usually refer one 
or two patients with a possible inherited condition (or anxiety about their family 
history) every couple of years. If a genetic diagnosis is confirmed, the patient 
and family are then likely to be referred on to another hospital specialty (e.g. 
lipid clinic, paediatrics or haematology, where patients with the commonest 
single gene disorders are seen). From then on the interaction will be between 
the primary physician and secondary care specialist, rather than between the 
primary physician and clinical geneticist.
The narrow primary care view of genetics is slowly changing, partly because of the 
introduction of the national reproductive screening programmes, the increasing 
emphasis on family history, the establishment of the NHS National Genetics 
Education and Development Centre
186 and the work of the small number of 
GPs with a special interest in genetics. We are beginning to make some headway 
encouraging GPs, health visitors and community nurses to consider genetics 
as part of mainstream medicine. For example, the postgraduate curriculum of 
the RCGP includes a substantial section on genetics in primary care. In spite 
of that, there still often appears to be a gulf between primary care and clinical 
genetics. Perhaps the problem lies within primary care, though it is also possible 
that many (but certainly not all) clinical geneticists have difficulty relating to 
primary care because there is so much of it and it seems rather remote. Primary 
care has not figured much in today’s seminar.
dr Hilary Harris: The difficulties don’t lie in primary care. Of course, they do 
a little, but I think there is enormous synergy between genetics and primary 
care, because we look after families, we look after them for a long time, all 
the elements are in place, but, as Michael said, the anxieties about the work 
of genetics are sometimes overwhelming. I think where we have made huge 
progress – and where I think the building blocks are there – is in the take-up of 
IT within primary care. I’m quite surprised that that’s not come up at all this 
afternoon, because it’s such a major part of actually looking after people. When 
186  The NHS National Genetics Education and Development Centre, funded by the Department of Health 
and located at the Birmingham Women’s NHS Foundation Trust, was one of the major initiatives of the 
2003 genetics White Paper (DoH (2003)) to ensure that the potential benefits of genetics are realized by the 
NHS and is intended to improve the understanding of genetics among all health professionals and its role in 
modern healthcare. For further details, see www.geneticseducation.nhs.uk/about-us/key-aims.aspx (visited   
22 January 2010).Clinical Genetics in Britain: Origins and development 
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you think that in a practice of 5000, where I practised until quite recently, we 
had every major diagnosis on the computer. I’m quite sure that’s so for every 
practice in the country. It’s quite easy to have a register; it’s quite easy to look for 
people, to screen them, to put in prompts, to recall them, all the things which I 
think are also elements of genetics. 
Sadly, thinking back to the 1990s, and again we haven’t mentioned the Human 
Genetics  Commission  (before  that  the  Advisory  Committee  on  Genetic 
Testing)
187 both of which, I think, have had quite a large influence on not just 
clinical genetics but on public involvement as well. In primary care we are 
just beginning to make progress, and I have to say that I think some of the 
Government initiatives that followed in the early 2000s have set us back. I 
think the Quality and Outcome Framework,
188 which directed primary care 
towards common chronic conditions, very appropriately, but also tied income 
generation to that, which would never be appropriate for genetics because of 
the ethical issues involved. Secondly, of course, and much more recently, I think 
the possible devolvement to ‘polyclinics’ – and I hate the word, but in London 
you’re definitely going to have them – may well set back exactly what we need 
in genetics, where people are being looked after in a very comprehensive way by 
a small team of GPs and other primary care workers. All of that is meant to be 
possibly set aside. So I think we have got quite large difficulties. But, having said 
that, perhaps certainly the Genetic Education Centre in Birmingham has made 
enormous progress with general practice.
189 Things like the general practitioner 
with special interest (GPSI), which I have to say I think were a sop. Do you 
agree, Michael? Ten GPSIs, in this case in genetics, were never going to do 
anything. There were to be ten of them, and only nine were appointed.
Bobrow: So the synergies and the common interest are as obvious now as they 
were when I first met you, I guess. And the progress has been stodgy and it’s 
largely organizational. And it is difficult to see how one gets through that because 
of the way GPs’ lives are structured. That’s a slightly sour note on which to end. 
187  The Human Genetics Commission was established in 1999, following a comprehensive review of the 
regulatory and advisory framework for biotechnology by the UK Government. For further details of its 
work, see www.hgc.gov.uk/client/Content_wide.asp?ContentId=6 (visited 21 January 2010).
188  A voluntary annual reward and incentive programme was introduced for all GP surgeries in England by 
the Department of Health in 2004, detailing practice achievement results and rewarding good practice. The 
2008/9 programme contained four domains: clinical care, organization, patient experience and additional 
services. For further details, see www.qof.ic.nhs.uk/ (visited 22 January 2010).
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modell: We are beginning to move forward. For example, the Primary Care 
Genetics Society (PCGS) was established a couple of years ago (2006) to support 
primary care practitioners with an interest in genetic medicine.
190 The society 
is affiliated to the RCGP. So far it has organized two conferences focusing on 
education  of  practitioners,  links  with  support  organizations,  cancer,  family 
history, cardiovascular disease and over-the-counter testing. I believe that, so 
far, there are about 200 members from various health professions. This society 
seems to be getting off the ground rather more successfully than our previous 
efforts over the last two decades to raise the profile of primary care genetics.
Bobrow: I’m deeply grateful to you for a cheerier note on which to end. We 
are five past six, and that’s past the drinking hour. I’m extremely grateful to 
those who set up and organized this, and to all of you for an instructive and 
entertaining afternoon. There’s one thing that hasn’t been said about the way in 
which clinical genetics has evolved in this country over the last little while that I 
wanted to add at the end. My personal experience has been that I have worked 
with an enormously collegiate and pleasant group of people. I’m surprised at 
how few people there are in the profession that I know that I’ve come across 
that I dislike – in fact, hardly one. And it’s not because I’m naturally like that, 
believe me. I do think there’s been a very good common spirit, a spirit to solve 
problems rather than to make them, and to work across boundaries that has 
been reflected in a lot of advance, and it’s a great credit to all of you. So let’s 
hope the next lot do as well. Thank you very much indeed. 
tansey: Before we all go for our glass of wine, may I say that it’s been a very 
entertaining and fascinating afternoon. It’s been a privilege to listen to some of 
your stories, and indeed there are at least two or three further Witness Seminars 
that I can see developing out of this meeting. Two of them were suggested to me 
at tea time. So if you do want to develop something further, please let me know, 
or perhaps consult Peter Harper as well, because he’s now very experienced 
in these matters. I would like to repeat the appeal made earlier for any other 
archives or books, to talk to Peter Harper or Tim Powell about donating those, 
if you could. I would finally like to thank Peter Harper, who has worked very 
closely with my team in setting up this meeting, and certainly to Martin Bobrow 
for chairing it so ably and getting us to our drinks on time. Thank you.
190  See www.pcgs.org.uk (visited 6 May 2009).Clinical Genetics in Britain: Origins and development  – Appendix 1
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Appendix 1
initiatives supporting clinical genetics, 1983–99 
by professor rodney Harris
191
date initiative by intention action and publication
1983 Clinical Genetics 
Society, Working 
Party on the Role and 
Training of Clinical 
Geneticists, Rodney 
Harris (chair)
Clinical Genetics Society, 
Working Party (1983)
1987 Fourth King’s Fund 
Forum, London, 
30 November to  
2 December 1987
A single body 
representing clinicians, 
genetic nurses, scientists 
and the public, founded 
by the Association of 
Clinical Cytogeneticists, 
the Clinical Genetics 
Society, the Clinical 
Molecular Geneticists 
and others active in  
this field
Harris (1988)
191  Distributed at the Witness Seminar on 23 September 2008. Many initiatives were facilitated by 
successive Chief Medical Officers (Sir Henry Yellowlees and Sir Kenneth Calman) and by Dr Ian Lister 
Cheese of the DHSS.Clinical Genetics in Britain: Origins and development  – Appendix 1
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date initiative by intention action and publication
1990 Royal College of 
Physicians of London, 
Committee on Clinical 
Genetics, 1990
1. Genetic principles 
added to medical 
training
2. Manpower: 
consultant and senior 
registrar numbers and 
distribution: targets for 
regional genetic  
services
3. Clinical and 
laboratory genetic 
services organized 
‘Under one roof’
4. Establishment and 
training of genetic 
associates: key roles  
of nurses and others  
in genetic services  
and research
5. Special Medical 
Development: 
recognition of clinical 
importance of 
molecular genetics
1. Survey of undergraduate 
teaching in British medical 
schools reported by the 
medical Deans; Royal 
College of Physicians of 
London, Committee on 
Clinical Genetics (1990); see 
also Harris (1990)
2. Regular communications 
between RCP clinical 
genetics, specialty advisory 
committees, the JCHMT 
and DoH 
3. Harris (1991)
4. CMO and Ministers 
lobbied direct
5. NHS funding for special 
medical development: DNA 
laboratories. DHSS (1987); 
Harris et al. (1989)Clinical Genetics in Britain: Origins and development  – Appendix 1
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date initiative by intention action and publication
1995 European 
Commission, 
Concerted action 
on genetics services 
(CAGSE)
Medical genetics recognized 
as a specialty in the UK 
in 1980; CAGSE set up a 
clinical geneticists’ network 
to stimulate recognition 
of medical genetics across 
Europe; to investigate the 
structure, workloads and 
quality of genetic services 
and the different country 
response to the new 
opportunities and challenges 
of clinical genetics. Harris 
and Harris (1995)
1999 Royal College 
of Physicians of 
London, National 
Confidential Enquiry 
into counselling for 
genetic disorders by 
non-geneticists
To investigate the 
quality of genetic 
counselling provided 
by non-geneticist 
clinicians (obstetricians, 
paediatricians, 
physicians, etc.); 
to make general 
recommendations and 
specific standards for 
improving care
A review of clinical notes 
relating to avoidable births 
of Down’s, neural tube 
defects and thalassaemia, 
the birth of second or 
subsequent CF children 
in family cases of multiple 
endocrine neoplasia type 2, 
to ascertain what counselling 
was recorded. Chief finding 
was extremely poor records. 
Subsequently a wide 
dissemination of reports 
occurred. Royal College 
of Physicians of London, 
Committee on Clinical 
Genetics (1999)Clinical Genetics in Britain: Origins and development  – Appendix 2
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Appendix 2
the association of Genetic nurses and Counsellors (aGnC) 
by professor Heather skirton
192
date timeline
1960s–70s Appointment of few individual nurses and social workers to posts in 
genetic centres, variable roles.
1980 Genetic Nurses and Social Workers Association (GNSWA) established 
with nine nurses, one social worker and a written constitution.
1990 GNSWA had c. 100 members, one meeting a year as part of the 
Clinical Genetics Society (CGS) meeting. Development due to strong 
relationships between medical geneticists and nurses. Members had 
a background in midwifery and HIV; tradition of home visiting 
established. The Welsh Nursing Board module in genetics nursing ran 
for several years in the 1990s and many nurses completed this course, but 
most received on-the-job learning. 
1992 MSc in genetic counselling at Manchester, led by Lauren Kerzin-Storrar. 
1993 Education group set up by Penny Guilbert as GNSWA chair. 
1995 Decision to define role and scope of practice. Study of practice led by 
Heather Skirton. Around 200 AGNC members. 
1996 Association joined British Society for Human Genetics (BSHG) as 
constituent group, name changed to Association of Genetic Nurses and 
Counsellors (AGNC) and had a representative on BSHG council.
1997/8 Studies published in Journal of Medical Genetics; stand-alone Spring 
scientific meeting replaced CGS meeting and second meeting held with 
the BSHG conference. 
2000 MSc in genetic counselling in Cardiff. 
192  Distributed at the Witness Seminar on 23 September 2008. For relevant publications see Skirton et al. 
(1997, 1998, 2002a, b, c, d and e, 2003); AGNC Education Working Group (2003).Clinical Genetics in Britain: Origins and development  – Appendix 2
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date timeline
2001 Launch of registration programme ; Genetic Counsellor Registration 
Board started, chaired by Penny Guilbert. Around 250 AGNC members. 
Department of Health (DoH) commissioned five reports, work led by 
Heather Skirton.
2002 First counsellors registered by Genetic Counsellor Registration Board. 
2003–05 Input by association into DoH’s Agenda for Change final agreement in 
2004 (see www.dh.gov.uk/en/Managingyourorganisation/ 
Workforce/Paypensionsandbenefits/Agendaforchange/dh_424).  
White Paper (DoH (2003)) confirmed need to grow the genetic 
counselling profession; new training posts funded, administered by 
AGNC training panel. 
2008 More than 100 genetic counsellors registered, applied to Health 
Professions Council to register as a profession. More than 300 AGNC 
members. 
2009 Application to Health Professions Council to register as a profession 
approved, as recommended by the Secretary of State for Health.Clinical Genetics in Britain: Origins and development  – References
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professor sir donald acheson
KBE FRCP FFPH FFOM FRCS 
FRCOG HonFRSM (1926–2010) 
trained first as an internist at 
the University of Oxford and 
the Middlesex Hospital, and 
subsequently specialized in 
public health. He was an acting 
squadron leader at the RAF 
medical board (1953–55), a 
travelling fellow of University 
College, Oxford (1957–59), then 
medical tutor at the Nuffield 
department of medicine at the 
Radcliffe Infirmary and in 1968 
he began a long association with 
Southampton University, where 
he was professor of clinical 
epidemiology until 1983 and 
foundation dean of the faculty of 
medicine. He was Chief Medical 
Officer of England (1983–91), 
dealing with the HIV/AIDS 
crisis. His principal research 
contributions have been to 
discover the relationship between 
lack of exposure to UV light 
as a cause of multiple sclerosis 
and the association of cancer of 
the ethmoid sinus to inhalation 
of wood and leather dust in 
industrial workers.
ms Chris Barnes 
MSc RMN RGN (b. 1955) had 
a background in mental health 
nursing and nursing research before 
becoming a genetic counsellor 
at the genetics centre at Guy’s 
Hospital in 1988. She has been 
actively involved in the UK 
Association of Genetic Nurses 
and Counsellors (AGNC) since 
1990, and is a member of both the 
genetic counsellor training panel 
and the genetic counsellor statutory 
regulation steering group.
professor sir John Bell
Kt FRCP HonFREng FRS 
PMedSci (b. 1952) educated 
at the University of Alberta, he 
qualified in medicine at Oxford 
(Rhodes and Commonwealth 
scholar), with house jobs at John 
Radcliffe Hospital, Oxford, the 
department of clinical cardiology, 
Hammersmith Hospital, London; 
the renal unit, Guy’s Hospital, 
London and in neurology at 
Queen Square, London, becoming 
a research fellow at the Nuffield 
department of clinical medicine, 
Oxford. He was a clinical fellow, 
department of medicine and 
postdoctoral fellow, department 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources. 114
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of medical microbiology at 
Stanford University (1982–87) 
and a Wellcome senior clinical 
fellow and honorary consultant 
physician, Nuffield department 
of clinical medicine and surgery, 
John Radcliffe Hospital (1987–89). 
He was appointed university 
lecturer, Oxford (1989–92), 
Nuffield professor of clinical 
medicine (1992–2001) and Regius 
professor of medicine, University 
of Oxford (2001– ). He has 
been chairman of the Office for 
Strategic Co-ordination of Health 
Research (OSCHR) and the 
Oxford Health Alliance; founder 
of the Wellcome Trust centre for 
human genetics and a founder 
fellow of the Academy of Medical 
Sciences and has been president 
since 2006. He is also a member 
of the board of the UK Biobank 
Ltd and a trustee of the Rhodes 
Trust, Nuffield Medical Trust and 
the Ewelme Almshouse charity. 
His research has contributed to a 
clearer understanding of the genetic 
determinants of susceptibility in 
type 1 diabetes and rheumatoid 
arthritis and he has helped pioneer 
a large number of high-throughput 
genomic methodologies applied to 
biomedical science.
dr Julia Bell
FRCP (1879–1979) studied 
mathematics at Cambridge 
University before becoming 
statistical assistant to Karl Pearson 
at the Galton Laboratory for 
National Eugenics. She assumed 
principal responsibility for the 
Treasury of Human Eugenics, 
published between 1909 and 1958. 
She trained in medicine during the 
First World War (1914–20) and 
was a Medical Research Council 
research assistant (1920–65). In 
1944 she was made an honorary 
research associate at UCL. See 
Wolstenholme (ed.) (1984); 
Bundey (1996); Harper (2005).
dr Caroline Berry
PhD FRCP (b. 1937) qualified 
in 1961 and trained at Middlesex 
Hospital, London; was medical 
officer to the paediatric research 
unit at Guy’s Hospital from 1974, 
becoming a senior registrar in 
the South-east Thames Regional 
Genetics Centre in 1976. She 
was appointed consultant clinical 
geneticist in 1979 and clinical 
director in 1993. She served on the 
council of the Clinical Genetics 
Society and chaired the medical 
study group of the Christian 
Medical Fellowship.
professor martin Bobrow
CBE FRCP FRCPath FRS 
FMedSci (b. 1938) came to 
Britain after graduating in South 
Africa. He worked in Edinburgh 
and Oxford and held chairs of 
medical genetics in Amsterdam and Clinical Genetics in Britain: Origins and development – Biographical Notes 
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Guy’s Hospital before becoming 
professor of medical genetics 
in Cambridge in 1995. He has 
been on the council of the MRC, 
a governor of the Wellcome 
Trust, national chairman of the 
Muscular Dystrophy Campaign, 
and chairman of the Clinical 
Genetics Society. He has also held 
posts as chairman of COMARE 
(Committee on Radiation in the 
Environment), ULTRA (Unrelated 
Living Transplant Regulating 
Authority), deputy chairman of the 
Nuffield Council on Bioethics and 
a member of the Human Genetics 
Advisory Commission.
professor sir John Burn
Kt MD FRCP FRCPCH FRCOG 
FMedSci (b. 1952) completed 
an intercalated genetics degree in 
1973 and qualified in Newcastle 
in 1976. After medical and 
paediatric training he became 
clinical scientific officer in the 
MRC clinical genetics unit, Great 
Ormond Street Hospital, London, 
and returned to Newcastle as their 
first consultant clinical geneticist 
in 1984. He became first clinical 
director of the Northern Genetics 
Service (1989–2004) and professor 
of clinical genetics, Newcastle 
University (1991– ) and head of 
the Institute of Human Genetics 
(2004–10). He was president of 
the European Society of Human 
Genetics (2007), chair elect (2011) 
of the British Society for Human 
Genetics, chair of the National 
Institute for Health Research 
genetics specialty group, Leeds 
(2008– ) and director of the NIHR 
collaborative group on genetics in 
healthcare, Leeds (2009– ). He has 
been lead clinician, NHS North 
East, since 2009. 
professor stuart Campbell
DSc FRCPEd FRCOG FACOG 
(b. 1936) graduated from the 
faculty of medicine, University 
of Glasgow, in 1961 and in 1965 
worked as a research registrar under 
Professor Ian Donald at the Queen 
Mother’s Hospital, Glasgow. In 
1968 he took up a lectureship 
in obstetrics and gynaecology at 
the Queen Charlotte’s Maternity 
Hospital in London, working 
under Professor Sir John Dewhurst, 
and became senior lecturer in 1973 
and professor of clinical obstetrics 
and gynaecology in 1976. He 
was professor of obstetrics and 
gynaecology at King’s College 
Hospital, London (1976–96) and 
has been professor and chair at 
the department of obstetrics and 
gynaecology and the fetal medicine 
unit at St George’s, University 
of London, since 1996. He was 
president of the International 
Society of Ultrasound in Obstetrics 
and Gynaecology (1990–98) and is 
an honorary fellow of the American 
Institute of Ultrasound in Medicine 116
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and honorary life member of the 
British Medical Ultrasound Society. 
professor Cedric Carter
FRCP (1917–84) was director of 
the MRC genetics unit, Institute 
of Child Health (1964–82). He 
founded the UK Clinical Genetics 
Society in 1972 and, with John 
Fraser Roberts, conducted the first 
genetic counselling clinic in Britain 
at the Hospital for Sick Children, 
Great Ormond Street, London.  
See Wolstenholme (ed.) (1989); 
Figure 7.
dr ian lister Cheese
PhD FRCP FRCPH (b. 1936) 
read natural sciences followed by 
training in research, then trained 
in medicine, qualifying in 1966. 
After posts as medical registrar at 
the Radcliffe Infirmary, he entered 
general practice in Wantage, 
Oxfordshire, where he became a 
tutor in general practice, a trainer 
in the vocational training scheme, 
also serving in NHS management 
in Oxfordshire. In 1984 he entered 
the senior civil service and held 
appointments in the Department 
of Health and the Department 
of Education. His posts included 
responsibilities for the fitness 
of teachers, hospital services for 
children and for genetics services. 
He was secretary to the Standing 
Medical Advisory Committee and 
to the Gene Therapy Advisory 
Committee. He also served on the 
RCP Clinical Genetics Committee. 
Following notional retirement in 
1996 he became an adviser to the 
Department of Health on matters 
relating to clinical governance and 
the working of the Abortion Act, 
has undertaken policy work for the 
RCP and the Academy of Medical 
Royal Colleges, was a member of 
the editorial board that prepared 
the new formulary, Medicines for 
Children, and served as trustee to 
voluntary bodies concerned with 
the support of disabled children 
and their families.
professor angus Clarke
DM FRCP FRCPCH (b. 1954) 
studied medical and natural 
sciences at Cambridge, taking 
his Part II in genetics, and then 
qualified in medicine from Oxford 
University. After registration, he 
worked in general medicine and 
then paediatrics. He studied the 
clinical and molecular genetic 
aspects of ectodermal dysplasia 
in Cardiff and then worked in 
clinical genetics and paediatric 
neurology in Newcastle upon 
Tyne, developing an interest in 
Rett syndrome and neuromuscular 
disorders. He returned to Cardiff 
in 1989 as senior lecturer in clinical 
genetics and has been professor 
in clinical genetics since 2000. 
He has maintained his interests 
in Rett syndrome and ectodermal 
dysplasia and has developed further Clinical Genetics in Britain: Origins and development – Biographical Notes 
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interests in genetic screening, the 
genetic counselling process and 
the social and ethical issues around 
human genetics. He represents 
the CMO for Wales on the UK 
Human Genetics Commission. He 
has (co)authored and edited six 
books, including Genetics, Society 
and Clinical Practice (1997) and 
Living with the Genome (2006). He 
established and directs the Cardiff 
MSc course in genetic counselling.
professor sir Cyril Clarke
KBE FRCP FRCOG FRS 
(1907–2000) became consultant 
physician to the Liverpool teaching 
hospitals, was appointed professor 
of medicine at the Liverpool 
Medical School in 1963 and 
established the Nuffield Institute 
of Medical Genetics, University 
of Liverpool, which he directed 
(1963–72). He was professor and 
honorary Nuffield research fellow 
in the department of genetics at 
the University of Liverpool (1966–
76), later emeritus. He served as 
president of the Royal College of 
Physicians (1972–77) and was 
awarded the Lasker clinical research 
award for work on the genetics of 
Rh factor and haemolytic  
disease of the newborn, held 
jointly with Dr Ronald Finn, Dr 
John Gorman, Dr Vincent Freda 
and Dr William Pollack in 1980. 
See Weatherall (2002).
professor John Clegg
HonFRCP FRS (b. 1936) was 
on the Medical Research Council 
senior scientific staff (1979–2001) 
and has been professor of molecular 
medicine at the University of 
Oxford since 1996.
dr Gerald Corney
MD FRCOG (1928–2001) 
qualified at the University of 
Liverpool and trained in obstetrics 
and child heath. Following a short-
term commission in the Royal 
Navy as surgeon lieutenant, some of 
which was spent in the Far East on 
a survey ship, he was a member of 
scientific staff at the MRC human 
biochemical genetics unit at the 
Galton Laboratory at UCL, where 
he remained until his retirement 
in 1989 when he was made an 
honorary lecturer in the department 
of genetics and biometry, University 
of London. His interest in twinning 
began with his work with Percy 
Nylander on the Aberdeen registry 
of twin births and his MD thesis 
was on twin–twin transfusion 
in monozygotic twins. See 
MacGillivray (2002).
dr Clare davison
MD D(Obst) RCOG DPH 
(b. 1934) graduated at Queen’s 
University, Belfast. Following 
hospital appointments, general 
practice and obtaining DPH 
in 1962 she went to the MRC 118
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population genetics research unit 
in Oxford and stayed until 1970 
when she married and went to 
Cambridge. In 1974 she was 
appointed consultant clinical 
geneticist at Addenbrooke’s 
Hospital, Cambridge, and was 
responsible for setting up a regional 
genetics service in East Anglia. She 
retired in 1994 and in 1996 spent 
three months as locum clinical 
geneticist in Dublin, Eire.
professor Joy delhanty
PhD FRCPath FRCOG (b. 1937) 
graduated in zoology (with special 
emphasis on genetics) at University 
College London, University of 
London, gaining a doctorate in 
human genetics at UCL. She 
worked at the Galton Laboratory, 
UCL, under Lionel Penrose in 
the pioneering days of human 
cytogenetics. She has held academic 
posts at UCL from 1961, becoming 
professor of human genetics in 
1998, until her retirement in 
2003, later emeritus. She directed 
the clinical cytogenetics unit of 
University College Hospital (1994–
99) and has been director of the 
UCL centre for preimplantation 
genetic diagnosis since 1997.  
See Figure 4.
dr nick dennis
FRCP (b. 1944) trained in 
medicine at Cambridge and St 
Thomas’ Hospital, London. He 
was a member of scientific staff, 
MRC clinical genetics unit, 
Institute of Child Health,  
London, under Professor Cedric 
Carter (1972–76) and senior 
lecturer and honorary consultant in   
clinical genetics at Southampton 
(1978–2007).
professor dian donnai
CBE FRCP FRCOG(ad eundem) 
FMedSci (b. 1945) qualified 
at St Mary’s Hospital Medical 
School, University of London 
and trained in paediatrics at St 
Mary’s Hospital, Northwick Park 
Hospital and Sheffield. In 1978 
she took up one of the first senior 
registrar training posts in medical 
genetics at St Mary’s Hospital, 
Manchester, and became a 
consultant there in 1980. She was 
appointed honorary professor of 
medical genetics in the University 
of Manchester in 1994 and then 
to a substantive chair in 2001. 
She was president of the Clinical 
Genetics Society (1997–99), 
consultant advisor to the CMO 
(1998–2004) and president of 
the European Society of Human 
Genetics (2009–10). In 2005 she 
was appointed CBE for services  
to medicine.
professor alan emery
MD PhD DSc FRCP FRCPE 
FACMG FLS FRSA FRS(E)  
(b. 1928) after military service, Clinical Genetics in Britain: Origins and development – Biographical Notes 
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he graduated BSc in biological 
sciences and subsequently took 
a medical degree at Manchester 
University in 1960. After junior 
hospital appointments, he gained a 
PhD at Johns Hopkins University 
in genetics. Returning to the UK 
in 1964, he set up a small medical 
genetics unit at Manchester and 
was appointed foundation professor 
of human genetics at Edinburgh 
University in 1968. He has made 
a life-long study of muscular 
dystrophy: the disease Emery–
Dreifuss muscular dystrophy and 
its defective protein product, 
emerin, are both named after him. 
Subsequently he established the 
European Neuromuscular Centre 
(ENMC) based first in Paris then 
in the Netherlands (1989–99) 
and was its chief scientific advisor 
from 1999. He established the 
Royal Society of Medicine’s Section 
of Medical Genetics and was its 
first president (2001–04). He 
has been a research fellow and 
later an honorary fellow of Green 
Templeton College, University of 
Oxford since 1985.
sir ronald aylmer Fisher
Kt FRS (1890–1962) was Galton 
professor of eugenics at UCL in 
1933, and Arthur Balfour professor 
of genetics at the University of 
Cambridge (1943–57). See Yates 
and Mather (1963).
dr Charles Ford
FRS (1912–99) was head of the 
cytogenetics section at the Medical 
Research Council radiobiology 
unit, Harwell (1949–71) and a 
member of the Medical Research 
Council’s external staff at the Sir 
William Dunn School of Pathology, 
University of Oxford (1971–78). 
In 1959 he was responsible for 
some of the first studies of human 
chromosome abnormalities. See 
Lyon (2001).
professor George Fraser
MD PhD DSc FRCP FRCPC 
(b. 1932) qualified in medicine at 
Cambridge, followed by a PhD 
from the University of London 
and fellowships at the Canadian 
College of Medical Genetics and 
the American College of Medical 
Genetics. He was appointed 
scientific officer, MRC population 
genetics research unit, Oxford 
(1959–61); research fellow, division 
of medical genetics, University of 
Washington, Seattle (1961–63); 
lecturer, department of research 
in ophthalmology, Royal College 
of Surgeons, London (1963–66); 
reader in genetics, University of 
Adelaide, Australia (1966–68); 
associate professor, division of 
medical genetics, University of 
Washington (1968–71); professor 
of human genetics, University of 
Leiden, Netherlands (1971–73); 
professor of medical genetics, 120
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consultant in clinical genetics, 
Memorial University, St John’s, 
Newfoundland, Canada (1973–76); 
chief of department of congenital 
anomalies and inherited diseases, 
department of national health and 
welfare, Federal Government of 
Canada, Ottawa, Canada (1976–
79); associate professor, centre for 
human genetics, McGill University, 
Montreal, Quebec, Canada 
(1979–80); special expert in 
human genetics, National Library 
of Medicine, National Institutes 
of Health, Bethesda, Maryland; 
attached to Moore clinic for 
medical genetics, Johns Hopkins 
University, Baltimore, Maryland 
(1980–84); senior clinical research 
fellow, Imperial Cancer Research 
Fund, honorary consultant in 
clinical genetics, cancer genetic 
clinic, Churchill Hospital, Oxford 
(1984–97) until his retirement 
in 1997. He has been honorary 
professor of human genetics, 
Institute of Child Health, UCL, 
since 2007.
dr John Fraser roberts
CBE DSc FRCP FRCPsych FRS 
(1899–1987) began research in 
human genetics in Edinburgh 
during the 1930s. After the Second 
World War, he was honorary 
consultant in medical genetics at the 
Royal Eastern Counties Hospital, 
Colchester (1946–57) and started 
a genetics clinic in 1946 at the 
Hospital for Sick Children, Great 
Ormond Street, London, the first 
in Europe (1946–64) and later at 
the Children’s Hospital, Bristol. 
The MRC created a clinical genetics 
research unit at the Institute of 
Child Health, Great Ormond 
Street, in 1957 with Fraser Roberts 
as director, where he remained until 
his retirement in 1964. See Pembrey 
(1987); Hill (1988); Polani (1987). 
See Figure 6.
mrs margaret Fraser roberts
(b. 1927) joined the junior staff of 
the department of epidemiology 
and medical statistics at the 
London School of Hygiene and 
Tropical Medicine in 1947 to be 
trained as a computer in medical 
statistics. She was appointed 
personal assistant/computer to 
Dr John Fraser Roberts in March 
1948 and worked with him for 
the next 33 years. In 1957 she 
moved with him to the clinical 
genetics unit at Great Ormond 
Street Hospital, London, until Dr 
Fraser Roberts’ retirement in 1964 
and then accompanied him to the 
paediatric research unit at Guy’s 
Hospital, London (1964–81). See 
Hill (1988).
professor John Burdon sanderson 
Haldane
FRS (1892–1964) was professor 
of genetics at UCL (1933–37), 
Weldon professor of biometry Clinical Genetics in Britain: Origins and development – Biographical Notes 
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there (1937–57) and head of the 
biometry, genetics and eugenics 
department of which the Galton 
Laboratory was part. In addition 
to numerous fundamental 
contributions to basic genetics, 
he was also much involved in 
early human genetics discoveries, 
including the first discovery of 
genetic linkage in man and the 
first estimate of mutation rate for 
a human gene. See Clark (1968); 
Pirie (1966); Kevles (2007).
professor david Harnden
FRCPath FRSE (b. 1932) was a 
scientific member of the Medical 
Research Council radiobiology 
unit, Harwell (1957–59) and a 
scientific member of the Medical 
Research Council clinical and 
population cytogenetics unit, 
Edinburgh (1959–69). He was 
professor of cancer studies at 
the University of Birmingham 
(1969–83) and honorary professor 
of experimental oncology at the 
University of Manchester (1983–
97) and director of the Paterson 
Institute for Cancer Research there. 
He was chairman of the South 
Manchester University Hospitals 
NHS Trust (1997–2002).
professor peter Harper
Kt FRCP (b. 1939) graduated 
from Oxford University in 1961, 
qualifying in medicine in 1964. 
After a series of clinical posts, he 
trained in medical genetics at the 
Liverpool Institute for Medical 
Genetics under Cyril Clarke and 
at Johns Hopkins University, 
Baltimore, under Victor 
McKusick. He was professor of 
medical genetics at the University 
of Wales College of Medicine, 
Cardiff, until his retirement in 
2004, later university research 
professor in human genetics 
(emeritus), Cardiff University. 
He has been closely involved with 
the identification of the genes 
underlying Huntington’s disease 
and muscular dystrophies, and 
with their application to predictive 
genetic testing. He has also been 
responsible for the development of 
a general medical genetics service 
for Wales and has a particular 
interest in the historical aspects of 
human and medical genetics. See 
Harper (1995).
professor Harry Harris
FRCP FRS (1919–94), biochemist 
and geneticist, qualified in 
medicine at Trinity College, 
Cambridge, served in the forces and 
joined the Galton Laboratory at 
UCL in 1947 where he pioneered 
the field of human biochemical 
genetics, became a lecturer in 
the department of biochemistry 
(1950–53), senior lecturer 
(1953–58), reader in biochemical 
genetics (1958–60) and professor of 
biochemistry, University of London 122
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(1960–65). He was honorary 
director of the MRC human 
biochemical genetics research unit 
(1961–76), professor of human 
genetics, University of London 
(1965–76); and Harnwell professor 
of human genetics, University of 
Pennsylvania (1976–90), later 
emeritus. See Hopkinson (1994); 
Harris (1959). 
dr Hilary Harris
FRCGP (b. 1943) qualified in 
medicine at the University of 
Liverpool, and was a principal 
in general practice, firstly in 
Liverpool, then for 27 years as 
senior partner and GP trainer 
in south Manchester. She ran a 
Wolfson Foundation trial on cystic 
fibrosis screening in early pregnancy 
in primary care. Following this 
she was appointed to the Advisory 
Committee on Genetic Testing 
and then as a member of the UK 
Government. Human Genetic 
Commission (1999–2004). See 
Harris et al. (1993). See Figure 14.
professor rodney Harris
BSc MD FRCP DTMH FRCPath  
(b. 1932) graduated in anatomy 
with physical anthropology at the 
University of Liverpool in 1956. 
He trained as a doctor in Liverpool 
in 1959 before working as the 
Darwin research fellow of the 
Eugenics Society in Nigeria in 1960 
and in South West Africa (now 
Namibia) in 1961. He subsequently 
held clinical and academic posts 
at Liverpool Royal Infirmary and 
the University of Liverpool before 
becoming professor of medical 
genetics and honorary consultant 
physician at Manchester Royal 
Infirmary and the University of 
Manchester. He was consultant 
advisor in medical genetics to 
several Chief Medical Officers at 
the DHSS, chairman of the Royal 
College of Physicians committee 
on clinical genetics, president 
of the Clinical Genetics Society 
and chairman of the European 
Concerted Action on Genetic 
Services. He was appointed CBE 
in 1996 and has been emeritus 
professor of medical genetics in 
Manchester since 1997. See  
Figure 14.
sir austin Bradford Hill
FRS (1897–1991), medical 
statistician, was professor of 
medical statistics at the London 
School of Hygiene and Tropical 
Medicine (1945–61). A series of 
17 articles published by him in 
the Lancet in 1937 introduced 
the medical researcher to the use 
of statistics, later reprinted as 
Hill (1937). His first attempts 
to introduce the concept of 
randomization in controlled trials 
were for the Medical Research 
Council. See Wilkinson (1997).Clinical Genetics in Britain: Origins and development – Biographical Notes 
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professor shirley Hodgson
DM D(Obst)RCOG DCH 
FRCP (b. 1945), daughter of 
Lionel Penrose: avoided working 
in genetics for many years, but 
after training in medicine and 
working in general practice while 
her children were young, she did a 
locum in clinical genetics at Guy’s 
Hospital, and found it irresistible. 
She went on to work in the field 
of clinical genetics for many years, 
promoting the development of 
cancer genetics clinics at Guys, St 
Mark’s and St George’s hospitals in 
London in the 1990s and ran the 
regional cancer genetics service at 
Guy’s. She has published widely on 
the subject, and co-authored several 
books. She has an active research 
programme investigating inherited 
aspects of cancer predisposition, 
particular in breast and colorectal 
cancers. She is particularly 
interested in international 
collaborative research. She took up 
a new post in cancer genetics at St 
George’s, University of London, in 
2003. Her current research looks 
at molecular changes in colorectal 
polyps in relation to inherited 
colorectal cancer susceptibility, and 
she was principal investigator of a 
five-year randomized study funded 
by Cancer Research-UK to evaluate 
whether the Mirena intrauterine 
progestagen-releasing system 
reduces the risk of endometrial 
cancer in women at increased risk 
of this condition (with Lynch 
syndrome). 
professor patricia Jacobs
OBE FRSE FRCPath FRCPE 
FRCOG FRS (b. 1934) was 
a Medical Research Council 
scientist (1957–72), professor 
in the department of anatomy 
and reproductive biology at the 
University of Hawaii School of 
Medicine (1988–2001), professor 
and chief of the division of human 
genetics in the department of 
paediatrics at Cornell University 
Medical College (1985–87) and 
director of the Wessex Regional 
Genetics Laboratory (1988–2001).
dr alan William Johnston
MD FRCP FRCP(Ed) FRCPG  
(b. 1928) qualified in medicine 
at University College Hospital 
Medical School, trained with Victor 
McKusick as a fellow in medicine at 
Johns Hopkins Hospital (1959/60), 
returned to complete an MD 
at Cambridge and was resident 
assistant physician at University 
College Hospital Medical School 
(1962–66). He was appointed 
consultant physician, Aberdeen 
teaching hospitals (1966–92) and 
clinical senior lecturer in medicine 
and genetics until his retirement 
in 1992. He was president, 
Clinical Genetics Society (1987/8); 
president, Scottish Society of 
Physicians (1988). He has been a 
member of the Christian Medical 124
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Fellowship since 1950 and an elder 
in the Church of Scotland  
since 1977.
mrs ann kershaw
MSt BA RGN RHV (b. 1949) 
trained as a nurse at Guy’s Hospital, 
London, qualifying in 1972. She 
worked in the community in 
Sheffield, and then trained and 
subsequently worked as a health 
visitor and clinical teacher in 
Cambridge (1985–89). She joined 
the East Anglian medical genetics 
department at Addenbrooke’s 
Hospital, Cambridge, in 1989, 
was appointed senior genetic nurse 
counsellor in 1995 and a consultant 
genetic counsellor in 2008. She was 
a member of the genetic counsellor 
registration working party and 
is a former section editor for the 
BSHG News and has recently 
joined their editorial board. She has 
a long interest and commitment 
in working with families with 
Huntington disease and sits on two 
working groups for the European 
Huntington Disease Network 
(EURO HD). She is a member 
of the United Kingdom Genetic 
Testing Network (UKGTN) 
working party on systems and 
communications.
mrs lauren kerzin-storrar
MS (b. 1955) studied biology and 
genetics at University of California, 
San Diego before qualifying as a 
genetic counsellor at the University 
of California, Berkeley and San 
Francisco in 1979. She was the first 
Master’s trained genetic counsellor 
to be appointed in the UK in 1981 
at St Mary’s Hospital, Manchester, 
where she has continued to work 
(as consultant and head genetic 
counsellor since 1993). She 
has been director of the MSc 
genetic counselling programme 
at University of Manchester since 
it was established in 1992 as 
the first training programme for 
non-medical genetic counsellors 
in Europe. Through clinical 
practice, teaching, research and 
professional body contributions 
she has promoted the integration 
of psychosocial considerations 
alongside genetic science in the 
training and practice of both 
doctors and genetic counsellors.
professor michael laurence
DSc FRCPE FRCPath (b. 1924) 
qualified at Liverpool and trained 
in Wales and was career registrar 
in pathology at Portsmouth 
(1953–55), research fellow in 
hydrocephalus and spina bifida at 
the Hospital for Sick Children, 
Great Ormond Street, London 
(1955–58). He was appointed 
senior lecturer in paediatric 
pathology at the Welsh National 
School of Medicine (1959–69), 
reader in applied genetics (1969–
76) and professor of paediatric Clinical Genetics in Britain: Origins and development – Biographical Notes 
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research (1976–89), later emeritus. 
He was project leader, Euroregister 
of Congenital Malformations, for 
Wales (1985) and published over 
300 scientific papers on congenital 
malformations, clinical genetics, 
paediatric pathology, hydrocephalus 
and spina bifida, prenatal diagnosis 
and prevention of malformations. 
He was a member of the Clinical 
Genetics Society, later secretary 
and president; of the British 
Paediatric Association, the Society 
for Research into Hydrocephalus 
and Spina Bifida (past secretary 
and president). See Rocker and 
Laurence (eds) (1981).
professor victor mckusick
(1921–2008) qualified in medicine 
at Johns Hopkins University and 
completed his internship and 
residency in internal medicine 
there. He was executive chief of the 
cardiovascular unit at Baltimore 
Marine Hospital (1948–50) while 
progressing through the ranks in 
the Johns Hopkins department 
of medicine. He also held joint 
professorships in epidemiology 
in the Johns Hopkins University 
school of public health and 
in biology at Johns Hopkins 
University. He founded the division 
of medical genetics in 1957, which 
he headed until 1973, when he 
became the William Osler professor 
and chairman of the department of 
medicine and physician in chief of 
Johns Hopkins Hospital. He held 
these posts until 1985, when he 
was named university professor of 
medical genetics.
professor Ursula mittwoch
DSc (b. 1924) entered the 
Galton Laboratory as a student 
for a doctorate in 1947 and later 
postdoctoral appointments to 
work on the biochemistry of 
cystinuria (in collaboration with 
Harry Harris and Bette Robson) 
and on cytogenetics. During the 
1960s she carried out genetic 
testing by demonstrating muco-
polysaccharide inclusions in the 
lymphocytes of patients with 
Hurler and Hunter syndromes. 
Since then she has specialized in the 
genetics of sex determination with 
special reference to cell proliferation 
and energy metabolism. She retired 
as professor of genetics in 1989, 
later emeritus. See Mittwoch 
(1995). 
professor Bernadette modell
FRCP FRCOG (b. 1935) started 
her academic life in 1952 as a 
biologist with a particular interest 
in genetics, embryology and 
anthropology. She studied for 
her PhD in Cambridge when 
the science of molecular biology 
was in its earliest exciting stages. 
She was professor of community 
genetics in the department of 
obstetrics and gynaecology and 126
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then the department of primary 
care and population sciences at 
the Royal Free and University 
College Medical School, London 
(1993–2000), later emeritus in the 
department of health informatics 
and multiprofessional education 
(CHIME). She began her work on 
thalassaemia at UCL and University 
College Hospital in 1964, 
pioneering the treatment, and 
prenatal diagnosis of the disease, 
and then with WHO and others 
to develop the global concepts of 
community genetics. She was a 
Wellcome principal research fellow 
(1992–2000).
professor michael modell
FRCP FRCGP DCH (b. 1937) 
qualified at University College 
Hospital and University College 
Medical School and worked as 
a partner in a large multi-ethnic 
general practice (James Wigg 
Practice; Kentish Town Health 
Centre, London, 1963–93). The 
main focus of his academic work 
has been on undergraduate and 
postgraduate medical education 
and primary care genetic research. 
He was the acting head and 
professor of the UCL department 
of primary care and population 
sciences (2000–02) until his 
retirement, later emeritus. In recent 
years he has represented the Royal 
College of General Practitioners 
on the fetal anomaly screening 
programme steering group and the 
Genetics Commissioning Advisory 
Group (GenCAG).
sir alan moncrieff
KBE OBE MD FRCP 
HonFRCOG (1901–71) qualified 
at the Middlesex Hospital and 
joined the staff of the Hospital for 
Sick Children as house physician 
in 1925. He studied in Paris and 
then in Hamburg and returned 
to become the medical registrar 
and pathologist to Great Ormond 
Street Hospital. In 1945 he was 
appointed the first Nuffield 
professor of child health at the 
University of London until his 
retirement in 1964, later emeritus. 
He was medical correspondent to 
The Times and author and editor 
of many books. In 1961 he was the 
first to receive the James Spence 
Medal of the British Paediatric 
Association, and was knighted in 
1964. See Norman (1983).
professor marcus pembrey
FRCP FRCPCH FRCOG FMedSci   
(b. 1943) trained in medical 
genetics in Liverpool (1969–71) 
and Guy’s Hospital, London 
(1973–78). In 1979 he moved 
to the Institute of Child Health, 
London, as head of the mothercare 
unit of paediatric genetics where 
he led a team that helped to 
introduce DNA testing into clinical 
genetics in the 1980s. He was also Clinical Genetics in Britain: Origins and development – Biographical Notes 
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consultant clinical geneticist at the 
Hospital for Sick Children, Great 
Ormond Street, London (1979–98) 
and consultant adviser in genetics to 
the Chief Medical Officer (CMO), 
Department of Health (1989–98). 
After early retirement in 1998, he 
continued as visiting professor and 
director of genetics within the Avon 
Longitudinal Study of Parents and 
Children, University of Bristol, 
until 2006. See Pembrey (2004).
professor lionel penrose
FRCP FRS (1898–1972) was 
resident director of the Royal 
Eastern Counties Institution, 
Colchester (1930–39). He was 
Galton professor of eugenics 
(1945–62) and of human genetics 
(1962–65) at University College 
London. See Harris (1973);  
Figure 1.
sir robert platt (lord platt of 
Grindleford from 1967)
Bt FRCP (1900–78) was professor 
of medicine at the University of 
Manchester (1945–65) and a 
member of the Royal Commission 
on medical education (1965–68). 
He was president of the Royal 
College of Physicians (1957–62). 
See Platt (1972).
professor paul polani
FRCP HonFRCP(Ire) FRCPCH 
FRCOG HonFRCPath DCH 
FRS (1914–2006), geneticist 
born in Trieste, who showed that 
Down syndrome and Klinefelter 
syndrome were both caused by the 
presence of an extra chromosome, 
and Turner syndrome by a missing 
chromosome. He qualified at 
Siena and Pisa, became a ship’s 
surgeon lieutenant on a British 
merchant vessel and was interned 
as an enemy alien on the Isle of 
Man when Italy joined the war in 
1940. He was released in 1941 and 
appointed medical and surgical 
officer at the Evelina Children’s 
Hospital, Southwark, London. In 
1948 he was appointed assistant to 
the director, department of child 
health, Guy’s Hospital Medical 
School, London (1950–55), 
director, paediatric research unit 
(renamed the division of genetics 
and development, King’s College, 
London; 1960–83); director, 
medical research unit, National 
Spastic Society (1955–60); Prince 
Philip professor of paediatric 
research, University of London 
(1960–80), later emeritus, and 
honorary paediatrician, Guy’s 
Hospital and Medical School 
(1960–85). He was also director, 
South East Thames Regional 
genetics centre (1976–82), a fellow 
of King’s College London, and 
geneticist, division of genetics and 
development at Guy’s Hospital. See 
Richmond (2006); Adinolfi and 
Alberman (2006); Harper (2007). 
See Figure 8.128
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professor sue povey
MD FMedSci (b. 1942) graduated 
in natural sciences (genetics) at 
Cambridge in 1964 and qualified 
in medicine in 1967. After brief 
clinical experience at University 
College Hospital, London, 
Huddersfield and working for Save 
the Children Fund in Algeria, she 
returned to UCL to join the MRC 
human biochemical genetics unit 
under Harry Harris in 1970. Having 
obtained an MD in 1977, she was 
deputy director of the unit (1989–
2000) and was appointed Haldane 
professor of human genetics at 
UCL and editor of the Annals of 
Human Genetics until her retirement 
in 2007. Her interest in tuberous 
sclerosis continues in the curation of 
the TSC1 and TSC2 locus-specific 
mutation databases and she has 
chaired a working group drafting 
ethical guidelines for such databases.
dr robert race
CBE FRS (1907–84) was director 
of the Medical Research Council 
blood group unit (1946–73). See 
Clarke (1985).
professor andrew read 
MA PhD FRCPath FMedSci  
(b. 1939) trained in organic 
chemistry in Cambridge and did 
his PhD on RNA chemistry in 
Sir Alexander Todd’s department 
there. After postdoctoral work in 
Heidelberg and Warwick, he joined 
the department of medical genetics 
at the University of Manchester, 
in 1977 as lecturer, subsequently 
senior lecturer, reader and, in 1995, 
professor of human genetics. His 
early work was on the diagnosis 
of neural tube defects and their 
prevention by periconceptional 
vitamin supplementation. In 1982 
he established one of the first DNA 
diagnostic laboratories in the UK, 
now one of the two national genetics 
reference laboratories. He was a 
founder member, and subsequently 
chairman, of the Clinical Molecular 
Genetics Society and later founder 
chairman of the British Society 
for Human Genetics. His research 
focused on mapping and identifying 
the genes responsible for Mendelian 
conditions, including PAX3, the first 
homeodomain gene found to cause 
a human genetic condition, type 1 
Waardenburg syndrome.  
He is co-author of two of the 
leading textbooks in the area 
(Strachan and Read (1996); Read 
and Donnai (2007)).
professor James renwick
(1926–94), worked initially at the 
Galton Laboratory, UCL, London, 
and subsequently at University 
of Glasgow. He was responsible 
for some of the earliest human 
genetic linkage studies, as well 
as for developing computerized 
approaches to genetic linkage 
analyses. His later work, again at 
UCL, was on the teratological basis 
of congenital malformations.Clinical Genetics in Britain: Origins and development – Biographical Notes 
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professor derek roberts
FRSE (b. 1925) was professor of 
human genetics at the University 
of Newcastle upon Tyne until his 
retirement in 1990, later emeritus; 
honorary consultant to the Royal 
Victoria Infirmary, Newcastle 
upon Tyne; and honorary director, 
Genetic Advisory Service NHS 
Northern Region (1965–90).
professor elizabeth (Bette) 
robson
PhD (b. 1928) obtained her PhD 
with Penrose and Haldane in 1954. 
After a Rockefeller fellowship at 
Columbia University, New York, 
in 1954/5 she worked with Harry 
Harris at the London Hospital 
Medical College and then King’s 
College London (1955–62) where, 
together with Oliver Smithies and 
David Hopkinson, they developed 
pioneering methods for the 
detection of enzymes after starch 
gel electrophoresis. In 1962, as 
a founder member of the MRC 
human biochemical genetics 
unit, she moved back to UCL, 
succeeding Harry Harris as Galton 
professor of human genetics (1978–
93). In 1969 she mapped the 
Haptoglobin locus to chromosome 
16 by linkage analysis, one of the 
earliest autosomal assignments. 
With a younger colleague, the late 
Dr Peter Cook, she continued to 
play a major role in the application 
of protein polymorphisms and 
blood groups in linkage analysis, 
being a founder member of the 
Human Genome Organization and 
a great supporter of the human 
gene mapping meetings. She was 
joint editor of the Annals of Human 
Genetics (1978–93). See Figure 4.
professor Heather skirton
PhD MSc RGN (b. 1953), a 
qualified midwife and registered 
genetic counsellor, trained as a 
nurse and midwife in Melbourne, 
Australia, emigrated to the UK 
in 1988 and worked as a genetic 
counsellor (1989–2000) and 
nurse consultant in genetics 
(2000–04), during which time 
she completed a PhD on the 
outcomes of genetic counselling 
(1996–99). Her academic posts 
include appointments as co-director 
of the MSc in genetic counselling 
at Cardiff University (2000–03) 
and reader in health genetics 
at the University of Plymouth 
(2004–08). She was promoted to 
professor of applied health genetics 
at the University of Plymouth 
in 2008. She chaired the Joint 
Committee on Medical Genetics 
(2003–05), established in 1999 and 
representing the Royal College of 
Pathologists (RCPath), the Royal 
College of Physicians (RCP) and 
the British Society for Human 
Genetics (BSHG) to provide a 
unified forum. She is past president 
of the International Society of 
Nurses in Genetics (2006).130
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dr alan stevenson
CBE FRCP (1909–95) was the 
director of the Medical Research 
Council population genetics unit, 
Oxford, and lecturer in human 
genetics at the University of 
Oxford (1958–74). See Gillam and 
Macdonald (eds) (2001).
professor e m (tilli) tansey
PhD PhD HonFRCP FMedSci 
(b. 1953) is convenor of the 
History of Twentieth Century 
Medicine Group and professor 
of the history of modern medical 
sciences at the Wellcome Trust 
Centre for the History of Medicine 
at UCL.
lord Walton of detchant
TD MD DSc FRCP HonFRCPE 
FRCPath FRCPsych FRCPCH 
FMedSci (b. 1922) qualified at 
King’s College Medical School, 
trained at the Universities of 
Durham and Newcastle upon Tyne; 
served in the Royal Army Medical 
Corps, commanded the Territorial 
Army’s I(N) General Hospital 
(1963–66), becoming an honorary 
Colonel (1968–73). He worked 
at the Massachusetts General 
Hospital and Harvard University; 
was appointed as a consultant 
neurologist, University of Newcastle 
Hospitals (1958–83) where he 
studied muscular dystrophy, 
building up an extensive research 
team at the Newcastle General 
Hospital in the muscular dystrophy 
group research laboratories, 
discovering a new classification 
based on genetic information. 
He was professor of neurology, 
University of Newcastle upon Tyne 
(1968–83), dean of medicine there 
(1971–81) and warden of Green 
College, Oxford (1983–89). He was 
a member of the MRC (1974–78) 
and was a member of the House 
of Lords’ Select Committee on 
science and technology (1991–
97 ). He was chairman of the 
Hamlyn national commission on 
education (1991–93); a member 
of the General Medical Council 
(1971–90), chairman of the 
education committee (1975–82), 
and president (1982–89); president 
of the British Medical Association 
(1980–82), Association for the 
Study of Medical Education  
(1982–94), Royal Society of 
Medicine (1984–86), Association 
of British Neurologists (1987/8); 
first vice-president of the World 
Federation of Neurology (1981–
89), president (1989–97), and has 
been life president of the Muscular 
Dystrophy Group GB since 2000 
and chairman (1970–95). See  
Rose (1992). 
professor sir david Weatherall
Kt DL FRCP FRCPE FRS  
(b. 1933) qualified at Liverpool 
University in 1956 and was 
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the University of Liverpool 
(1971–74), Nuffield professor 
of clinical medicine at the 
University of Oxford (1974–92), 
Regius professor of medicine 
at the University of Oxford 
(1992–2000); honorary 
director of the MRC molecular 
haematology unit (1980–2000) 
and the institute for molecular 
medicine, Oxford (1988–2000, 
renamed the Weatherall Institute 
of Molecular Medicine from 
2000), later emeritus. His major 
research contributions have been 
in the elucidation of the clinical 
and molecular basis for the 
thalassaemias and the application of 
this information for the control and 
prevention of these diseases in the 
developing countries. He has been 
Chancellor of Keele University 
since 2002.
professor robin Winter
(1950–2004) geneticist and 
dysmorphologist, qualified at 
University College Hospital 
Medical School and took an 
intercalated degree in genetics 
at the Galton Laboratory. After 
various house jobs, he was a 
visiting fellow at the department 
of human genetics, Richmond, 
Virginia, where he studied under 
Walter Nance. On his return he 
took up a senior registrar post, and 
was appointed clinical geneticist 
at the Kennedy-Galton Centre 
at Northwick Park in 1981, 
where he and Michael Baraitser 
began their work on the London 
dysmorphology and neurogenetics 
databases (Winter et al. (1984)). In 
1992 he moved to the Institute of 
Child Health and Great Ormond 
Street Hospital for Children NHS 
Trust, and was appointed to a 
personal chair in clinical genetics 
and dysmorphology there from 
1994 until his death in 2004, 
aged 53, after a short illness with 
cancer of the oesophagus. He was 
an active member of the council of 
the Clinical Genetics Society and 
served as president (2001–03). See 
Baraitser (2004); Nance (2004); 
Rosser and Wilson (2004);  
Figure 12.
professor John Woodrow
FRCP (b. 1924) was on the staff 
of the department of medicine, 
University of Liverpool (1961–91), 
and was consultant physician in 
general medicine and rheumatology 
to the Liverpool United Hospitals. 
He formed part of the research 
team at the Liverpool Institute for 
Medical Genetics.Clinical Genetics in Britain: Origins and development – Glossary 
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alphafetoprotein
One of the principal plasma 
proteins present in the fetus, whose 
altered level in maternal blood and 
amniotic fluid may be useful in the 
prenatal diagnosis of neural tube 
defects and Down syndrome.
amniocentesis
The technique of removal of fluid 
from the pregnant uterus for 
genetic and other analyses.
Barr body
See sex chromatin
Bayesian risks
An approach to risk estimation 
based on the combination of 
prior and modified risks, first 
proposed by the eighteenth-century 
philosopher and cleric, Thomas 
Bayes.
β-thalassaemia
A severe form of anaemia resulting 
from failure of red blood cells to 
produce adequate amounts of the 
haemoglobin β chain.
coarctation of the aorta
A congenital heart malformation, 
seen more often in males and also 
in the chromosome disorder Turner 
syndrome.
creatine kinase
An enzyme present in muscle. An 
elevated level is found in the blood 
of those affected by many types of 
muscle damage, including those 
affected by or carrying several types 
of muscular dystrophy. This can be 
useful in their diagnosis.
cytogenetics
The study of chromosome structure 
and function.
dna probes
Lengths of DNA sequence labelled 
so as to allow their corresponding 
sequence to be identified by 
hybridization for diagnosis or 
research.
down syndrome
One of the most common human 
chromosome abnormalities, 
caused by presence of an extra 
copy of chromosome 21. Named 
after Langdon Down, the original 
describer.
drumstick
A darkly staining nuclear appendage, 
representing a second X chromosome 
in polymorphonuclear leucocytes, 
first described by Davidson and 
Smith (1954).
Glossary*
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duchenne muscular dystrophy
The most common form of 
childhood muscular dystrophy, 
determined by a gene on the X 
chromosome and occurring mainly 
in young boys.
dysmorphology
The study of human malformation 
syndromes.
epiloia
A previous name for tuberous 
sclerosis.
eugenics
The study of ways in which 
the overall genetic constitution 
of human populations can be 
‘improved’.
genetic linkage
The occurrence of genes close 
together on the same chromosome, 
resulting in co-inheritance of 
characteristics more often than 
expected by chance.
haemoglobinopathies
A group of inherited anaemias, 
including sickle cell disease and 
thalassaemias, resulting from 
abnormality in the structure or 
production of haemoglobin.
Huntington’s disease
A progressive brain disease, 
following autosomal dominant 
inheritance, resulting in abnormal 
movements, with motor and 
mental deterioration.
ichthyosis
A scaly appearance of the skin 
usually caused by a mutation in 
one of the many structural proteins 
expressed in the skin (especially the 
keratin proteins and filaggrin). The 
associated conditions are known 
collectively as the ichthyoses.
karyotype
The overall chromosome 
complement of a cell or individual.
klinefelter syndrome
A condition of infertility and 
hypogonadism in males, resulting 
from an XXY chromosome 
constitution.
leopard syndrome
An inherited condition 
characterized by multiple 
pigmented lesions (lentigines), 
deafness and cardiac defects.
molecular genetic tests
Tests based on analysis of DNA.
mongolism
A previous name for Down 
syndrome.
monozygotic
Twins derived from the same 
fertilized egg.
muscular dystrophy
A group of inherited and 
progressive neuromuscular 
disorders of childhood and later 
life. See myotonic dystrophy, 
Duchenne muscular dystrophy.Clinical Genetics in Britain: Origins and development – Glossary 
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myotonic dystrophy
The most common form of adult 
muscular dystrophy, characterized 
also by numerous non-muscular 
features.
neural tube defects
Developmental disorders of the 
nervous system, including spina 
bifida and anencephaly, caused by 
incomplete closure of its primitive 
tube structure.
pharmacogenetics
The scientific field of genetic 
variation in the response to or 
metabolism of drugs.
phenylketonuria
An inherited metabolic disorder 
resulting in accumulation of the 
amino acid phenylalanine, and 
causing mental handicap if not 
detected and treated early.
polymorphonuclear leucocyte
One form of white blood cell, 
particularly responsible for 
combating bacterial infection.
preimplantation genetic diagnosis 
(pGd)
The diagnosis of genetic conditions 
by analysis of cells taken from the 
embryo prior to its implantation in 
the uterus.
renpenning syndrome
A form of X-linked mental 
handicap.
rhesus haemolytic disease
Anaemia of a Rhesus positive fetus 
in a Rhesus negative mother, caused 
by destruction of fetal red blood 
cells by maternal antibodies to the 
Rh blood group substance on the 
red blood cells of the fetus while in 
the uterus.
robertsonian translocation
A form of chromosome 
abnormality resulting from fusion 
of the short arms of particular 
chromosome pairs, such as of 
chromosome 21 and chromosome 
14 in rare cases of Down 
syndrome. See Figure 3.
rubinstein taybi syndrome
A rare developmental syndrome 
with characteristic facial and other 
features.
sex chromatin (Barr) body
A body seen microscopically under 
the nuclear membrane in most 
female mammalian cells, first 
described by Murray Barr and 
Ewart Bertram. It represents the 
inactivated member of the pair 
of X chromosomes in a female 
mammalian cell.
triploidy
Presence of a complete additional 
set of chromosomes and therefore 
giving a chromosome count of 69.
trisomy
Presence of an additional copy of a 
specific chromosome.136
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tuberous sclerosis
An inherited neurodevelopmental 
disorder causing mental handicap, 
epilepsy, tumours and skin 
pigmentary changes, among other 
features. 
turner syndrome
A condition of infertility and 
gonadal maldevelopment in females, 
commonly with heart defects, 
and due to an XO chromosome 
constitution and the presence of 
a single sex chromosome (an X 
chromosome) instead of the usual 
two sex chromosomes (XX or XY).
tylosis
Severe thickening (hyperkeratosis) 
of the palms of the hands and the 
soles of the feet, which is associated 
with cancer of the oesophagus and is 
inherited in a dominant fashion.
Werdnig Hoffman disease
A severe form of spinal muscular 
atrophy, caused by inherited 
degeneration of the anterior horn 
nerve cells of the spinal cord.
X-linked
Determined by a gene located on the 
X chromosome.Clinical Genetics in Britain: Origins and development – Index
137
Aberdeen, 48
ABO incompatibility, 38
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